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2  Abstract 
The development of new drugs against Human African Trypanosomiasis is much needed 
due to toxicity, efficacy and availability problems with current drug treatments for this 
resurgent parasitic disease. Delivery  of drugs into cells is an important determinant of 
therapeutic  efficacy  of  drugs.  An  effective  means  of  selective  drug  delivery  is  to  use 
plasma membrane transport systems to mediate the entry of drugs into the cell. 
Some  amino  acid  transporters  fulfil  the  criteria  needed  for  successful  exploitation  of 
nutrient transport systems for drug delivery. The Trypanosoma brucei genomic database 
was screened to identify the full gene repertoire of amino acid transporters. From this, 
candidate  genes  were  selected  and  functional  genetic  approaches  were  employed  to 
characterise candidate amino acid transporter genes. Further characterisation of TbAATP1, 
a RNAi cell line shown to be a transporter of small neutral amino acids (serine, glycine, 
cysteine, asparagine and alanine), showed a role in threonine uptake. 
Amino  acid  analogues  were  tested  for  trypanocidal  activity.  Of  the  96  tested,  two 
(Azaserine and Levodopa) were investigated in more detail, paying special attention to the 
nature  of  their  trypanocidal  action  and  possible  route  of  entry  through  an  amino  acid 
transporter. Azaserine showed a trypanostatic action as well multiple routes of entry into 
the protozoan interior (as shown by inhibition of glutamine, phenylalanine and tyrosine 
uptake). The trypanocidal Levodopa showed entry through a tyrosine specific transporter. 
However, it is possible that Levodopa’s trypanocidal activity may not be as a result of the 
analogue itself, but secondary products of the analogue. 
Amino acids are important for protozoa as energy sources as well as forming pools of 
soluble osmolites. Amino acid usage in trypanosomes was investigated. Upregulation of 
proline transport and catabolism in response to reduced glucose availability was exhibited 
by the genome strain of T. brucei. Moreover, this metabolic shift could be mimicked by 
addition of GlcNAc to the medium, which blocks the hexose transporter limiting glucose 
entry to the cell. Systems biology approaches were initiated to investigate the undergoing 
metabolic changes. More specifically, mass spectrometry methodologies were employed to 
investigate  underlying  metabolite  changes  in  procyclic  form  trypanosomes  grown  in 
differing medium. iv 
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1  Introduction 
The underlying goal of this project is to assess the suitability of amino acid transporters to 
deliver  trypanocidal  compounds  to  the  interior  of  the  trypanosome,  encompassing  the 
investigations  of  selected  aspects  of  amino  acid  usage  (from  transport  capacity  to 
metabolic  usage).  Molecular,  biochemical,  pharmacological  and  ultimately  systems 
biology approaches were employed, specifically to: (1) characterise amino acid transporter 
genes by RNA interference; (2) test amino acid analogues for trypanocidal activity; (3) test 
the ability of GlcNAc to induce a metabolic shift from glucose to proline metabolism; (4) 
investigate changes to the trypanosome metabolome as a result of utilisation of different 
carbon sources. Charles E. Ebikeme, 2007     Chapter 1, 2 
1.1  The Disease 
Parasitic protozoa infect hundreds of millions of people every year and are collectively 
some of the most important causes of human misery (Barrett et al., 2003). Human African 
Trypanosomiasis (HAT), or sleeping sickness, is in resurgence (Moore & Richer, 2001). 
Devastating  epidemics  of  HAT  re-emerged  in  many  sub-Saharan  countries  in  the  late 
1990’s (Stich et al., 2003). The invariably fatal disease puts at risk 60 million of the 400 
million people inhabiting 36 sub-Saharan African countries (Barrett, 1999). Of those at risk 
from the disease only a mere 4 million are under surveillance (Etchegorry et al., 2001). 
The annually reported cases are therefore an underestimation of the real problem. 
 
Figure 1-1: Human African trypanosomiasis endemicity in the WHO African Region. 
Number of reported cases from 2000-2005 (www.who.int). 
 Charles E. Ebikeme, 2007     Chapter 1, 3 
The disease spreads in poor settings. Displacement of populations by war and poverty are 
important  factors  which  lead  to  increased  transmission.  The  disease  develops  in  areas 
whose size can range from a village to entire regions, and within a given area, the intensity 
of disease can vary. There have been several human epidemics of HAT in Africa over the 
last century. The major one occurred between 1896 and 1906, and affected mostly Uganda 
and the Congo basin. This was followed by one in 1920 which struck a number of African 
countries.  The  disease  did  resurge  in  the  1970’s  leading  to  alarming  epidemics  in  the 
1990’s.  Recently  in  2005,  outbreaks  were  still  reported  in  Angola,  the  Democratic 
Republic  of  Congo  and  Sudan.  In  the  Central  African  Republic,  Chad,  Congo,  Côte 
d’Ivoire, Guinea, Malawi, Uganda and United Republic of Tanzania the threat of HAT still 
remains an important public health problem, with 50-1000 new cases reported every year 
(www.who.int). Countries such as Burkina Faso, Cameroon, Equatorial Guinea, Gabon, 
Kenya, Mozambique, Nigeria, Rwanda, Zambia and Zimbabwe are reporting fewer than 50 
new cases per year (Figure 1-1). In countries such as Benin, Botswana, Burundi, Ethiopia, 
Gambia,  Ghana,  Guinea  Bissau,  Liberia,  Mali,  Namibia,  Niger,  Senegal,  Sierra  Leone 
Swaziland and Togo transmission seems to have stopped and no new cases have been 
reported  for  several  decades  (www.who.int).  However,  any  assessment  of  the  current 
situation of sleeping sickness in Africa will always be, at best, an underestimate due to the 
fact that a lack of surveillance as well as clinical and diagnostic expertise does exist. 
Trypanosoma species of the order Kinetoplastida are early branching eukaryotes and are a 
major public health problem across the new and old world. Trypanosoma brucei is the 
agent of two major afflictions affecting the African continent, sleeping sickness (human 
form) and nagana (animal form) (Lecordier et al., 2005). Possibly no other disease, with 
the exception of Malaria, HIV and Tuberculosis, has a stranglehold on the development of 
a continent that trypanosomiasis has on Africa. The disease in domestic animals especially 
cattle, is also a major obstacle to the economic development of the region. Biting tsetse 
flies of the genus Glossina transmit the subspecies of the salivarian Trypanosoma brucei 
group across east, west and central Africa to both livestock and humans. The “Gambian” 
infection, caused by Trypanosoma brucei gambiense, which accounts for 90% of reported 
cases, is characterised by a long asymptomatic stage (2 or more years) that gives way to 
febrile illness followed by late stage chronic meningoencephalitis (Murray et al., 2000). 
The “Rhodesian” infection caused by Trypanosoma brucei rhodesiense progresses more 
quickly (few weeks to 2 months). Gambian infection has a mainly human reservoir while 
Rhodesian infection is fuelled by a large animal reservoir. Charles E. Ebikeme, 2007     Chapter 1, 4 
During  the  first  stage  of  HAT,  after  infection  from  the  bite  of  an  infected  tsetse  fly, 
parasites spread to the draining lymph node and bloodstream. General malaise, headache, 
fever,  peripheral  oedema  and  anaemia  characterise  the  early  stages,  which  may  be 
accompanied by a series of other more problematic symptoms like myocarditis, pulmonary 
oedema, splenomegaly and hepatomegaly. These are problematic because these symptoms 
are  not  specifically  diagnostic  for  African  sleeping  sickness.  These  symptoms  are  also 
associated with other diseases, frequently leading to misdiagnosis (Bogitsh et al., 2005). 
Second  stage  is  more  serious,  with  the  parasites  crossing  the  blood-brain  barrier  and 
invading  the  central  nervous  system.  This  invasion  is  accompanied  by  infiltration  of 
lymphocytes. General malaise worsens, headaches become more severe and patient sleep 
pattern is altered as a result of alterations in brain function later escalating in to coma and 
eventually leading to death (Barrett et al., 2003). 
1.2  Vector Biology & Control 
According  to  some  authorities,  trypanosomiasis  has  kept  Africa  ‘green’.  By  allowing 
survival of the native fauna and preventing overstocking of fragile land with cattle, and 
hence  preventing  widespread  erosion.  Conversely,  trypanosomiasis  disrupts  the 
development  of  sustainable  mixed  farming  over  large  and  potentially  productive  areas 
(Hursey,  2001).  The  ultimate  result  being  agricultural  impoverishment.  A  burden  that 
accounts for a reduction in agricultural production, and further enhances the struggle of 
this developing continent. 
The long history of trypanosomiasis control started at the turn of the 20
th century with the 
identification of the infectious agents and their vectors (Evans, 1881; Dutton, 1902; Kleine, 
1909 – as reviewed by  Cox, 2004). The first stage of disease  control  must always be 
stopping transmission. This is even more apt for trypanosomiasis as clinical treatment has 
always been problematic (chapter 1.5). Different species of tsetse have different habitats, 
mainly found in vegetation by rivers and lakes, in gallery forests and in vast stretches of 
wooded savannah (www.who.int/mediacentre/factsheets/fs259/en/). Control of the tsetse 
fly vector was initially a large undertaking. Large areas of vegetation where the flies rested 
were cleared and the wild game that acted as an animal reservoir for the disease were shot 
(Schofield & Maudlin, 2001). Although proving effective, such methods are not employed 
today. Synthetic insecticides were the next major advent in disease control. During the 
1940’s  large  landmasses  were  sprayed  with  Dichloro-Diphenyl-Trichloroethane  (DDT), 
pyrethroids, and other organochlorides (Vreysen, 2001; Vreysen et al., 2000). Although Charles E. Ebikeme, 2007     Chapter 1, 5 
Glossina was once widespread, it is now limited to continental Africa south of the Tropic 
of Cancer (Bogitsh et al., 2005). Tsetse transmitted trypanosomiasis affects a 9-million 
km
2 area in sub-Saharan Africa (Hursey, 2001). Vector life cycle is an important facet of 
transmission. Fertilised eggs, within the female, hatch at intervals into larvae (Bogitsh et 
al., 2005). A single female tsetse will deposit up to 10 larvae at any one time, usually at 9 
day intervals. The adult fly emerges after a month in gestation. 
Tsetse control in Africa has become multi-faceted. Fly biology, behaviour and life cycle 
have allowed more methods of control. The problem of insecticide resistance faced by 
mosquito control has never been seen with tsetse flies, possibly due to slower reproduction 
time of the flies (female flies gestate once every 9 days). Some problems faced at the turn 
of the 21
st century still remain, but an understanding of the seasonal movements of the flies 
to more humid areas during the dry seasons has allowed use of this natural limitation of 
tsetse  movement  to  great  advantage  (Schofield  &  Maudlin,  2001).  Ground  and  aerial 
spraying remain the first method of effective control. However, despite being effective, 
these processes are not only costly but also labour and management intensive. Continuous 
monitoring,  sustainability  and  vigilance  are  serious  requirements  to  prevent  against  re-
invasion  and  re-infestation  of  cleared  areas  (Schofield  &  Maudlin,  2001).  This 
sustainability  relies  on  effective  co-operation  of  concerned  governments  and  the 
consolidating  of  peoples  affected.  International  declarations,  programme  activities, 
mandates and campaign strategies are a step forward, but without the infrastructure needed 
to maintain such initiatives, Africa will always fall victim to trypanosomiasis. 
The other form of control is on a much smaller scale and involves odour-baited traps and 
applying insecticides to the animal reservoir on which tsetse flies feed. Odour traps attract 
flies  over  a  relatively  small  distance  towards  visual  ‘targets’  (dark  blue)  treated  with 
insecticides  (Schofield  &  Maudlin,  2001).  This  local  population  control,  together  with 
cattle  dipping  helped  reduce  the  vast  amounts  of  insecticides  used  when  spraying 
(Esterhuizen et al., 2006; Torr et al., 2007) and also meant that the control method was 
sustained all year round, which is an added advantage. 
In recent years, control has taken a more molecular biology orientated approach, using 
molecular  genetics  and  vector-parasite  interactions  to  help  curb  the  resurgence  of  the 
disease. These control methods are often seen as ‘high-tech’ especially when compared to 
the  control  methods  already  previously  discussed.  These  high-tech  methods  employ 
detailed  analysis  of  tsetse  fly  variation,  population  structure,  evolutionary  dynamics, 
behaviour, susceptibility, and ecology as the basis for control (Aksoy, 2003). The sterile Charles E. Ebikeme, 2007     Chapter 1, 6 
insect technique (SIT), where infertile flies are released into wild populations to compete 
with  natural  males,  is  a  method  that  employs  genetic  population  suppression  with  the 
ultimate  result  of  eradication.  An  area-wide  tsetse  eradication  project  was  initiated  in 
Zanzibar in 1994, consisting of the release of gamma-sterilised males and resulting in the 
successful  eradication  of  Glossina  austeni  from  the  island  of  Unguja  (Vreysen  et  al., 
2000).  The  SIT  has  the  advantage  in  that  tsetse  flies  are  slow  to  reproduce,  meaning 
eradication is a distinct possibility. However, the large numbers of irradiated sterile males 
needed and the implementation of such a release method mean that it is not viewed as a 
favourable method of control (Rogers & Randolph, 2002). 
All  tsetse  are  potential  vectors,  and  their  presence  thus  presents  a  risk  for  parasite 
transmission (Fèvre et al., 2006). With all species of Glossina able to carry the parasite, 
vector biology is becoming more important in terms of control. The focus in the past has 
been  only  to  concentrate  on  the  human-parasite  interaction.  Now,  investigations  are 
underway to identify factors that influence parasite transmission as a way to intervene at 
the level of the fly. The flies own innate immune system and trypanocidal midgut lectins 
are just two potential areas that could lead to fruitful knowledge. There is still a huge 
deficit  in  what  is  known  on  tsetse  biology  (Aksoy  et  al.,  2002).  Information  on  the 
genome,  proteins  and  metabolic  pathways  are  needed  to  understand  how  the  parasite 
infestation works, with the hope of ultimately bringing about new applications for vector 
control. 
1.3  Life Cycle 
Introduction of the infective stage of the parasite into the human host begins with the bite 
of an infected tsetse fly vector (Figure 1-2). Blood clotting is prevented by factors in the 
saliva of the insect (Bogitsh et al., 2005). The metacyclic trypomastigote is a distinctive 
life  cycle  stage  not  only  in  terms  of  morphology  but  also  in  certain  biochemical 
characteristics. Its morphology is blunt with a short free flagellum and the mitochondrion 
has few cristae and it has diminished classical electron transport complexes (Vickerman, 
1985). Metacyclic trypanosomes transform to the long slender form, eventually finding 
their way into the cerebrospinal fluid (chronic form of the disease diagnosed by parasites 
found in lumbar punctures). The mammalian bloodstream form stage exhibits three distinct 
forms;  the  long  slender  form  with  a  free  flagellum  extending  from  the  undulating 
membrane, a short stumpy form and an intermediate form that is not that clearly defined 
(Vickerman, 1985). Charles E. Ebikeme, 2007     Chapter 1, 7 
 
Figure 1-2: Life cycle of the African trypanosome in the human and tsetse fly. 
Image credit: da Silva & Moser, Public Health Image Library. 
 
Completion of the life cycle comes with ingestion of infected blood by the tsetse fly vector. 
The  short  stumpy  form  bloodstream  trypomastigote  is  pre-adapted  for  life  within  the 
vector. Upon entering the midgut of the fly complete adaptation is rapid. Transformation to 
the procyclic insect form is characterised by the loss of the surface coat and antigenic 
identity. Procyclics invade the extraperitrophic spaces, migrating anteriorly towards the 
foregut  where  they  transform  once  again  to  the  epimastigote  form  trypomastigote. 
Migration continues through the oesophagus into the salivary gland of the fly. The final 
metamorphosis comes with the transformation  of the epimastigote into the mammalian 
infective metacyclic form (Bogitsh et al., 2005). 
1.4  Control Strategies 
Control  of  African  trypanosomiasis  is  multifactorial  and  relies  initially  on  identifying 
(usually  by  microscopic  detection  of  parasites  on  a  thick  blood  smear)  the  largely 
asymptomatic  human  reservoir  (Murray  et  al.,  2000).  Diagnosis  forms  one  step  in  the Charles E. Ebikeme, 2007     Chapter 1, 8 
range of control strategies. The diagnosis of HAT is based upon a combination of clinical 
and investigative data (Kennedy, 2004). The non-specific nature of many of the clinical 
symptoms, together with the epidemiological context of geographical location shared with 
many other tropical infections means it is important to rule out other diseases such as 
malaria, tuberculosis, HIV and various other wormal infections. Differentiating between 
acute and chronic stages of the disease is the next important step once the disease has been 
confirmed. This is mainly due to the drug treatment regimes that differ for the different 
stages of the disease. 
The definitive diagnosis of the rhodesiense form of the disease is made by identifying 
parasites  in  the  peripheral  blood  using  thin  or  thick  films  (Kennedy,  2006).  For  the 
gambiense  form  of  the  disease,  serological  methods  are  used  due  to  the  fact  that 
parasitaemia is usually intermittent. The card agglutination trypanosomiasis test (CATT) is 
a quick and easy test for screening potential HAT cases and also allows the collection and 
storage of dried blood samples on filter-paper for future serological analysis (Magnus et 
al., 1978; Truc et al., 2002). Parasite identification, however, is crucial given the dangers 
associated with treatment (chapter 1.5). 
CNS involvement with HAT is the key issue for diagnosis and subsequent therapeutics. 
Hence, a lumbar puncture for collection of cerebro-spinal fluid (CSF) is essential. The 
criterion for defining late-stage HAT as set by the World Health Organisation (WHO) is 
based on the presence of trypanosomes in the CSF and/or a CSF white blood cell count of 
>5/uL (WHO, 1983). However, the CSF white blood cell count cut-off varies for different 
countries (www.who.int). Other methods of detection exist for diagnosis of CNS involved 
HAT, which include PCR, raised CSF proteins, EEG abnormalities, and the presence of 
intrathecal IgM synthesis. However, such tests are not easily applicable in the field and as 
such are not convenient methods of diagnosis. 
Vector control and chemotherapeutic regimes are present as control strategies. With no 
vaccine under development, the impetus is to improve existing strategies and formulate 
new drug regimes. Emphasis is on development of new orally effective trypanocides and 
vector control with new technology (Stich et al., 2003). Halting the surgence of the disease 
is a realistic goal. This can only come from the co-operation of the international public 
health communities as well as the drug companies that once, and to some extent still do, 
view development of anti-trypanosomiasis drugs as not economically viable. Evidently, the 
emergence  of  public-private  partnerships  aimed  at  developing  new  drugs  for  various 
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funding bodies like the Drugs for Neglected Diseases Initiative (DNDi), the Wellcome 
Trust, the Bill & Melinda Gates Foundation, Médecins Sans Frontières (MSF), Malteser, 
WHO/Special Programme for Research and Training in Tropical Diseases (WHO/TDR), 
and Caritas, to name just a few are providing not only the funds but also the infrastructure 
to combat HAT from the bench to the field. Moreover, the WHO surveillance and control 
programme collaborates with a number of international organizations, research institutions, 
development agencies, NGOs and private firms to achieve its objective of ensuring that a 
broader  context  of  the  disease,  in  terms  of  social  and  urban  development,  is  met 
(http://www.who.int/mediacentre/factsheets/fs259/en/). 
A network of field researchers, operational agents, epidemiologists, and scientists work 
under an umbrella created by the WHO in order to monitor drug resistance as well as 
finding solutions to the problems of treatment of trypanosomiasis (Etchegorry et al., 2001); 
including  the  dissemination  of  information  on  current  regimes,  availability  and 
affordability  of  current  drugs,  as  well  as  the  promotion  of  research  on  the  causes  of 
treatment failure (Legros et al., 1999). Treatment failure is a big issue when combating 
sleeping sickness, especially gambiense sleeping sickness (Brun et al., 2001). The fact that 
treatment relies on very few drugs means that resistance and relapse plays an important 
part in disease burden. Refractoriness and unresponsiveness to drug also fall under the term 
treatment failure. Reasons for this are not always parasite related, with host related factors 
(patient’s metabolism resulting in altered pharmacokinetics) also a relevant cause. 
Some initiatives are already in place (Stich et al., 2003). The release of sterile tsetse flies 
has  been  proposed  by  the  International  Atomic  Energy  Agency  (IAEA).  The  WHO  in 
collaboration with MSF are encouraging drug companies to donate the vital drugs needed 
and  commit  themselves  to  continued  production.  In  addition,  funding  from  notable 
benefactors like the Bill & Melinda Gates Foundation has allowed progression of drug 
trials for novel drug candidates (Jannin & Cattand, 2004). Campaigns initiated to stimulate 
efforts  in  combating  neglected  diseases  such  as  this  perpetuate  the  false  belief  that 
persistence of disease is solely due to a lack of effective and affordable treatments by 
focussing on the absence of appropriate research and the unaffordability of current drugs 
(Anon, 2006). Access to medicines is as much a crucial issue as the development of new 
drugs, and only when infrastructures are put in place to aid support delivery of drugs to 
people most in need will the disease burden be lightened.  
No  vaccines  exist  against  sleeping  sickness,  and  the  prospects  of  prophylactic 
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process  termed  antigenic  variation  (Van  der  Ploeg  et  al.,  1992).  Current  drug  regimes 
suffer many drawbacks. Some are decades old, toxic and would never achieve licensing 
today. This is the problem faced. 
1.5  Chemotherapy 
Only  four  drugs  are  licensed  for  treatment  against  African  sleeping  sickness:  suramin 
(Germanin), pentamidine (Pentamidine isethionate), melarsoprol (Arsobal) and eflornithine 
(Ornidyl).  Drug  of  choice  depends  on  whether  the  parasite  has  established  within  the 
central  nervous  system.  Suramin  first  came  into  use  in  1922  and  is  a  colourless 
polysulphonated symmetrical naphthalene derivative (Voogd et al., 1993). Suramin covers 
treatment  of  early  stage  sleeping  sickness,  but  is  the  drug  of  choice  for  Rhodesian 
infection. The drug’s mode of action is obscure. The highly charged molecule accumulates 
in  trypanosomes  very  slowly  and  is  believed  to  be  taken  up  via  receptor-mediated 
endocytosis  possibly  bound  to  low  density  lipoproteins  (Vansterkenburg  et  al.,  1993). 
Dosage for suramin starts at 20 mg/kg on a weekly basis for children whereas the adult 
dose is a 100–200 mg test dose then 1 g given intravenously on a weekly interval for 6 
weeks. 
Pentamidine,  the  drug  of  choice  for  early  stage  Gambian  infection,  is  an  aromatic 
diamidine (Sands et al., 1985) that was developed from a related compound (synthalin) 
that  induces  hypoglycaemia  in  mammals.  Although  the  mode  of  action  has  not  been 
established it is observed to accumulate to high levels within the parasite, where it possibly 
reacts electrostatically with cellular polyanions, including the network of circular DNA 
that  make  up  the  mitochondrial  genome  (kinetoplast)  (Burchmore  et  al.,  2002).  While 
much  remains  unclear  about  the  precise  mechanism  of  action  in  kinetoplastids, 
longstanding issues like selective uptake and mechanism of (cross) resistance have now, 
for the most part, been resolved (Bray et al., 2003). It is administered every two days by 
intramuscular injection for 3 weeks at a dose of 4 mg/kg for both adults and children. 
Pentamidine  is  far  from  ideal.  The  range  of  side  effects  caused  by  this  drug  includes 
hypotension, nausea and nephrotoxicity (Burchmore et al., 2002). Diabetes mellitus is not 
uncommon  after  therapy.  New  classes  of  orally  available  diamidines  with  fewer  side 
effects or improved central nervous system penetration are being developed (Bray et al., 
2003). 
Melarsoprol  is  a  dangerous  drug  (Stich  et  al.,  2003),  one  that  would  never  achieve 
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effective treatment for the chronic  form of the  disease caused by  Trypanosoma brucei 
rhodesiense,  due  to  its  ability  to  cross  the  blood-brain  barrier.  A  mode  of  action  for 
melarsoprol  is  yet  to  be  established.  Cell  lysis  upon  exposure  to  melarsoprol  occurs 
rapidly. Biochemical targets of melarsoprol have been postulated to include trypanothione 
and  glycerol-3-phosphate  dehydrogenase  (Burchmore  et  al.,  2002).  Melarsopol  has  the 
most complicated chemotherapeutic regimen of all the sleeping sickness drugs. For adults 
it has traditionally been administered intravenously in three series each at 2-3.6 mg/kg per 
day for 3 days at intervals of 1 week., then followed by another 3.6 mg/kg per day dose for 
a further 3 days. This regimen must be repeated again after 2-3 weeks. For children it 
needs administration at 18-25 mg/kg total over a 1 month period with an initial dose of 
0.36 mg/kg increasing gradually to a maximum of 3.6 mg/kg at intervals of 1-5 days. 
Recently, a new treatment schedule comprising of 10 daily injections of 2.2 mg/kg was 
shown to have a similar treatment outcome and is now in use in most areas (Burri et al., 
2000).  The  new  schedule  therefore  offers  economic  and  practical  advantages  over  the 
standard 26-day treatment schedule, with a similar outcome. Melarsopol kills around 5-
10% of patients treated due to drug enduced encephalopathy. Frequent adverse effects of 
this antiparasitic drug include, but are not limited to, myocardial damage; hypertension; 
vomiting;  peripheral  neuropathy;  Herxheimer-type  reaction,  whereas  the  rare  adverse 
effect is almost always shock. 
Treatment failure has become an increasing problem in melarsopol therapy (Brun et al., 
2001;  Legros  et  al.,  1999).  A  possible  link  between  the  emergence  of  melarsoprol 
resistance in man and imprudent use of diamidine drugs in livestock has been speculated 
(Barrett, 2001). Selection of resistance to veterinary trypanocides is suggested to lead to 
cross-resistance to drugs used in the treatment of African trypanosomiasis in man. Drug 
entry into the cell has been elucidated and resistance is conferred without loss of parasite 
viability by the loss of the unusual amino-purine transporter called P2 (encoded by the 
TbAT1 gene) (Carter & Fairlamb, 1993). However, deletion of TbAT1 by gene knock-out 
revealed only a 2-3 fold resistance to melarsen oxide in vitro thereby implicating other 
factors (Matovu et al., 2003). Drug mode of action has been attributed to cell lysis due to 
loss  of  ATP  which  occurs  as  a  result  of  glycolysis  inhibition  (Denise  et  al.,  2001). 
However, the glycolytic pathway has not yet been verified as a target for arsenical action. 
The debate still goes on with other targets being postulated, including glycerol-3-phosphate 
dehydrogenase  and  the  low  molecular  weight  thiol  trypanothione.  The  link  between 
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Because  of  their  capacity  for  rapid  growth  within  mammals,  trypanosomes  have  been 
likened to some types of cancer cell (Barrett & Barrett, 2000). The inhibitor of polyamine 
biosynthesis difluoromethylornithine (DFMO) or eflornithine was originally developed as 
an anti-cancer agent (Siimes et al., 1981; Jänne et al., 1981). Uptake of this analogue of 
ornithine has been proposed to occur via passive diffusion, although a transport component 
has been implicated (Bacchi et al., 1983; Bitonti et al., 1987). It acts as a specific suicide 
inhibitor  of  the  enzyme  ornithine  decarboxylase  (ODC).  Even  though  its  specificity 
originates from the fact that the protozoan has an ODC that is degraded and replenished 
much more slowly than that of its mammalian host (Phillips et al., 1987), DFMO needs to 
be given in large doses to be of any effect. Again, expense of treatment as well as the fact 
that it has no activity against rhodesiense sleeping sickness is a major drawback. A dosage 
of 400 mg/kg given by intravenous infusion in 4 equal doses (100 mg/kg every 6 hours) 
over the course of 2 weeks is the suggested regimen for eflornithine. 
Few new drugs show promise as effective treatments against sleeping sickness (Legros et 
al., 2002). One drug which has been developed recently and is currently in trials is the 
diamidine derivative DB289 (Jannin & Cattand, 2004). DB289 is only active against the 
early stage of the disease and will possibly be available in 2 years time (www.who.int). 
With  the  limitations  of  drug  candidates  already  in  the  field,  drug  combinations  are  a 
potential  method  to  increase  the  treatment  options.  Clinical  trials  of  potential  drug 
combinations have been initiated, one of which evaluated the efficacy and toxicity of three 
drug  combinations using doses smaller than those used in monotherapy  (Priotto et al., 
2006; Bisser et al., 2007). Drug combinations have the advantage of protection from the 
selection of resistant strains (or at least, slow down the emergence). Combinations also 
allow dosage reduction of each drug, hence reducing the overall toxicity while maintaining 
good efficacy. 
1.6  The Genome & Genomics 
The gap between research and clinical need is being bridged; although not at a rate needed 
to provide immediate relief. Despite the medical and healthcare revolution of the late 20
th 
century, billions of people still suffer from one or more tropical parasitic disease and the 
constant drain imposed by chronic sickness, loss of productive labour and premature death, 
imposes a multibillion dollar restriction on the economic development of the Third World 
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The  ever-emerging  availability  of  genome  sequences  for  hosts,  vectors  and  numerous 
parasites, our rapidly expanding repertoire of computational methodologies and internet 
databases,  functional  genomics,  proteomics,  gene  knockout/silencing  protocols,  and 
transgenesis  strategies,  provide  the  requisite  tools  needed  to  begin  unravelling  the 
intricacies of the host-pathogen-environment relationship (Christensen, 2004). 
Recent  technological  advances  have  permitted  the  identification  and  validation  of 
numerous drug targets. And the advent of molecular biology has highlighted the unique 
biochemical physiology in the protozoa when compared to their mammalian hosts. The 
Parasite Genome Initiatives are ongoing efforts of full genomic sequencing to facilitate full 
understanding of how parasites develop, survive and reproduce in their respective hosts, of 
parasite-host and parasite-immune system interactions and of the factors that determine 
behaviour, pathogenicity, drug resistance and antigenic variation (Johnston et al., 1999). 
Traditionally, the route for drug identification has been through comparative biochemistry. 
Biochemical pathways present in the protozoa but absent from the mammalian host should, 
in theory, provide targets for drug design. However, this rationale is complicated by other 
factors: drug entry, if the drug has to cross more than one plasma membrane, especially if 
one  of  the  membrane’s  is  mammalian  in  the  case  of  Leishmania  which  reside 
intracellularly. 
The natural progression from comparative biochemistry has been the genome sequencing 
projects. These provide automation and informatics, allowing rapid identification of drug 
targets. The parasites that cause most parasitic diseases do not pose as ‘model organisms’ 
to  analyse  gene  function.  The  yeasts  and  nematodes  like  Saccaromyces  cerevisiae  and 
Caenorhabditis elegans are ideal model organisms. Most of all they are easy and cheap to 
maintain in the laboratory since they show rapid growth and can be obtained in very large 
numbers.  Genome  organisation  is  conventional  and  amenable  to  a  wide  variety  of 
functional  assays.  Parasites  often  prove  more  difficult,  needing  more  ‘real  world’ 
maintenance (Johnston et al., 1999) including animal passaging. Many cannot be cultured 
in vitro, restricting experimental manipulations. But, most crucially of all, their genomes 
may display complicated characteristics which make it difficult for functional analysis. 
Classical genetic analysis of Trypanosoma brucei is possible, but restricted by difficulties 
in  obtaining  large  numbers  of  hybrid  offspring  from  tsetse  fly  infections.  The 
characteristics of individual parasitic genomes (haploid genome size, chromosome number, 
size, and codon content) impose limitations on the type of analysis possible (Johnston et 
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Despite the limitations of the biological systems involved, the Parasite Genome Initiatives 
have provided a wealth of information. This, coupled with in vivo genetic manipulation, 
proves to be the most exciting prospect for parasitic diseases. Gene knockout approaches 
and transfection systems have become fashionable for the identification of functionally 
important genes. Gene knockout involves introducing a DNA construct that contains an 
antibiotic resistance gene, flanked by the 5’ and 3’ untranslated sequences from the gene to 
be  knocked  out.  This  leads  to  replacement  of  the  gene  via  homologous  recombination 
(Conway et al., 2002). However, due to its complex genome repertoire, sometimes more 
than one round of gene knockout needs to be done. Trypanosoma brucei holds a unique 
advantage  over  the  other  kinetoplastida  in  that  because  both  forms  (procyclics  and 
bloodstream forms) can be cultivated in vitro, selective gene replacements can be done 
before placing transfectants in vivo. 
With  the  genome  of  trypanosomatid  organisms  now  complete,  a  huge  door  has  been 
opened that has the potential to decipher the long unanswered questions (Ash & Jasny, 
2005); from RNA editing to immune evasion to antigenic variation to energy metabolism. 
The sequence analysis of the 11 megabase-sized chromosome of T. brucei revealed a 26 
megabase  genome  containing  9068  predicted  genes,  including  ~900  pseudogenes  and 
~1700 T. brucei specific genes (Berriman et al., 2005). 
Annotation of genetic information (Aslett et al., 2005) is only the first step. It only allows 
target identification and selection of potential virulence determinants, protein antigen and 
drug target. Due to the complexity involved this needs to be coupled to a more in-depth 
analysis of metabolic pathways. The sequential interconvertions of every single compound 
within a cell, building up into metabolic pathways and further still into metabolic networks 
allows  the  entire  picture  to  be  seen,  defining  specific  processes  at  the  biological  level 
(Fairlamb, 2002). The full cellular component of RNA molecules (transcriptome), proteins 
(proteome)  and  metabolites  (metabolome)  can  be  used  to  predict  the  full  potential 
biosynthetic  capability  of  an  organism,  in  studying  the  response  of  a  parasite  when 
invading a host cell and vice-versa. The same can be applied in the discovery of potential 
drug  targets  and  determining  the  implications  associated  with  applied  drug  pressure 
(Breitling et al., 2006). 
1.7  Metabolomics 
Systems  biology  is  a  rapidly  emerging  field.  Technological  advances  have  allowed 
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(Breitling et al., 2006). Individual metabolites, and their relative abundance in different 
cell  types,  or  similar  cell  types  exposed  to  different  environmental  conditions,  can  be 
assessed by a range of techniques (Breitling et al., 2006; Goodacre, 2004; Dettmer et al., 
2007). Arguably, the most powerful technique involves Fourier transform ion cyclotron 
resonance  mass  spectrometry  (FT-ICR-MS)  (Brown  et  al.,  2005;  Hirai  et  al.,  2004; 
Marshall et al., 1998). The recently introduced Orbitrap mass analyser (Hu et al., 2005) 
offers resolution and accuracy close to that of classical high field FT-ICR-MS (Brietling et 
al., 2006). However, the Orbitrap operates using electrostatic rather than magnetic fields 
and hence by-passes the requirement of a large, super-cooled magnet. This allows it to be 
linked to chromatographic columns and thus avoids the risk of ion suppression effects 
which  can  occur  with  directly  infused  complex  samples.  This  technique  can  resolve 
thousands of metabolites, in the molecular mass range of 100–1500, with extreme mass 
accuracy  (routinely  <2  ppm).  This  technique  has  been  employed  to  build  ab  initio 
networks of metabolites whose masses can be linked by masses of common biochemical 
transformations in trypanosomes (Brietling et al., 2006). Exact mass can also be used to 
predict likely formulae for metabolites and tentatively to identify compounds based on 
comparison to databases of known metabolites. The fact that multiple formulae can yield 
masses within 2 ppm (Kind & Fiehn, 2006) means that orthogonal approaches are required 
to confirm identity such as Tandem mass spectrometry (Breitling et al., 2006). 
In FTMS (including Orbitrap analysis), ions, generated from soft ionisation methods (e.g. 
electrospray) are excited into cyclotron resonances that are a function of mass and charge. 
The frequency of gyration of these ions is detected in the mass spectrometer and then 
converted to high accuracy masses using the Fourier transform. The determined mass is as 
a result of several different physical principles within the analyser (Hu et al., 2005). The 
ionized metabolite mixture is trapped in an orbital trajectory of which the frequency of the 
orbit depends on mass/charge ratio. 
In the case of the orbitrap, the trapping is achieved without the need of a magnetic field, 
with ions trapped in a radial electric field between a central and outer cylindrical electrode. 
The ultra-high resolution enables simultaneous identification of ions that would not be 
resolved using less accurate mass determination approaches. The combined advantage of 
accurate mass determination and resolution makes it possible to restrict the number of 
possible molecular formulae that represent an individual molecular mass (Hu et al., 2005; 
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The number of metabolites present in trypanosomes is sufficiently small enough to ensure 
very good resolution using high resolution, high mass accuracy mass spectrometry without 
the  need  for  subcellular  fractionation.  Metabolomics  requires  special  approaches  for 
sample preparation, separation, and mass spectrometric analysis (Dettmer et al., 2007). The 
metabolome  represents  a  vast  number  of  components  belonging  to  a  wide  variety  of 
compound classes (amino acids, lipids, organic acids, nucleotides etc). Such diversity of 
compounds have reflecting diversity in their physical and chemical properties and occur in 
a wide range of abundances. To this effect, a careful experimental design is needed for the 
success of metabolomic investigations (Dettmer et al., 2007). While processing samples, 
formation and degradation of metabolites due to remaining enzyme activity or oxidation 
processes  is  a  possibility  (Dettmer  et  al.,  2007).  Therefore,  rapid  quenching  and 
metabolism  inhibition  is  required.  Rapid  quenching  of  metabolism  with  hot  HEPES-
buffered ethanol with subsequent freezing in liquid nitrogen has proven the most effective 
method of identifying metabolites in our hands (D. Wildridge, personal communication). It 
is necessary to also analyse culture medium without cells in order to generate spectra of 
medium associated metabolites to subtract from the metabolic profile. Any and every kind 
of preparation step will involve metabolite loss (Dettmer et al., 2007). For example, the 
aqueous  extraction  employed  here  (chapter  5)  results  in  poor  recovery  of  very  polar 
compounds as well as the loss of volatile organic compounds. 
Within the metabolomics field three distinct definitions of investigations exist; metabolic 
profiling,  metabolic  fingerprinting  and  metabolic  footprinting  (Dettmer  et  al.,  2007). 
Profiling  involves  quantitative  targeted  metabolite  analysis  of  metabolites  of  a  specific 
class or related to a selected pathway. The disadvantage of profiling is the fact that targeted 
analysis is a hypothesis-driven approach rather than a hypothesis-generating one, and that 
the data generated is not a global view of occurrences within the metabolome. Metabolic 
fingerprinting  involves  an  unbiased  global  screening  approach.  The  intention  is  not  to 
identify each observed metabolite but allows comparison of patterns or “fingerprints” as a 
result of cellular perturbations. Fingerprinting observes the true phenotype, however, the 
causal  metabolites  of  the  observed  phenotype  must  be  identified  if  any  biochemical 
understanding is to be gained from the data. With this in mind, metabolomic fingerprinting 
can be used to classify or diagnose a particular perturbation. Metabolomic footprinting 
involves  the  analysis  of  extra-cellular  metabolites  in  cell  culture  medium,  which  is  a 
reflection  of  metabolites  used  or  excreted  by  cellular  processes.  These  three  different 
metabolomic investigative methods shall be employed to address the question of metabolic 
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1.8  Trypanosome Molecular Biology 
In  conjunction  to  the  unique  biochemical  characteristics  of  trypanosomes  that  make 
attractive drug targets, other aspects of their biology including gene expression, antigenic 
variation, genetic diversity, are a necessity when trying to decipher the complex life cycle 
of these parasites. 
Antigenic  variation  is  an  important  aspect  of  African  trypanosome  molecular  biology 
because this is what makes the possibility of a vaccine virtually impossible. Antigenic 
variation is the process by which the parasite evades the immune system of their animal 
host  (Vickerman,  1978).  Covered  on  the  surface  membrane  of  the  parasite  is  a  dense 
surface  coat  composed  of  a  unique  protein  known  as  the  variant  surface  glycoprotein 
(VSG) (Englund et al., 1982). Recognition of this surface coat by the host immune system 
results  in  killing  of  the  parasite.  Evasion  of  this  killing  involves  antigenic  variation, 
whereby the parasite switches to the synthesis of a different variant surface glycoprotein 
(Barry,  1979).  This  indefinite  process  of  variation  is  what  gives  rise  to  the  relapsing 
parasitemia seen in patients of sleeping sickness. About 1000 VSG  genes (VSGs)  and 
pseudo-VSGs  are  scattered  throughout  the  trypanosome  genome  (Barry  et  al.,  2005). 
Transcriptional activation of VSGs comes with the copying of a particular VSG into a 
bloodstream expression site (BES) (Horn, 2004). All expressed VSGs are located at the 
telomere, suggesting that VSG genes are translocated into these specific sites (Donelson, 
2003). Different molecular mechanisms exist for the introduction and removal of VSG 
genes from these sites, but not all have been accurately characterised. 
Regulation of antigenic variation is as complex as the event itself. The presence of a VSG 
in a sub-telomeric expression site, although necessary, does not seem to be sufficient for 
expression;  with  further  events  required  for  activation  of  the  particular  expression  site 
(Donelson,  2003).  And  because  only  one  VSG  is  expressed  at  a  time,  the  parasite 
mechanism  must  also  involve  silencing  of  other  expression  sites  as  well  as  specific 
transcription  at  a  particular  site.  Suggestions  have  been  made  for  the  presence  of  a 
modified base (base J) being involved in the stabilisation of repression of expression sites 
(Ulbert et al., 2004). The genome sequence has revealed not only the location of most of 
the VSG genes towards the telomeric ends of chromosomes but also the fact that most 
VSG genes are incomplete (Barry et al., 2005). Of all the identified VSGs, 95% do not 
properly encode protein, 5% are  fully  functional, 9% are atypical, 62% are full-length 
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VSG population seem to have full functional ability (as predicted from gene sequences) 
suggest that the possibility of incomplete genes provide a level of complexity and diversity 
involving mosaic gene formations. 
In contrast to the bloodstream form of the African trypanosome, the procyclic form also 
possesses a glycoprotein coat composed of procyclins. Procyclins are first expressed in the 
midgut of the tsetse fly, upon bloodstream form differentiation to the procyclic form. The 
fact that expression of the procyclin coat is coupled to the loss of the VSG coat means a 
tightly regulated system is highly likely to be involved (Roditi et al., 1998). Procyclin 
genes are organised in tandem arrays of two or three copies on two pairs of chromosomes, 
encoding proteins with internal dipeptide or pentapeptide repeats. Control of expression is 
multifactorial  involving  both  positive  and  negative  control  elements  (Matthews,  1999). 
Phenotype of expression is related to the ability of the trypanosome to infect the tsetse fly. 
Its  repeat  domains  are  protease  resistant,  providing  a  protective  glycocalyx  in  the 
hydrolytic environment of the tsetse fly midgut (Gruszynski et al., 2006). 
Control  of  gene  expression  in  trypanosomes  has  several  novel  features  to  it.  In 
trypanosomes,  genes contain no introns and  appear packed in dense clusters along the 
genome, with tandem repeats of either the same or very similar genes. Gene arrays are 
transcribed into long polycistronic units and, uniquely, individual genes belonging to the 
same transcriptional unit will show significantly different expression patterns. Processing 
of primary transcripts into individual mature mRNAs occurs by the trans splicing of a 5’ 
cap (a 39 nt RNA spliced leader sequence bearing a trimethyl cap) and the addition of a 3’ 
poly(A)  tail  (Vanhamme  et  al.,  1995).  The  splice  acceptor  site  is  an  AG  dinucleotide 
immediately downstream of a polypyrimidine tract and polyadenylation sites are usually 
located 100-300 nucleotides upstream from the trans splicing signal (Clayton & Shapira, 
2007). 
Polyadenylation  is  dependent  on  downstream  splicing  which  means  independent 
processing  regulation  for  adjacent  genes  are  absent.  This  is  due  to  the  fact  that  poor 
transplicing of a particular mRNA results in poor polyadenylation of the mRNA directly 
upstream  (Clayton  &  Shapira,  2007).  No  known  polyadenylation  signal  exists  for 
trypanosomes,  in  contrast  to  other  many  eukaryotes.  The  genome  encodes  very  few 
potential regulatory transcription factors, meaning regulation of gene expression is post-
transcriptional. With genes encoding the major surface proteins of African trypanosomes – 
the EP procyclin of the procyclic (insect) stage and the VSGs of the bloodstream stage 
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sequences  in  the  3’-UTR  determine  developmental  regulation  of  the  mRNA  transcript. 
Indeed, regulation of an amino acid transporter in T. brucei has been investigated (Robles 
&  Clayton,  2007;  chapter  1.17).  Investigations  into  regulatory  sequences  commonly 
employ cloning the intergenic region in question downstream of a reporter gene, with the 
reporter  either  as  an  episome  or  integrated  into  a  different  chromosomal  location. 
However, this poses the problem that the regulatory sequence is removed from its usual 
chromosomal context, plus the fact that expression is driven by polymerases other than 
RNA polymerase II. 
1.9  RNA Interference & Gene Knockout 
The  discovery  of  double-stranded  RNA  interference  (dsRNAi)  in  Trypanosoma  brucei 
provides a convenient method to generate knockout phenotypes and has allowed the advent 
of  rapid-to-employ  reverse-genetic  approaches  (Ngo  et  al.,  1998).  The  introduction  of 
double-stranded RNA molecules in cells triggers what is thought to be a mechanism that 
has  evolved  to  protect  cells  against  undesirable  RNAs  (e.g.  viruses  or  mobile  genetic 
elements) (Clayton, 2004; Rusconi et al., 2005). The mechanism is simple and, on the 
surface, highly specific (Figure 1-3). Introduced dsRNA proceeds through a number of 
sequential steps. Firstly, there is cleavage by the RNase III enzyme DICER into shorter 21-
23 nucleotide dsRNA pieces termed short interfering RNAs (siRNA). These siRNAs have 
a characteristic phosphorylated 5’ end and a two nucleotide overhang at the 3’OH end. The 
siRNAs then enter a RNA-induced silencing complex (RISC). A helicase, belonging to the 
argonaute  (AGO1)  family  or  Slicer,  unwinds  the  two  strands  of  the  siRNA  to  form 
singlestranded RNAs (ssRNA), and RISC scans the mRNAs in the cytoplasm and cleaves 
the molecules that are found complementary to the RISC-contained siRNA. Hence, leading 
to down regulation of mRNA transcript and gene silencing. Charles E. Ebikeme, 2007     Chapter 1, 20 
 
Figure 1-3: General RNAi mechanism (taken from Balaña-Fouce & Reguera, 2007). 
 
This RNAi mechanism has been found in a number of organisms including the nematode 
worm C. elegans, flies and mammals (Fire et al., 1998). RNAi potency and flexibility has 
allowed  use  of  high  through-put  genetic  screen  methodologies  in  several  organisms. 
Although, there is some recent debate as to the specificity of RNAi. The triggering of a 
number of unspecific targets is a possibility that has been postulated. The degradation by 
the RISC complex of partially complementary mRNA due to cross hybridisation leads to a 
phenotypic  effect  that  is  not  due  to  silencing  of  the  target  gene.  Reports  of  these 
phenomena have prompted scientists into assessing the specificity of RNAi silencing and 
posing solutions. One of which is based on the rescuing of the RNAi-mediated loss-of-
function phenotype by expressing an RNAi-resistant version of the target gene (Rusconi et 
al.,  2005).  Functional  complementation  (using  an  orthologue  protein  different  in  gene 
sequence  but  identical  in  function)  offer  a  way  to  ascertain  that  phenotypic  effects 
observed upon RNAi experiments are indeed due to the specific silencing of the targeted 
gene. 
The development of tetracycline-regulated vectors for production of dsRNA has facilitated 
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of dsRNA into cells, leading to potent but transient phenotypes (Motyka et al., 2004). The 
utility of RNAi was greatly enhanced with the production of vectors that stably integrate 
into the genome and that express dsRNA in an inducible manner. The first such vector 
used a tetracycline-inducible promoter to drive RNA expression. Lately, there has been 
development of newer vector that surround a fragment of the gene between two opposing 
tetracycline-inducible T7 promoters (Wang et al., 2000; LaCount et al., 2000). The dual T7 
promoter system is applicable for both the procyclic and bloodstream forms of the parasite. 
It also possesses the advantage of also using a single construct to carry multiple genes, 
allowing simultaneous targeting (Motyka et al., 2004). However, it has been noted that the 
two  promoter  system  does  not  work  for  all  genes  (La  Count  et  al.,  2000).  Mutant 
phenotypes may not be seen due the fact that the genes chosen are non essential or because 
they have overlapping functions in other proteins. 
The T. brucei Functional Genomics Project (TrypanoFAN), funded by the Wellcome Trust, 
aimed to utilise the information from the T. brucei genome project to produce a research 
resource and systematic collection of mutants by targeted gene inactivation using RNAi 
(http://trypanofan.path.cam.ac.uk/). To date, 272 gene products have been assessed by the 
RNAi method. This represents the first systematic analysis of gene function in a parasitic 
organism (Subramaniam et al., 2006). 
With  the  completion  of  the  sequence  of  the  megabase  chromosomes  of  Trypanosoma 
brucei,  it  has  become  straightforward  to  design  primers  and  amplify  the  appropriate 
flanking sequences to knock out genes by homologous recombination (ten Asbroek et al., 
1990).  Homologous  recombination  in  biology  has  important  implications  for  growth, 
development and adaptation of all organisms. It has roles in DNA damage repair (van Gent 
et al., 2001), for the generation of genetic diversity (Masson & West, 2001), and to ensure 
chromosomal segregation at meiosis (Masson & West, 2001). In African trypanosomes 
homologous recombination has implications in the antigenic variation processes (Conway 
et al., 2002). Recombination is used to move new VSG genes into specialised bloodstream 
VSG  transcription  sites.  Genetic  and  molecular  evidence  has  suggested  that  antigenic 
variation uses homologous recombination; however the detailed reaction pathways are yet 
to be elucidated (Conway et al., 2002). Recently the techniques of stable transformation, 
exploiting the natural phenomenon of homologous recombination have been successfully 
applied  to  trypanosomes  (ten  Asbroek  et  al.,  1990).  Linearised  DNA  constructs, 
transfected  into  the  cell,  allows  replacement  of  a  gene  to  occur  by  homologous 
recombination. This means highly specific targeting of a chosen genomic locus. In the 
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achieve  stable  transformations  (Clayton,  1999);  the  blasticidin  (Izumi  et  al.,  1991), 
puromycin (Vara et al., 1986), neomycin (ten Asbroek et al., 1990), hygromycin B (Lee & 
van der Ploeg, 1991), and bleomycin (Jefferies et al., 1993) antibiotic resistance genes. 
The one pitfall of gene knockout experiments is to think that the product of an essential 
gene  is  automatically  a  good  drug  target.  Although  gene  knockout  removes  functional 
protein  from  the  cell,  that  level  of  inhibition  would  be  hard  to  achieve  with 
pharmacological  agents  because,  rarely  is  100%  inhibition  of  target  enzyme  activity 
achieved. 
1.10   Perspectives for Drug Targets 
A substantial proportion of research into trypanosomes over the past two decades has been 
devoted to target identification and development of lead compounds that interact with these 
targets (Barrett et al., 2003). A proven drug target is the well-known enzyme ornithine 
decarboxylase in T. brucei, inhibited by the suicide inhibitor DFMO (eflornithine) at the 
early  stages  of  the  polyamine  biosynthesis  pathway  (chapter  6).  Validation  in  vitro  is 
conditional  (polyamines  must  be  of  limiting  availability  in  medium),  whereas  under 
mammalian  physiological  conditions  (where  polyamines  are  scarce)  cell  death  is  a 
certainty. Turnover for ornithine decarboxylase in T. brucei gambiense is less rapid than in 
its mammalian host (Phillips et al., 1987), hence the parasite is deficient in polyamines for 
a prolonged period of time once the enzyme has been inactivated by DFMO. However, a 
functional immune system is also needed to clear parasites. 
The  first  seven  enzymes  of  the  glycolytic  pathway  reside  in  unusual  peroxisome-like 
organelles termed glycosomes (Michels et al., 2000). Glycolysis in the bloodstream form 
of Trypanosoma brucei provides a convenient context for studying the prospects for using 
enzyme inhibitors as antiparasitic drugs (Bakker et al., 1999; Bakker et al., 1999; Eisenthal 
et  al.,  1998).  Glucose  metabolism  and  the  glycosome  prove  an  attractive  target,  as 
bloodstream  African  trypanosomes  are  solely  dependent  on  glycolysis  for  their  ATP 
energy production needs. The kinetics of these glycolytic enzymes are known in detail as 
well as crystal structures of some enzymes of the pathway. Hence, the impetus has been 
“intelligent drug design” based on inhibitory molecules. However, it is usually the case 
that production of substrate analogues is the method of choice. This proves problematic, as 
novel  substrate  analogues  usually  do  not  out-compete  the  natural  substrate.  Binding  is 
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Hexose analogues may represent good compounds to inhibit glucose metabolism (chapter 
4) in trypanosomes. Several sugar analogues were developed in order to test the limits of 
the  structure-activity  relationship  of  the  THT1  hexose  transporter  in  bloodstream 
trypanosomes (Azema et al., 2004). THT1 is the principal hexose transporter exhibited by 
bloodstream form  Trypanosoma brucei. THT1 itself proves an attractive cellular target 
because it differs markedly from all of the mammalian GLUT transporters (Tetaud et al., 
1997). 
There  are  two  basic  metabolic  methods  of  killing  an  organism;  either  flux  through  an 
essential metabolic pathway can be decreased to the point where life is no longer possible, 
or a metabolite’s concentration can be increased to toxic levels (Eisenthal et al., 1998). The 
difference  being  that  decreasing  flux  need  not  be  accompanied  by  large  changes  in 
metabolite concentration and increases in metabolite concentration  may not necessarily 
lead to changes in flux. It all depends on the integrated enzyme system involved. 
Glucose is also metabolised by a second route, the pentose phosphate pathway (PPP); a 
pathway that does play a crucial role both in the metabolism of many parasitic protozoa 
and in the host's relationship with these organisms (Barrett, 1999). The pentose phosphate 
pathway of trypanosomes poses another attractive target mainly because of the fact that 
enzymes of that pathway are more closely related to cyanobacterial isoforms than they are 
to eukaryotes (Barrett et al., 2003). The PPP serves to convert glucose 6-phosphate (G6P) 
to ribose 5-phosphate (R5P), which is used in nucleotide biosynthesis. In some systems, it 
also provides other important phosphorylated carbohydrates, such as erythrose 4-phosphate 
(E4P), which serves as a precursor in the synthesis of aromatic amino acids and vitamins, 
as well as sedoheptulose 7-phosphate (S7P), an important component of some bacterial cell 
walls. The other key product of the pathway is NADPH, which serves as a hydrogen donor 
in reductive biosynthesis, and plays an integral role in the defence against oxidative stress. 
The enzyme 6-phosphogluconate dehydrogenase may prove to be a potential target for 
chemotherapy. This has been elucidated from the fact that in other eukaryotic organisms, 
absence  of  the  6PGDH  gene  has  been  shown  to  be  conditionally  lethal  (Barrett, 
unpublished).  The  Trypanosoma  brucei  6PGDH  gene  has  been  cloned  and  its  enzyme 
purified (Barrett, 1994). Subsequently, it has been found to not only have a number of key 
kinetic features that distinguish it from its mammalian counterpart but also interact with 
suramin and trivalent aromatic arsenoxides (Hanau et al., 1996). Recently, three series of 
inhibitors have been designed for this target. These include phosphorylated carbohydrate 
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triphenylmethane-based  compounds.  All  have  shown  selective  inhibition  of  the 
trypanosomal  6-phosphogluconate  dehydrogenase  and  representatives  of  each  have 
trypanocidal activity (Hanau et al., 2004). More recently, crystal structures of recombinant 
Lactococcus lactis 6-phosphogluconate dehydrogenase (LlPDH), which shares significant 
sequence identity with the enzymes from sheep liver and the protozoan parasite, have been 
determined  (Sundaramoorthy  et  al.,  2007).  Studies  through  complex  with  substrate, 
cofactor, product and inhibitors showed high conservations of key residues in the active 
site,  allowing  LlPDH  to  serve  as  a  model  system  for  further  structure-based  inhibitor 
design. 
Thiol metabolism is also a much studied system in trypanosomes (Comini et al., 2004). 
The  role  of  glutathione  in  most  eukaryotes,  is  undertaken  by  a  unique  low  molecular 
weight  thiol  called  trypanothione  (N
1,N
8-bis-glutathionylspermidine).  Low  molecular 
weight thiols contribute to defence against reactive oxygen species, which arise internally 
through the normal respiration or from the host. The biosynthetic pathway of trypanothione 
consists  of  two  steps;  formation  of  glutathionylspermidine  from  spermidine  and 
glutathione by glutathionylspermidine synthetase, and the formation of trypanothione from 
glutathionylspermidine  and  glutathione  by  trypanothione  synthetase  (Fairlamb  et  al., 
1990). The enzymes of trypanothione biosynthesis are also potential targets for drug design 
(Schmidt et al., 2002), due to the fact that dithiol trypanothione has many downstream 
cellular  processes  including  DNA  synthesis,  ascorbate  regulation,  and  detoxification  of 
hydrogen peroxides. 
1.11   Drug Uptake via Nutrient Transporters 
Drug uptake via nutrient transporters is the one field that has received a lot of interest in 
recent times (Barrett & Gilbert, 2006). Trypanosoma brucei, in comparison to the other 
trypanosomes which reside intracellularly, is in the privileged position of being exposed in 
the bloodstream. Privileged from a drug design point of view meaning potential drugs do 
not have to cross mammalian cell membranes prior to reaching their target. A dense coat of 
variant surface glycoprotein (VSG) prevents complement from reaching the membrane and 
immunoglobulin from “seeing”  membrane proteins (Borst &  Fairlamb,  1998). There is 
sufficient space between VSG dimers to allow low molecular weight compounds to reach 
transporters in the membrane. This has the added advantage of allowing selective targeting 
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the case of the TbAT1 nucleoside transporter, P2 (Barrett & Gilbert, 2006; Carter et al., 
1995; Carter & Fairlamb, 1993).  
The role of the P2 transporter was discovered when it was found that Trypanosoma brucei 
cultures  selected  for  resistance  to  melamine  based  arsenicals  had  lost  this  transporter 
(Carter & Fairlamb, 1993). The trypanosomal gene TbAT1 has been found to encode the P2 
adenosine/adenine transporter (Maser et al., 1999; Matovu et al., 2003). Diamidine and 
melamino phenyl arsenical entry into the cell, via this transporter, is due to the similarity in 
recognition motifs between diamidines and arsenicals and the transporter’s normal amino-
purine substrates (Tye et al., 1998; Barrett & Fairlamb, 1999; de Koning et al., 1999). The 
6-amino group of the purine ring, attached to a carbon, in turn bound via a double bond to 
a nitrogen is crucial for recognition. Identification of this recognition motif has led to the 
development of cytotoxic molecules with that motif grafted on (Tye et al., 1998). Several 
compounds  have  been  identified  through  the  empirical  route  and  are  getting  some  use 
(Barrett  et al., 2002).  For example, the triazine derivative SIPI 1029 is used in China 
against Trypanosoma evansi infections in domestic livestock, as well as another inhibitor 
of  polyamine  biosynthesis:  CGP40215,  which  interacts  via  S-adenosylmethionine 
decarboxylase. 
In general, exploitation of nutrient transport systems for delivery of new drugs needs to 
confer to several key conditions; namely selectivity and efficacy. More specifically, there 
needs to be high affinity of the trypanocide for the particular transporter, coupled with low 
affinity for the mammalian transporter. Furthermore, there needs to be low abundance of 
competing substrates and ideally there needs to be concentrative rather than equilibrative 
uptake (Hasne & Barrett, 2000; Barrett & Fairlamb, 1999; De Koning et al., 1999). The P2 
purine  transporter,  thus  far,  appears  to  satisfy  these  two  conditions  but  has  one  major 
disadvantage:  the  fact  that  the  parasite  can  lose  this  transporter  without  compromising 
viability. Therefore, developing resistance without a loss in virulence. Hence, new routes 
of drug delivery are essential. 
1.12   Transport Phenomena across Membranes 
A cell or an organelle cannot be either wholly open or wholly closed to its surroundings. 
Its interior must be protected from certain toxic compounds, and yet metabolites must be 
taken in and waste products removed. As well as uptake of nutrients, all communication 
among cells and between cells and their environment must occur through the membrane 
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hydrocarbon tail of the lipid molecules allows bilayer formation rather than the micelle 
formation  that  would  occur  with  the  single  tail.  Lipids  are  the  major  constituents  of 
biological membranes with glycerophospholipids, sphingolipids, glycosphingolipids, and 
glycoglycerolipids the four main classes of membrane-forming lipids. Membrane fluidity 
is essential for all living cells. At low temperatures, the head groups and hydrocarbon tails 
pack closely, forming an almost solid gel state. As the temperature increases the membrane 
“melts” and becomes thinner as a more fluid state is adopted. 
For essential small molecules, such as amino acids, sugars and ions, crossing the plasma 
membrane  is  through  the  action  of  integral  membrane  protein  pumps,  channels,  or 
transporters.  Internalisation  of  particles,  macromolecules  and  solutes  occurs  by 
endocytosis. This involves the membrane folding around material on the outside the cell 
(Conner & Schmid, 2003). Vesicles are then pinched off from the cell surface so that it lies 
within the cell. Endocytosis can be separated into pinocytosis and phagocytosis. These two 
can  be  distinguished  from  one  another  by  the  size  of  particle  ingested  and  by  its 
dependence on actin polymerization (Liu & Shapiro, 2003). Phagocytosis can be described 
as “cell eating” (the uptake of large particles) whereas pinocytosis or “cell drinking” can be 
described as the uptake of fluids and solutes. 
Three categories of transport across biological membranes exist – passive, facilitated and 
active. All have quite different properties and serve different purposes for the cell. There is 
an equilibrium approached by transport across any membrane. That is, a substance that can 
traverse  the  membrane  will  eventually  reach  the  same  concentration  on  both  sides, 
meaning  no  net  transport.  This  equalisation  can  only  be  circumvented  under  certain 
conditions; preferential binding and subsequent modification of substrate upon transport, 
membrane  potential  that  influences  the  distribution  of  ions,  or  coupling  of  a 
thermodynamically favoured process to transport. 
It has been said that transporters cannot catalyse an increase in the rate of biomembrane 
transport to near that which would occur if simple diffusion across the membrane was 
possible (Van Winkle, 1999). Passive transport is essentially diffusion and occurs via the 
random  motion  of  molecules  (Brownian  motion).  This  leads  to  equilibrium  of  free 
concentration across the membrane. The net rate of transport depends on the concentration 
difference  across  the  membrane  –  the  higher  the  difference,  the  higher  the  net  rate. 
However, with hydrophilic substances, diffusion occurs very slowly due to the insolubility 
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Facilitated transport, sometimes called accelerated diffusion, occurs via two methods – 
pores,  formed  by  transmembrane  proteins,  or  by  carrier  molecules.  Pore  formation 
increases  the  diffusion  rate  by  a  large  order  of  magnitude.  Carrier  facilitated  transport 
effectively increases the solubility of its substrate in the membrane. Flow is never directed 
and  thus  can  occur  in  both  directions.  The  distinguishing  feature  of  both  types  of 
accelerated diffusion  methods is the fact that carrier facilitated diffusion is a saturable 
process,  due  to  the  fact  that  there  is  a  limited  number  of  carrier  molecules  within  a 
membrane system. Whereas the rate of passive diffusion can increase linearly with the 
concentration difference. 
Active  Transport  is  transport  of  a  substrate  against  its  concentration  gradient  and  this 
requires a free energy source. The free energy source comes from the hydrolysis of ATP. 
Coupling of the energy to the transport process can either be direct or indirect. Ion pumps 
directly couple the hydrolysis of ATP to transport, with a subunit of the protein being 
enzymatically active. The pump exists in two conformational states – open to the cytosol 
and open to the cell exterior. Transition between the states is directly linked to the free 
energy change. Transition to the cytosol-open state is triggered by the binding of ATP and 
release of phosphate, whereas transition to the outside-open state occurs when ADP is 
released. 
The  other  form  of  active  transport  does  not  depend  directly  on  ATP  but  employs  the 
hydrolysis of ATP in an indirect way. In this instance, a favourable gradient is used to 
drive the transport of another molecule against its unfavourable concentration gradient. 
Transport  of  both  molecules  can  occur  in  the  same  direction  (symport)  or  in  opposite 
directions (antiport). 
One other method that achieves transport against a concentration gradient is transport by 
modification. Upon moving into a cell by diffusion the molecule is modified in a way that 
prohibits its exit through the membrane. The modified molecule accumulates within the 
cell but the apparent concentration gradient is maintained. 
1.13   Amino Acid Transporters 
Protein  phylogeny,  based  upon  primary  amino  acid  sequence  relatedness,  reflects  the 
evolutionary  process  and  therefore  provides  a  guide  to  structure,  mechanism  and 
underlying function (Chang et al., 2004). Any two proteins that are related by a common 
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sequence similarity. The transporter classification system (TC) (http://www.tcdb.org) has 
been adopted based on similarity between transporters (Busch & Saier, 2003; Busch & 
Saier, 2004). This employs computational methods to determine distant relationships. In 
general,  transporter  types  can  be  distinguished  according  to  phylogeny,  substrate 
specificity, transport mechanism and cell specificity. Amino acids and their derivatives are 
known  to  be  transported  by  21  families  of  secondary  carriers,  13  families  of  ATP-
dependent transporters, and 3 families of channel proteins (Saier, 2000). 
The primary modes of transport with transporters of amino acids and their derivatives have 
always  been  thought  to  involve  channels  and  carriers  (Saier,  2000)  with  most  being 
secondary  carriers.  Mechanisms  of  channel  transport  are  well  understood  whereas  the 
carrier  system  is  still  unclear.  This,  in  large  part,  is  due  to  the  availability  of  high-
resolution three-dimensional structural data for channel systems. 
Work by Saier has provided a comprehensive guide to the diversity of carriers that mediate 
the transport of amino acids across membranes. The range of substrates transported by an 
individual member of a family can be narrow or broad and structural similarity in substrate 
is not a requirement. With regards to energy-coupling mechanisms employed for transport, 
amino  acid  transporters  use  chemical  energy  in  the  form  of  ATP  and  electrochemical 
energy stored in favourable ion gradients (H
+, Na
+). Syntheses, activities, and degradation 
of  amino  acid  transport  proteins  are  similar  to  the  mechanisms  employed  for  other 
transport  proteins  and  cytoplasmic  enzymes.  Classification  and  characterisation  of 
transporter  families  from  studies  have  shown  underlying  evolutionary  traits.  Transport 
mode and energy coupling mechanisms are highly conserved, protein topology, polarity of 
transport and substrate specificity are conserved to an intermediate degree, whereas the 
regulatory mechanisms imposed on transporters are poorly conserved (Saier, 2000). 
Conserved  amino  acid  transporters  among  three  sequenced  eukaryotic  genomes  – 
Saccharomyces cerevisiae, Arabidopsis thaliana and Homo sapiens showed transporters 
belonging to five different superfamilies: amino acid/polyamine/organocation transporter 
superfamily (APC), sodium/dicarboxylate symporter superfamily (SDS), neurotransmitter 
superfamily  (NTS),  amino  acid  transporter  superfamily  1  (ATF1),  and  the  amino  acid 
transporters within major facilitator superfamily (MFS) (Wipf et al., 2002). 
Classified among the transporter superfamilies is the amino acid/polyamine/organocation 
(APC) superfamily, which includes proteins that function as solute-cation symporters and 
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several related, or even a wide spectrum of structurally different amino acids including 
sometimes D-isomers (Wipf et al., 2002). APC transporters are ubiquitous; homologues 
are found in animals, plants and bacteria but are best understood in yeast. Amino acid 
transport mediated by members of the APC family is diverse; has functions in uptake and 
nutrition and is ion coupled with all members  catalysing transport using a monovalent 
cation symport mechanism (Chang et al., 2004). In multicellular organisms they might 
function  as  exchangers  for  both  selective  accumulation  of  specific  amino  acids,  and 
redistribution and homeostasis of the intracellular concentrations. The majority of proteins 
exhibit uniform topology with twelve transmembrane α-helical domains (Jack et al., 2000) 
although exceptions to this trend do exist. 
Distantly  related  to  the  APC  superfamily  are  the  amino  acid/auxin  permease  family 
(AAAP) and the hydroxyl and aromatic amino acid porter family (HAAAP). The AAAP 
family includes hundreds of proteins from plants, animals, yeast and fungi. They exhibit 
very broad specificities as well as transporting D-isomers. The proteins have 11 putative 
transmembrane spanning domains and show limited sequence similarity with members of 
the  large  APC  superfamily  (Saier,  2000).  The  HAAAP  family  is  found  exclusively  in 
bacteria,  transporting  aromatic  amino  acids,  but  show  topological  features  common  to 
members of the eukaryotic AAAP family. 
The sodium/dicarboxylate symporter superfamily (SDS) and neurotransmitter superfamily 
(NTS)  are  exclusive  to  animal  genomes,  with  no  homologues  found  in  yeast  or  plant 
genomes. SDS members mediate electrogenic  glutamate and aspartate uptake and their 
proteins  contain  10  putative  membrane  spanning  domains  (Wipf  et  al.,  2002).  NTS 
members  share  a  common  structure  with  12  transmembrane  domains  and  include 
membrane carriers for γ-aminobutyric acid (GABA), proline and glycine. 
ATF1 family members were first seen in plants with homologues later found in yeast and 
animals. Membrane domains differ from 9-11 segments. This superfamily contains plant-
specific sub-branches and branches that are more related to yeast and human transporters 
(Wipf et al., 2002). 
Within two subfamilies of the major facilitator superfamily (MFS) amino acid transporters 
were found. MFS proteins transport a wide spectrum of substances unrelated to amino 
acids,  including  sugars,  polyol  drugs,  neurotransmitters,  phosphorylated  glycolytic 
intermediates,  peptides,  nucleosides  and  organic  anions  (Saier,  2000).  They  employ 
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2002). They are ubiquitous in all three domains of organism and each of the 29 currently 
recognised families is specific for one class of compound. 
1.14   Human Amino Acid Transporters 
Mammalian amino acid transporters consist of a complex system allowing amino acids to 
be  transported  through  a  number  of  different  carrier-proteins  exhibiting  overlapping 
specificity. In general, they are divided into Na
+-dependent and Na
+-independent groups. 
The  mammalian  amino  acid  carrier  proteins  belong  to  different  gene  families,  exhibit 
overlapping but distinctive substrate specificities, and can further be distinguished by their 
requirement for the co-transport or counter-transport of inorganic ions (Closs et al., 2004). 
The  main  functional  criteria  used  to  define  amino  acid  transporters  in  mammals  are 
substrate specificity and the thermodynamic properties of transport (Palacin et al., 1998). 
One of the first amino acid transport systems described for mammalian cells was a Na
+-
independent system termed System L (Kilberg et al., 1993), named ‘L’ because of its high 
affinity for leucine, it is also able to transport large apolar branched amino acids, catalysing 
exchange of amino acids rather than net uptake. 
System A, originally described four decades ago is a pH-dependent transporter of alanine, 
glycine and proline  (Oxender & Christensen, 1963). The activity of this system is pH 
dependent and is expressed in response to substrate deprivation. There is the suggestion 
that it provides the concentrations of cytosolic amino acids necessary to drive the uptake of 
other amino acids by exchange through other systems. Unusually, System A recognises N-
methylated amino acids and can tolerate the substitution of Na
+ with Li
2+ (Christensen et 
al., 1965). Other homeostatic roles have been implicated in its repertoire and it has been 
shown that in many cell types its activity is highly regulated, including upregulation during 
cell-cycle progression and hormonal control (Palacin et al., 1998). 
System  Gly,  first  identified  in  isolated  rat  hepatocytes  that  were  shown  to  contain  a 
glycine specific system (Christensen & Handlogten, 1981), occurs in several cell types 
(Eavenson & Christensen, 1967). Glycine and sarcosine are the two known substrates for 
this system with a strict dependence on Na
+ and Cl
- availability. The hepatic System Gly is 
Na
+-dependent and appears to transport two sodium ions for each glycine (Kilberg et al., 
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System  N,  called  System  N  to  reflect  an  apparent  affinity  for  neutral  amino  acids 
containing  nitrogen-bearing  side  chains,  is  involved  in  the  Na
+-dependent  uptake  of 
glutamine and histidine and other amino acids with nitrogen in their side chain (Kilberg et 
al., 1980). Present mainly in liver cells, it has been suggested that a System N-like activity 
is  an  important  component  of  histidine-induced  gastric  acid  secretion.  It  has  high  pH 
sensitivity and resembles System A in sequence but differs in mechanism (Reimer et al., 
2000). 
System  ASC  shows  variable  pH  dependency  for  transport  of  the  amino  acids  alanine, 
serine, cysteine, and threonine but also recognises other aliphatic amino acids. Although 
Na
+  dependent,  System  ASC  appears  to  mediate  amino  acid  exchange  rather  than  net 
uptake (Reimer et al., 2000). 
System  β β β β  is  used  to  transport  taurine  and  alanine  in  erythrocytes,  cardiac  muscle  and 
kidney, with differences in substrate affinity and specificity (Miyamoto et al., 1990). 
Systems y
+, B
0,+, b
0,+, b
+ and y
+L are the five transport systems that mediate the uptake of 
cationic amino acids (Palacin et al., 1998). System y
+ is the most widespread, transporting 
lysine, histidine and arginine in a selective sodium independent manner. The rest have 
been described only in specific tissues. System B
0,+ is found in only blastocysts and oocyte 
fibroblasts  and  transports  alanine,  valine  and  lysine.  System  b
0,+  shows  similarity  to 
System  B
0,+  but  is  only  found  in  kidney,  small  intestine  and  blastocysts.  System  y
+L 
transport neutral amino acids, with Na
+ dependency, while for lysine transport there is no 
sodium requirement. Systems b
0,+ and y
+L are the result of activity of heteromeric amino 
acid transporters, meaning transporter activity is elicited by coexpression of a heavy and 
light subunit (Palacin et al., 2001). 
Conversely,  the  two  acidic  amino  acids,  glutamate  and  aspartate  are  transported  into 
mammalian cells via five different transporters: ASC, GLT-1 (Glutamate transporter 1), 
GLAST (Glutamate/aspartate transporter), EAAT4 (excitatory amino acid transporter 4) 
and EAAC1 (excitatory amino acid carrier 1). Recently, it has been found that glutamate 
transporters in the mammalian central nervous system exhibit glutamate-gated chloride-
channel activity in addition to glutamate-transport activity (Slotboom et al., 2001). The 
physiological  function  of  this  chloride-channel  activity  is  still  unknown,  however,  an 
excitatory response might be a consequential result. The transporters remove the excitatory 
neurotransmitter  glutamate  from  the  synaptic  cleft  driven  by  the  sodium/potassium 
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Mammalian cells express many amino acid transport systems which differ in mechanism 
and substrate specificity (Ganapathy  et al., 2004). Many  are needed because no single 
transport system can satisfy the structural requirements to take up all the different amino 
acids. The fact that amino acid requirements differ for each cell type means that expression 
profiles  of  transport  systems  will  also  differ.  The  potential  for  any  given  amino  acid 
transport system will depend on its substrate specificity and its tissue expression profile 
(Ganapathy & Ganapathy, 2005). Different cells contain a distinct set of transport systems, 
as a combination of common or almost ubiquitous (Systems A, ASC, L, and y
+) and tissue-
specific (systems B
0,+, N
m, and b
0,+) transport systems (Palacin et al., 1998). The vast range 
of  amino  acid  transporters  with  overlapping  substrate  specificities  means  uptake  of  a 
particular amino acid within a given type of cell is always as a function of many different 
transporters. 
1.15   Amino Acids & Trypanosomes 
In  yeast,  animals  and  plants  amino  acids  play  an  essential  role  in  various  processes, 
including protein synthesis, hormone metabolism, cell signalling, nerve transmission, cell 
growth,  osmoregulation,  cell  cycling,  production  of  metabolic  energy,  nucleobase 
synthesis, nitrogen metabolism and urea biosynthesis. The digenetic life cycle of T. brucei, 
which involves a complex development of morphologically distinct forms in the insect 
vector and the mammalian host, indicates that the parasites are exposed to ever changing 
environments (Besteiro et al., 2005). Of the three trypanosomatids, T. brucei has the most 
restrictive  metabolic  repertoire,  reflecting  its  extracellular  bloodstream  form  life  cycle 
(Berriman et al., 2005), which has greater access to nutrients in the plasma. Trypanosomes 
lack biosynthetic pathways for the essential amino acids and the procyclic form requires 
exogenous proline as an energy source. 
Plants and fungi can synthesise each of the 20 amino acids by using biosynthetic pathways 
inherited from their bacterial ancestors and the ability to synthesise the nine amino acids 
(Phe, Trp, Ile, Leu, Val, Lys, His, Thr, and Met) was lost in a wide variety of eukaryotes 
that evolved to feed on other organisms (Payne & Loomis, 2005). The genome of the 
African trypanosome (Berriman et al., 2005) has revealed that most of the enzymes of the 
classical  pathways  for  aromatic  amino  acid  oxidation  are  missing.  Conversion  of 
phenylalanine to tyrosine does not occur in T. brucei, due to the fact that it does not have 
the  enzyme  phenylalanine-4-hydroxylase.  All  trypanosome  species  have  genes  for 
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found that aromatic amino acids were the preferred amino donors for the transamination of 
α-ketomethiobutyrate to methionine (Berger et al., 1996). The transamination of aromatic 
amino acids is essential to regenerate methionine from α-ketomethiobuytrate (KMTB), an 
end product of S-adenosylmethionine from the synthesis of polyamines. 
Catabolism of histidine is absent in T. brucei and a functional urea cycle is missing across 
the trypanosomes. Branched chain amino acids can be converted to acetyl-CoA derivatives 
within the mitochondria. 
In  T.  brucei,  threonine  is  not  oxidised  via  the  2-oxobutyrate  pathway,  instead  being 
degraded to acetyl-CoA and glycine by a mitochondrial specific threonine dehydrogenase. 
Threonine has been found to be a precursor for acetate (which feeds into lipid biosynthesis, 
Figure 4) in Trypanosoma brucei (Cross et al., 1975). There is cleavage of threonine to 
form glycine and acetate within the mitochondrial compartment. Preliminary examination 
of changes in medium amino acid levels during growth of Trypanosoma brucei revealed 
complete utilisation of threonine (Cross et al., 1975). 
Alanine was found to be the most abundant amino acid present in T. gambiense (Chappell 
et al., 1972). Cysteine is an essential growth factor for bloodstream form trypanosomes and 
is  involved  in  protein  biosynthesis  as  well  as  in  the  production  of  glutathione  and 
trypanothione (Duszenko et al., 1992). Cysteine essentiality was discovered by  mishap 
when cysteine was added into the culture medium instead of cystine (Cross & Manning, 
1973).  In  a  mammalian  culture  system,  feeder  cells  can  take  up  cystine  and  excrete 
cysteine,  which  is  otherwise  toxic  to  the  cells  being  cultured.  Cross  &  Manning 
demonstrated that the addition of cysteine eliminated the feeder-cell requirement for T. 
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Figure 1-4: Schematic representation of carbon source metabolism in the procyclic form of 
T. brucei (taken from Lamour et al., 2005). 
Enzymatic steps of D-glucose and L-threonine metabolism are represented by gray arrows, 
while those for L-proline are represented by black arrows. Excreted end products (acetate, 
L-alanine,  L-glycine,  lactate,  succinate,  and  CO2)  are  in  white  characters  on  a  gray 
background (from D-glucose and L-threonine metabolism) or on a black background (from 
L-proline  metabolism).  The  metabolic  flux  at  each  enzymatic  step  is  tentatively 
represented by arrows with different thicknesses. Dashed arrows indicate steps which are 
supposed to occur at a background level or not at all, under the standard growth conditions 
(glucose-rich  medium).  The  enzymatic  reaction  leading  to  the  production  of  lactate 
(possibly  from  pyruvate)  is  not  known  and  is  indicated  by  a  question  mark.  The 
glycosomal and mitochondrial compartments and the tricarboxylic acid cycle (TCA) are 
indicated.  The  underlined  and  boxed  ATP  molecules  are  produced  by  substrate  level 
phosphorylation  and  oxidative  phosphorylation,  respectively.  The  circled  metabolites 
(phosphoenol- pyruvate (PEP), pyruvate, and acetyl-CoA) are located at a branching point. 
Abbreviations:  AA,  amino  acid;  AOB,  amino  oxobutyrate;  1,3BPGA,  1,3-
bisphosphoglycerate;  C,  cytochrome  c;  Cit,  citrate;  CoASH,  coenzyme  A;  DHAP, 
dihydroxyacetone phosphate; F-6-P, fructose 6-phosphate; FBP, fructose 1,6-bisphosphate; 
G-3-P, glyceraldehyde 3-phosphate; G-6-P, glucose 6-phosphate; GLU, glutamate; Gly-3-
P, glycerol 3-phosphate; IsoCit, isocitrate; 2Ket, 2-ketoglutarate; OA, 2-oxoacid; Oxac, 
oxaloacetate;  3-PGA,  3-phosphoglycerate;  Pi,  inorganic  phosphate;  PPi,  inorganic 
pyrophosphate;  γ-SAG,  glutamate  γ-semialdehyde;  SucCoA,  succinyl-CoA;  UQ, 
ubiquinone  pool.  Enzymes  are  as  follows:  1,  hexokinase:  2,  glucose-6-phosphate 
isomerase; 3, phosphofructokinase; 4, aldolase; 5, triose-phosphate isomerase; 6, glycerol-
3-phosphate  dehydrogenase;  7,  glycerol  kinase;  8,  glyceraldehyde-3-phosphate 
dehydrogenase; 9, phosphoglycerate kinase; 10, phosphoglycerate mutase; 11, enolase; 12, 
pyruvate  kinase;  13,  phosphoenolpyruvate  carboxykinase;  14,  pyruvate  phosphate 
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dependent fumarate reductase; 18, glycosomal adenylate kinase; 19, malic enzyme; 20, 
alanine  aminotransferase;  21,  pyruvate  dehydrogenase  complex;  22,  acetate:succinate 
CoA-transferase; 23, unknown enzyme, possibly acetyl-CoA synthetase; 24, succinyl-CoA 
synthetase;  25,  citrate  synthase;  26,  aconitase;  27,  isocitrate  dehydrogenase;  28,  2-
ketoglutarate  dehydrogenase  complex;  29,  succinate  dehydrogenase  (complex  II  of  the 
respiratory chain); 30, mitochondrial fumarase; 31, mitochondrial malate dehydrogenase; 
32,  proline  dehydrogenase;  33,  pyrroline-5  carboxylate  dehydrogenase;  34,  glutamate 
aminotransferase;  35,  glutamate  dehydrogenase;  36,  L-threonine  dehydrogenase;  37, 
acetyl-CoA:glycine C-acetyltransferase; 38,  glycerol-3-phosphate oxidase; 39, rotenone-
insensitive NADH dehydrogenase; 40, alternative oxidase; 41, F0/F1-ATP synthase; I-IV, 
complexes of the respiratory chain. 
 
Proline is the principal source of carbon and energy of procyclic forms provided glucose is 
absent (Lamour et al., 2005; Evans & Brown, 1972; L’Hostis et al., 1993). The proline 
ring is opened up and oxidised to α-ketoglutarate and subsequently to succinate which 
forms  part  of  the  Kreb’s  Cycle  (Figure  1-4).  Proline  has  also  been  implicated  in  the 
differentiation  from  the  non-infective  to  the  infective  stage  within  the  insect  vector 
(Contreras  et  al.,  1985).  Within  the  tsetse  fly,  proline  is  the  principal  energy  source 
(Balogun, 1974), as the digestive contents of the gut are rich in amino acids but lacking in 
glucose. Proline metabolism has been studied in procyclic form Trypanosoma brucei and 
its implications with glucose availability are intertwined (Lamour et al., 2005; chapter 4). 
Trypanosomes  seem  to  be  able  to  use  proline  as  an  energy  source  in  the  absence  of 
glucose. Similarly, Leishmania donovani has adapted to the extreme changes in proline 
environments, from the sandfly  gut to the mammalian intracellular environment. Three 
proline transport systems have been identified in axenic cultures of Leishmania donovani 
(Marazeb  et  al.,  1999).  Systems  A  and  B  are  cation  dependent  and  independent  in 
promastigotes,  respectively.  Whereas,  System  C  is  cation  independent  in  amastigotes. 
Proline uptake in procyclic forms of the African trypanosome has been shown to be carrier 
mediated with an apparent Km of 21 +/-2.9 µM and a Vmax of 7.0 nanomoles/min/10
8 cells. 
This level of uptake is modulated by the presence or absence of glucose in the growth 
media (Lamour et al., 2005, chapter 4). 
Methionine  is  involved  in  protein  synthesis  and  is  a  primary  sub-unit  source  in  the 
polyamine biosynthetic pathway. Methionine uptake in procyclic and bloodstream form 
trypanosomes has been shown to be mediated by a similar transporter with a high affinity 
(Hasne & Barrett, 2000). Exogenous methionine is adenosylated by S-adenosylmethionine 
synthase  to  form  S-adenosylmethionine  (AdoMet).  AdoMet  is  a  key  metabolite  in 
transmethylation reactions and its decarboxylated derivative provides aminopropyl group 
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The  by-product  of  polyamine  synthesis  is  5’-methylthioadenosine  (MTA).  MTA  is 
enzymatically degraded to adenine and 5’-methylthioribose-1-phosphate, a carbohydrate 
intermediate that is recycled to methionine in the methionine cycle (Goldberg et al., 1997; 
Berger et al., 1996). 
African  trypanosomes  have  been  proposed  to  exhibit  a  dedicated  transporter  for  S-
adenosylmethionine that is independent of methionine uptake (Goldberg et al., 1999). This 
has been shown by challenging uptake of AdoMet with methionine and compounds which 
compete with adenosine for transport. Goldberg et al found that neither methionine nor 
adenosine analogues significantly inhibited AdoMet uptake. However, certain aspects of 
their methodology do not stand up to criticism. Challenging compounds were never in 
excess  within  the  uptake  assay  (Goldberg  et  al.,  1997).  A  unique  transporter,  highly 
specific  for  AdoMet,  was  not  confidently  shown  and  was  only  assumed  from  other 
compounds (not in excess concentrations) not inhibiting AdoMet uptake. 
1.16   Amino Acid Transporters in Trypanosomes 
The metabolism of the protozoan parasites of the Trypanosoma and Leishmania genus is, 
in  general,  strongly  based  on  amino  acid  consumption  (the  BSF  African  trypanosome 
being an exception). Amino acid transporters are key to this process. However, amino acid 
transporters can provide another function – as environmental sensors (Holsbeeks et al., 
2004).  The  duality  of  the  life  cycle  of  these  parasites  requires  that  changes  in  its 
surrounding environment be observed. Membrane proteins, including transporters, are the 
first cell proteins to come into contact with its surrounding  environment and therefore 
provide the cues for many downstream cell processes. 
Most  work  in  the  area  of  amino  acid  transporters  in  trypanosomatids  only  deals  with 
general uptake and biochemical characterisation of uptake. Only recently have researchers 
gone  on  to  isolate  or  characterise  transporters  or  transport  systems.  RNAi  and  gene-
knockout are methods that allow a specific gene to phenotype characterisation, yet have 
gone unused by much of the research into amino acid transport to date. 
Since around 5-10% of the genes of most organisms encode membrane transporters, there 
is likely to be in the order of 400 membrane transporters in Trypanosoma brucei. Amino 
acid  transporters  constitute  one  of  the  largest  families  of  permeases  in  the  genome 
(Berriman  et  al.,  2005).  A  family  of  amino  acid  transporters  exist  with  overlapping 
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genome  project.  One  amino  acid  transporter,  TbAATP1,  has  been  preliminarily 
characterised by RNAi (Accoceberry & Barrett, unpublished data). This transporter has 
been shown to be a transporter of small uncharged amino acids (serine, threonine, alanine, 
glycine, cysteine and asparagine), with uptake of these amino acids being repressed in cell 
lines that contained down-regulation of this transporter (chapter 3). With the use of uptake 
assays  to  screen  potential  trypanocidal  amino  acid  analogues  and  RNAi  cell  lines  of 
parasites with reduced transporter activity, more insight into the role of this transporter can 
be gained, not only in the identification of trypanocidal properties of amino acid analogues 
but also in the uptake mechanisms involved. 
Work has also been published on the family of amino acid transporters in Leishmania and 
Trypanosoma cruzi. Work done on Leishmania donovani revealed genus specific motifs as 
well as motifs common across the trypanosomatidae family (Akerman et al., 2004). A 
large number of amino acid transporters have been located in the T. cruzi genome (Bouvier 
et al., 2004). The tandem organisation of such genes seems to be a feature common to 
trypanosomatidae. Whereas in Trypanosoma brucei there is indication of the presence of a 
family  of  amino  acid  transporters  with  broad  substrate  specificity,  the  substrate 
specificities  for  T.  cruzi  and  Leishmania  remain  unclear,  although  in  the  case  of 
Leishmania, developmental regulation has been shown to be exhibited for one amino acid 
transporter gene (Geraldo et al., 2005) as well as for general proline transport (Mazareb et 
al., 1999). 
In Trypanosoma brucei, amino acid transport has been studied since the 1970’s. These 
studies highlighted the potential of the amino acid transport system as drug targets. The 
aim  was  to  separate  various  trypanosomal  carriers  from  each  other  by  kinetic  means, 
showing a transport system specific for neutral amino acids (Owen & Voorheis, 1975). 
Amino  acid  transport  was  divided  into  certain  systems;  the  neutral  amino  acid  carrier 
mediating transport of glycine, alanine, serine and threonine, the second neutral amino acid 
carrier mediating transport of valine, leucine, proline and methionine, the first acid amino 
acid carrier mediating transport of glutamic acid, and the first basic amino acid carrier 
mediating lysine transport (Voorheis, 1973). With the vast information now available on 
the genome we know there is a more complex story at play, with many transporter genes 
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1.17   Genes of the Amino Acid Transporter Family 
The amino acid transporter family constitutes one of the largest families of permeases in T. 
brucei.  From  the  genome  database  46  amino  acid  transporter  genes  were  identified 
(including  3  pseudogenes)  in  T.  brucei,  however,  only  38  were  initially  annotated 
(Berriman et al., 2005). 
 
Figure 1-5: Amino acid permeases from L. major, T. brucei and T. cruzi, respectively (taken 
from Berriman et al., 2005). 
In L. major 3 belong to the amino acid/polyamine/organocation transporter superfamily 
(APC), 26 to the amino acid/auxin permease family (AAAP), with no lysosomal cystine 
transporter members present. In T. brucei 3 belong to the APC family, 35 to the AAAP 
family and no LCT family members are present. In T. cruzi 8 belong to the APC family, 32 
to the AAAP family and 2 to the LCT family. 
 
Large amino acid transporter gene families have been identified across the trypanosomatid 
species (Bouvier et al., 2004; El-Sayed et al., 2005; Jackson, 2007; Berriman et al., 2005). 
Biochemical characterisation of amino acid transport has been studied but no study has 
linked transport to a specific genomic locus. It is clear that the genomic repertoire far 
exceeds biochemical characterisation, especially given the fact that transport of a particular 
amino acid can be shared with other structurally or functionally similar amino acids. 
A systematic approach was taken to the assessment of the origin of those genes as well as 
associations with homolog genes in the other trypanosomatid species (Jackson, 2007). The 
large number of amino acid transporter genes and the fact that they are often arranged in 
arrays  point  to  mechanisms  by  which  new  loci  originated  during  evolution.  It  seems 
possible  that  the  multitude  of  diverse  amino  acid  transporter  repertoires  enables 
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modulation of incoming amino  acids in response to environmental changes. The study 
undertaken  by  Jackson  applied  a  comparative  approach  to  gene  family  evolution, 
investigating the mechanisms responsible for loci differences between species. Charles E. Ebikeme, 2007     Chapter 1, 40 
 
Parallel Classifications 
Gene I.D. 
AATP# 
(from GeneDB) 
AAT 
Locus 
Tb927.8.7610  AATP1  AAT7 
Tb927.8.7620  AATP1  AAT7 
Tb927.8.7630  AATP1  AAT7 
Tb927.8.7640  AATP1  AAT7 
Tb927.8.7660  AATP1  AAT7 
Tb927.8.7600    AAT7 
Tb927.8.7650    AAT7 
Tb927.8.7670    AAT7 
Tb927.8.7690    AAT7 
Tb927.8.7680    AAT7 
Tb927.8.7700    AAT7 
Tb927.4.4830    AAT4 
Tb927.4.4850    AAT4 
Tb927.4.4870    AAT4 
Tb927.4.4840  AATP7  AAT4 
Tb927.4.4820  AATP10  AAT4 
Tb927.4.4860  AATP8  AAT4 
Tb927.4.3990    AAT2 
Tb927.4.4000    AAT2 
Tb927.4.4010    AAT2 
Tb927.4.4020    AAT2 
Tb927.8.8290  AATP5  AAT10 
Tb927.8.8300    AAT10 
Tb11.017590    AAT17 
Tb11.01.7600    AAT17 
Tb927.6.4660  CAATP  - 
Tb927.8.5450    AAT6 
Tb09.211.1760    AAT11 
Tb10.6k15.0450    AAT14 
Tb927.8.7740    AAT8 
Tb927.4.4730  AATP11  AAT3 
Tb927.4.3930    AAT1 
Tb927.8.4700  AATP6  AAT5 
Tb927.8.4710    AAT5 
Tb927.8.4720    AAT5 
Tb927.8.4730    AAT5 
Tb927.8.4740    AAT5 
Tb927.8.4750    AAT5 
Tb11.01.7500    AAT16 
Tb11.01.7520    AAT16 
Tb927.8.8220    AAT9 
Tb927.8.8230    AAT9 
Tb927.8.8240    AAT9 
Tb927.8.8250    AAT9 
Tb927.8.8260    AAT9 
Tb10.70.1170    AAT12 
Tb11.02.4520    AAT15 
Tb10.70.0300    AAT13 
Table 1: Amino acid transporter genes from T. brucei. 
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Table  1  shows  GeneDB  identification  cross-referenced  to  AATP  number  classification 
(Hasne & Barrett, 2000) and AAT loci (Jackson, 2007). The three genome sequences were 
compared and defined by their genomic position, giving specific gene loci which could be 
defined as shared or distinct across the tritryp genomes (Figure 1-6). Loci that are found in 
different  genomic  locations  or  different  loci  in  same  position  point  to  evolutionary 
influences. 
 
Figure 1-6: Trypanosoma brucei AAT loci (taken from Jackson, 2007). 
11 Chromosomes are arranged circularly and labelled by number in clockwise fashion. 
Dark shaded bars across chromosomes represent AAT loci and are labelled with locus 
number,  GeneDB  identifier  and  copy  number  (also  reflected  in  the  band  width).  Grey 
shaded bars represent the genomic positions of AAT loci found in L. major or T. cruzi, but 
absent in T. brucei, and are labelled inside the circle. The status of each AAT locus in L. 
major and T. cruzi are represented by red and black circles respectively; shaded circles Charles E. Ebikeme, 2007     Chapter 1, 42 
indicate the presence of a homoeologous gene, open circles indicate the absence of any 
AAT gene, but with typically conserved synteny around the location. 
 
This throws up an obvious problem due to the fact that the primary definition of an amino 
acid  transporter  locus  is  gene  location,  and  not  sequence.  This  presents  numerous 
problems, for example the AATP1 locus of T. brucei includes an array of 11 genes but is 
classed as a single locus based on location (AAT7), when in reality those 11 genes group 
together more subtly, with 3 distinct groups emerging when comparing gene sequences 
(chapter 3). 
Jackson  concluded  that  the  repertoires  of  amino  acid  transporter  loci  are  fluid  in  both 
complement  and  gene  dosage,  although  there  seems  to  be  a  somewhat  customised 
transporter repertoire when comparing the three species. A vacant locus in a particular 
species  was  attributed  to  either  a  loss  or  an  origin  of  genomic  content.  However,  the 
statement of a “customised AAT  gene repertoire” is likely to translate  into the unique 
amino acid requirements for each species but, at the same time, is unlikely to be a distinct 
characteristic. However, several gene loci specific to T. brucei (one without homeologous 
loci in other species) were identified (AAT2, AAT3, AAT4, AAT6, AAT7, AAT9, and 
AAT10). 
The digenetic lifestyle of the African trypanosome, involving the mammalian bloodstream 
and  the  tsetse  midgut,  offers  variation  in  temperature  and  nutrient  availability. 
Developmental regulation of certain genes to adapt to divergent environments is necessary 
and investigations into these processes will provide more information on the cues leading 
up to differentiation from one life cycle stage to the next. Developmentally regulated genes 
in two strains of T. brucei have been reported using microarray analysis (Brems et al., 
2004).  Expression  patterns  obtained  showed  that  2%  of  trypanosome  genes  showed 
developmental  regulation  at  the  mRNA  level  –  including  3  groups  of  amino  acid 
transporter  genes  upregulated  in  procyclic  forms  (Tb927.4.4730,  AAT3;  Tb927.8.4700, 
AAT5; and Tb927.4.3990, AAT2). 
Differential  expression  of  genes  between  the  bloodstream  form  and  procyclic  form 
trypanosome has been investigated (Clayton, unpublished data). From this, key amino acid 
transporters that were upregulated in either the BSF or the PCF have been identified. In 
PCF  trypanosomes,  a  single  amino  acid  transporter  Tb04.3I12.190  (Tb927.4.4730, 
AATP11, AAT3) has been shown to be upregulated. Regulation of TbAATP11 mRNA has Charles E. Ebikeme, 2007     Chapter 1, 43 
been  investigated  (Robles  &  Clayton,  2007),  showing  that  the  3’-UTR  causes  higher 
expression of the reporter gene in PCF trypanosomes, with multiple elements within the 
intergenic sequence being required for this control. The mRNA of this particular amino 
acid transporter seems to be under the control of the 5’-3’ exonuclease XRNA and shows a 
half-life of 10 mins and 60 mins in BSF and PCF trypanosomes respectively (Robles & 
Clayton, 2007). 
In BSF trypanosomes, two amino acid transporters, Tb04.3I12.30 (Tb927.4.4820, AAT4, 
AATP7/8/10)  and  Tb04.3M17.60  (Tb927.4.4870,  AAT7,  AATP1)  are  shown  to  be 
upregulated. Tb927.4.4730 is closely related to Tb927.8.7740, showing greater than 90% 
similarity. Tb927.4.4820 sits at the start of a six gene array comprising of Tb927.4.4820, 
4830,  4840,  4850,  4860  and  4870.  At  this  point  in  time  we  are  unable  to  assign  a 
phenotype to those amino acid transporters that are differentially upregulated. However, by 
analysing the amino acid requirements of both forms of the parasite we can infer metabolic 
consumption of amino acids and relate that to amino acid transporters (chapter 3). 
1.18   Drug Uptake via Amino Acid Transporters 
Amino acids are important for protozoa as energy sources as well as forming pools of 
soluble osmolites (Burchmore et al., 2002). Selective plasma membrane transporters can 
be exploited in the delivery of drug targeting. Amino acid transporters are one group of 
transporters that fulfil the criteria needed for successful exploitation of nutrient transport 
systems for drug delivery (chapter 1.11). 
The precedent set by work with the P2 transporter, with regard to targeting toxins to the 
trypanosome interior via nutrient transporters, inspired a search for amino acid analogues 
with trypanocidal activity that might enter trypanosomes through members of the amino 
acid transporter family. Several amino acid analogues that kill trypanosomes are known. 
Most  notably,  Acivicin  and  6-diazo-5-oxo-l-norleucine  (DON),  which  are  glutamine 
analogues and inhibit CTP synthetase and can kill trypanosomes in vitro. Trypanosomes 
have very low levels of CTP due to limited capacity for de novo synthesis and lack of 
salvage pathways for cytidine (Hofer et al., 2001). Acivicin and DON reduce CTP levels 
even further, inhibiting parasite growth in vitro. The similarity between trypanosomiasis 
and  cancer  (Barrett  &  Barrett,  2000)  is  further  exemplified  by  the  fact  that  the 
pharmacological properties of acivicin and DON have been extensively studied as cancer 
drugs. However, these glutamine analogues only arrest the proliferation of the parasites. A 
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et  al.,  2007).  Most  recently,  the  methionine  analogue  buthionine  sulphoxamine  (BSO) 
(Huynh TT et al., 2003; Arrick et al., 1981) has been identified as a potential trypanocide. 
The mode of action of BSO seems to involve inhibition of γ-Glutamylcysteine synthetase 
(γ-GCS) resulting in trypanolytic effects. However, γ-GCS inhibition was not conclusively 
shown to be the sole target for BSO. 
1.19   Trypanosomes & the Blood-Brain Barrier 
The  neurological  manifestations  of  “sleeping  sickness”  in  man  are  attributed  to  the 
penetration  of  the  blood-brain  barrier  and  invasion  of  the  central  nervous  system  by 
Trypanosoma  brucei  gambiense  and  Trypanosoma  brucei  rhodesiense.  However,  how 
African trypanosomes cross the blood-brain barrier remains an unresolved issue. Recent 
progress in understanding the neuropathological mechanisms of sleeping sickness reveals a 
complex relationship between the parasite and the host nervous system (Engana et al., 
2002; Mulenga et al., 2001). 
Following  the  insect  bite,  parasites  replicate  at  the  site  of  infection,  producing  a  local 
inflammatory  reaction  (Winterbottom’s  sign),  then  spread  to  the  lymph  nodes  and 
eventually throughout the entire blood stream with final parasite establishment in the CNS. 
This is known as late stage HAT, or sleeping sickness, and it compromises the integrity of 
the  blood-brain  barrier  due  to  the  inflammation  that  occurs  when  parasites  become 
associated with the brain capillaries. It is as yet unknown how trypanosomes penetrate the 
blood-brain barrier but it is thought that the general permeabilisation of the barrier during 
the accumulation of mononuclear cells to the site of infection could influence the migration 
of  trypanosomes  (Engana  et  al.,  2002).  Moreover,  it  has  been shown that  IFN-γ is an 
essential  cytokine  in  allowing  trypanosomes  to  circumvent  the  BBB  (Masocha  et  al., 
2004). There is also evidence that parasites can cross the BBB without a generalised loss of 
tight  junction  proteins  (Mulenga  et  al.,  2001),  suggesting  migration  of  parasites  by 
transcytosis through the cerebral endothelial cells rather than between them. 
As well as multiple systemic features seen in the early acute stage, the late chronic stage is 
associated with a wide range of neurological features; including neuropsychiatric, motor 
and sensory abnormalities, all of which may not occur in the same patient. Late stage 
trypanosomiasis  is  often  gradual  in  onset  and  differs  depending  on  the  gambiense  or 
rhodesiense  disease  (Kennedy,  2006).  The  CNS  features  observed  in  trypanosomiasis 
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The features can broadly be divided into psychiatric disturbances, sleep disorders, motor 
system disorders, sensory syndromes and abnormal reflexes (Kennedy, 2006). In the final 
stages  of  the  disease  the  sufferer  develops  seizures,  incontinence,  cerebral  oedema, 
progressive  mental  deterioration,  and  finally  death  as  a  direct  result  of  the  disease  or 
indirect result such as intercurrent infection or heart failure. 
Psychiatric disturbances of the late stage CNS involvement of African trypanosomiasis 
include, but are not limited to, anxiety and irritability, lassitude and indifference, mania 
and agitation, violent and suicidal behaviour, uncontrolled sexual impulses, hallucinations 
and  delirium.  Sleep  disturbances  include  daytime  somnolence,  nocturnal  insomnia, 
narcoleptic crises, and uncontrollable urges to sleep. Motor disturbances include limb and 
tongue  tremors,  muscle  fasciculation,  slurred  speech  and  cerebella  ataxia,  focal  motor 
weakness, neuritis and polyneuritis. Sensory involvement includes parathesia and pruritis. 
How the parasite perturbs brain function to bring about the various CNS features is a 
problem  that  is  not  well  understood  and  involves  many  possible  immunopathological 
pathways.  Many  abnormalities  of  CNS-involved  trypanosomiasis  have  been  reported 
(Kennedy,  2004),  some  of  which  include  a  diffuse  perivascular  infiltration  with 
lymphocytes, macrophages, and activated astrocytes. It seems evident from studies that 
early  astrocyte  activation  plays  an  essential  role  in  driving  the  inflammatory  response 
(Kennedy et al., 1997). Current understanding of parasite neuropathogenesis is based upon 
the balance between pro-inflammatory and counter-inflammatory cytokines, macrophage 
activation by cytokines and parasite components, and interactions between cytokines and 
chemokines (Kennedy, 2006). 
Any potential trypanocidal drug for late stage disease will need to cross the BBB. Entry 
into the CSF by potential drug candidates is by three main routes; passive diffusion of 
lipid-soluble  compounds,  trans-cytosis,  and  by  transport  of  specific  water-soluble 
substances using transporters (Engana et al., 2002). The brain is one of the least accessible 
organs for the delivery of active pharmacological compounds due to the fact it creates a 
unique physical and enzymatic barrier, capable of metabolising nutrients and drugs. BBB 
capillary endothelia lack fenestrations, are sealed by tight junctions and contain specific 
efflux transporters for nutrients, drugs and waste products (Witt & Davis, 2006). 
The  influence  of  brain  pathology  during  disease  must  be  taken  into  account  when 
developing drug delivery strategies. Several disease states have been reported to increase 
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them.  Increasing  bioavailability  to  the  CNS  can  be  achieved  via  different  methods 
depending on the class of drug in question, including pharmacological-based approaches to 
increasing specific biochemical properties and physiological-based approaches to exploit 
the various features and characteristics of the BBB. One such example  of the latter is 
exploiting  nutrient  transporters  of  the  BBB.  Levodopa  (L-Dopa),  a  lipid-insoluble 
compound used for the treatment of Parkinson’s disease, is the prime example. L-Dopa 
availability within the CNS is very high due to the fact that it is actively transported across 
the BBB by the large neutral amino acid carrier, System L (Wade & Katzman, 1975). 
Uptake has been shown to be time-dependent, temperature-sensitive, and Na
+-independent 
(Kageyama et al., 2000). 
There is evidence that changes in the concentrations of the monoamine neurotransmitters 
within the brain are associated with changes in mental processes, with disorders of control 
of  movement  and  with  certain  neuropsychiatric  diseases  (Daniel  et  al.,  1976).  These 
neurotransmitters are synthesized in the brain from aromatic amino acid precursors that 
have to be obtained from the circulating blood. Changes in the cerebral concentrations of 
one  or  more  neurotransmitters  are  the  cause  of  certain  neuropsychiatric  disorders 
(Fernstrom  &  Wurtman,  1971;  Shoemaker  &  Wurtman,  1971;  Bernheimer  & 
Hornykiewicz, 1973). Moreover, other amino acids like the branched-chain amino acids 
(leucine,  isoleucine  and  valine)  are  involved  directly  and  indirectly  in  a  variety  of 
important biochemical functions in the brain (Fernstrom, 2005). The branched-chain amino 
acids influence brain function by modifying transport of aromatic amino acids into the 
CNS. Transporter competition between the branched-chain amino acids and the aromatic 
amino acids mean that a rise in plasma branched-chain amino acid concentration leads to 
decrease  in  aromatic  amino  acid  availability  within  the  CNS.  The  formation  of 
neurotransmitters is largely determined by how the CNS can acquire pre-cursor aromatic 
amino acids from the circulating blood (Coppen et al., 1963; Daniel et al., 1976). More 
specifically, elevating brain tyrosine concentrations stimulates catecholamine production 
(Fernstrom & Fernstrom, 2007). 
Trypanosome-induced alterations and deprivations to host environment is wide ranging 
with  trypanosomiasis.  Evidently,  trypanosome  tryptophan  metabolism  is  thought  to 
contribute to the pathogenesis of trypanosomiasis (Vincendeu et al., 1999). The aromatic 
amino  acids  are  involved  in  transamination  reactions  of  α-ketomethiobutyrate  and 
methionine  recycling  in  trypanosomes  (Berriman  et  al.,  2005;  Berger  et  al.,  1996;  El 
Sawalhy et al., 1995; Vincendeau et al., 1999). It has been noted that a significant decrease 
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involvement (Vincendeau et al., 1999). Studies investigating the importance of tryptophan 
metabolism pointed to an essential role for tryptophan in parasite growth both in an in vivo 
and in vitro setting (Vincendeau et al., 1999). However, the aromatic amino acids do not 
serve as a carbon source for growth. Moreover, decreased levels of the neurotransmitter 
serotonin within the brain may be one of the pathophysiological mechanisms provoking 
sleeping  sickness.  The  functional  significance  of  tryptophan  catabolism  is  unclear. 
However, it is important to note that the range of pathophysiological effects associated 
with the disease are linked to trypanosome involvement, possibly by reducing host levels 
of  essential  amino  acids  (El  Sawalhy  et  al.,  1995).  Another  possibility  is  the  direct 
involvement of toxic or inhibitory actions of metabolites produced from aromatic amino 
acid metabolism in trypanosomes. The aromatic α-keto acids and indole-3-pyruvic acids 
have been shown to accumulate abnormally in the urine of infected mice (El Sawalhy et 
al., 1995). This pathological symptom has been likened to other inherited disorders of 
aromatic  amino  acid  metabolism.  Indeed,  the  correlation  between  the  physiological 
manifestations of trypanosomiasis and other neurological disorders cannot be discounted. 
It is evident that the perturbations of host environment brought about by  trypanosome 
amino acid metabolism result in pathogenesis and physiology of the disease. 48 
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2.1  Cell Culture 
2.1.1 Trypanosomes 
T. brucei procyclic form (PCF) strains 427, 927, and various derivatives were cultivated in 
SDM79 medium (Brun & Schonenberger, 1979), Cunningham’s medium (Cunningham, 
1972) and SDM80 medium (Appendix 8.2) supplemented with 10% (v/v) heat inactivated 
FCS (for SDM80 dialysed against 0.15 M NaCl with a molecular mass cut-off of 10,000 
Da), at 25-28˚C. A typical culture was started at 10
5 cells/ml. After 4 days, the culture 
reached mid-log phase (10
6 cells/ml) and after 7 days the stationary phase was reached (10
7 
cells/ml). 
T. brucei bloodstream form (BSF) strain 427 were cultured in HMI-9 medium containing 
10%  heat  inactivated  FCS  (Hirumi  et  al.,  1977;  Hirumi,  1994)  at  37˚C  in  a  5%  CO2 
incubator. 
T. brucei PCF strain 29-13 (La Count et al., 2000) were used in all RNAi experiments. For 
the transgenic trypanosomes, the tetracycline repressor constructs were maintained by the 
addition of 15 µg/ml G418 and 25 µg/ml Hygromycin B to the medium. To induce the 
RNAi effect, tetracycline was added at a concentration of 100 ng/ml. 
Development of cultures was monitored by microscopy and cell numbers were determined 
using an improved Neubauer haemocytometer (counting chamber; Weber Scientific). 
2.1.2 Mammalian cells 
The Human Embryonic Kidney cell line strain 293T (HEK) were cultured in Dulbecco’s 
Modified Eagle’s Medium (Sigma) with penicillin/streptomycin (10 mg/ml), L-Glutamax 
(200 mM), and 10%  FCS in vented  culture  flasks  at 37ºC in 5-10%  CO2 atmosphere, 
passaging when cells on the monolayer were 80-85% confluent. Cells were passaged by 
the addition of pre-warmed 0.25% Trypsin-EDTA solution (Sigma). After detachment of 
cells from the culture dish surface, cells were mixed with a further 8 ml of pre-warmed 
medium and spun down at 1,200 rpm for 5 mins. Supernatant was decanted and pelleted 
cells were resuspended in 10 ml of medium, with 1 ml of cell suspension added to a fresh 
sterile culture dish containing 10 ml of medium. 
Development of cultures was monitored by microscopy and cell numbers were determined 
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2.2  Alamar Blue Assay 
The  Alamar  blue  assay  is  used  to  determine  the  relative  number  of  live  cells  in  a 
population (Raz et al., 1997). The assay was employed to test potential trypanocidal drugs 
or as a measure of growth by different carbon sources. The assay was carried out on both 
PCF and BSF trypanosomes. 
Trypanosomes (typically at a density of 10
5 per 100 µl for PCF and 10
4 per 100 µl for 
BSF)  were  incubated  for  72  hrs  in  96-well  flat  bottomed  microtiter  plates.  Drug 
concentration started at 100 µM and decreased in doubling dilution across rows in the 
plate, with no drug used as a control. All experiments were performed twice with each 
drug in duplicate. 
Alamar blue reagent (Resazurin; Raz et al., 1997), at 12.5 mg per 100 ml, stored and 
protected from light at 4ºC, was added after 48 hrs incubation (at 10% - 20 µl per well). 
Measurement of fluorescence was carried out in a Millipore Cytoflour plate reader (Perkin 
Elmer, LS 55, Luminescence Spectrometer) at 530 nm excitation wavelength and 590 nm 
emission wavelength after a further 24 h incubation. The IC50 value is the concentration 
inhibiting a parameter (growth in this case, or conversion of oxidised to reduced resazurin) 
by 50%. 
Human Embryonic Kidney cells (strain 293T) were used as the mammalian cell line for 
comparative analyses and to give a preliminary therapeutic index. The Alamar blue assay 
protocol was modified from the one used for live trypanosomes. Briefly, 100 µl of a 3 x 
10
5 cells/ml suspension was added to each well of a 96-well plate and incubated at 37ºC 
for 3 hours to allow cells to adhere to the bottom of the wells. Preparation of drug stocks in 
doubling  dilution  was  added  after  the  incubation  period,  incubated  for  a  further  12-16 
hours before the addition of 10% resazurin. After 24 hours plates were read. 
In  all,  92  amino  acid  analogues  (Appendix  8.14,  chapter  6)  have  been  screened  for 
trypanocidal activity using the Alamar Blue method. 
2.3  Isolation of genomic DNA 
For  isolation  of  genomic  DNA  from  T.  brucei,  10
8  parasites  were  pelleted  by 
centrifugation at 2,000 g for 10 min at 4˚C and resuspended in 150 µl of TELT buffer 
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150 µl of Phenol-Chloroform was added and mixed gently by inversion. The aqueous mix 
was  centrifuged  at  13,000  g  for  5  mins  at  room  temperature.  The  aqueous  layer  was 
transferred into a sterile 1.5 ml Eppendorf tube and the DNA was precipitated by addition 
of 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol and placed on ice 
for 5 mins. The DNA was pelleted by centrifugation at 13,000 g at room temperature. The 
pellet was washed in 1 ml 70% ethanol, air dried for 5 mins and resuspended in TE buffer 
(Appendix 8.6). The DNA was incubated with 1 mg/ml RNAse (Sigma) for 30 min at 
room temperature and stored at -20˚C for further work. 
2.4  Total RNA Isolation 
A  pellet  of  10
8  cells  was  resuspended  in  1  ml  of  Trizol  reagent  (Gibco),  comprising 
monophasic solutions of phenol and guanidine isothiocyanate, to maintain the integrity of 
RNA (Sambrook & Russell, 2001). The mixture was incubated at room temperature for 5 
mins  before  200  µl  of  chloroform  was  added,  then  mixed  by  inversion.  Organic  and 
aqueous phases were separated after a further 2 min of incubation at room temperature. 
Addition  of  chloroform  generates  an  organic  phase  into  which  DNA  and  proteins  are 
extracted,  leaving  RNA  in  the  aqueous  supernatant.  After  centrifugation  for  15  min  at 
12,000 g and 4˚C, the aqueous phase was transferred to a fresh sterile 1.5 ml Eppendorf 
tube and 0.5 ml of isopropyl alcohol was added. The mixture was incubated for 10 min at 
room temperature to precipitate the RNA. The RNA pellet was collected by centrifugation 
at 12,000 g for 10 min at 4˚C, and then washed with 70% ethanol, air dried for 10 min and 
resuspended in RNAse-free water. RNA was then stored at -20˚C. 
RNA is chemically more active than DNA; ergo it is prone to digestion by contaminating 
RNases.  The  simple  and  most  effective  way  to  guard  against  RNase  contamination  is 
prevention. Sterile technique and proper sterile equipment were used throughout. RNases 
are  ubiquitous,  resistant  to  prolonged  boiling,  and  are  able  to  refold  after  denaturation 
(Sambrook  &  Russell,  2001).  All  equipment  and  reagents  were  made  RNAse  free  by 
treatment with 0.01% diethylpyrocarbonate (DEPC). DEPC is a highly reactive alkylating 
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2.5  Molecular Cloning Techniques 
2.5.1 Polymerase Chain Reaction (PCR) 
PCR  was  used  to  amplify  segments  of  DNA  between  two  known  regions  for  various 
cloning  exercises.  All  oligonucleotides  were  synthesized  by  MWG-Biotech.  The  two 
primers (forward and reverse) used in each amplification had sequences complementary to 
those flanking the region for amplification. One primer was designed in the 5’-3’ direction 
of the sense strand (forward primer) and the other was designed in the 5’-3’ direction of the 
anti-sense strand (reverse primer) of DNA. Enzymatic replication of DNA used Taq DNA 
polymerase (Promega). A 50 µl reaction contained 200 µM of dNTP, 50 µl of 10 X buffer, 
upstream and downstream primers at 0.1 µM, 200 ng of genomic DNA and 1 unit of Taq 
DNA Polymerase. The amplification was performed using a thermal cycler (PTC200 DNA 
Engine  Thermal  Cycler,  MJ  Research)  under  differing  conditions.  Temperature  and 
incubation  times  were  optimized  for  each  reaction.  The  PCR  was  performed  in  three 
stages: 94˚C for 2 min followed by 30 cycles composed of a denaturation step at 94°C for 
15 sec, an annealing step at Tm for 30 sec and an amplification step at 72°C for 2 minutes, 
a final extension at 72°C for 5 minutes. The Tm is the annealing temperature, which was 
chosen to be a few degrees below the predicted Tm of each primer pair. Correctly sized 
products  were  isolated  by  electrophoresis  on  a  1%  agarose  gel  containing  ethidium 
bromide  and  then  purified  using  a  QIAquick  PCR  purification  kit  according  to 
manufacturer’s instructions (Qiagen). 
2.5.2 Plasmid Vectors 
DNA fragments can be inserted into vectors and efficient cloning is achieved when DNA 
insert and plasmid are digested by restriction enzymes creating “sticky” ends. TA cloning 
takes advantage of the single A-residue at the 3’end of the insert generated during PCR by 
Taq DNA polymerase enzyme. The specific vector pGEM-T (Promega) contains a single 
T-residue overhang allowing ease of cloning. 
PCR fragments were cloned into the pGEM-T vector. Ligation reactions were carried out 
using a 3 fold-excess in terms of molar ends of the insert DNA and the vector. The ligation 
reaction was performed under the following conditions: final concentration of 1X ligation 
buffer, 1 µl vector (20-50 ng/µl), 3 µl PCR product, 1 µl T4 DNA Ligase (1 U/µl). The 
reaction was incubated for at 16˚C for at lest 5 hrs. A positive control (control insert DNA) 
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ligation of the vector. Once plasmid had been purified and the presence of insert verified 
the PCR products could then be digested, isolated and cloned into various other vectors 
depending on use (see relevant chapters). 
Restriction  enzymes  recognize  specific  palindromic  sequences  in  the  DNA.  Standard 
restriction  enzyme  digests  were  typically  performed  using  a  final  concentration  of  1X 
restriction enzyme buffer, 50-100 ng of DNA, 1 unit BSA, and 5 units of enzyme. The 
digest mixtures were incubated at 37°C for at least 2 hrs or until complete digestion was 
obtained. 
2.5.3 E.coli Transformations 
The  E.  coli  chemically  competent  cell  line  JM109  (Promega)  were  transfected  with 
plasmid containing the DNA segment of choice. 50 µl of cells were added to a chilled 
Eppendorf tube containing 10 µl of ligation mix. The tubes were left on ice for 30 min, 
then heat shocked for 3 min at 42°C and immediately placed on ice for 1 min and spread 
on LB agar plates containing ampicillin (100 µg/ml), isopropylthio-β-D-galactoside (IPTG; 
40 µg/ml), and 5-bromo-4-chloro-indolyl-β-D-galactoside (X-Gal; 40 µg/ml). IPTG and X-
Gal  were  added  for  blue/white  colony  screening.  Successful  cloning  of  the  insert  into 
pGEM-T was indicated by the presence of white colonies as opposed to blue colonies. 
Many  commonly  used  plasmid  vectors  carry  a  short  segment  of  DNA  containing  the 
regulatory  sequence  and  the  coding  information  for  the  first  146  amino  acids  of  ß-
galactosidase (lacZ). Usually, host cells express the complementary C-terminal portion of 
ß-galactosidase, and together host and transformed vector will express the active enzyme. 
This is known as α-complementation. Insertion of a fragment of foreign DNA results in the 
disruption of the lacZ gene, the resulting ß-galactosidase transcript is non-functional and α-
complementation  is  abolished.  Bacteria  that  result  from  α-complementation  form  blue 
colonies  in  the  presence  of  the  chromogenic  substrate  X-Gal.  Therefore  colonies 
containing  recombinant  plasmids  appear  white.  IPTG  is  an  analogue  of  lactose  that 
inactivates the lacZ repressor and therefore induces transcription of the lac operon. The 
fact that IPTG is nonfermentable means it can act as a gratuitous inducer of the lac operon. 
For other vectors that do not allow blue/white screening, insertion of correct insert was 
confirmed by PCR. Briefly, a PCR reaction was set up broadly as previously described, 
containing  primers  specific  for  the  insert.  The  DNA  template,  however,  was  simply  a 
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colony preserved as a culture). Generation of a PCR product indicated successful insertion 
of the gene target into the plasmid vector. 
For each transformation, single transformed colonies (containing vector and insert) were 
picked  from  plates  into  5  ml  of  LB/ampicillin  (100  µg/ml)  medium  and  incubated 
overnight  at  37°C  under  vigorous  shaking.  The  bacterial  cells  were  harvested  by 
centrifugation  at  13,000  rpm  for  15  minutes  at  4°C  and  the  pellets  processed  using  a 
Qiagen Plasmid Miniprep Kit according to the manufacturer’s specification. The plasmid 
DNA  quality  was  analyzed  by  agarose  gel  electrophoresis  after  the  liberation  of  the 
inserted fragment from the vector by restriction enzyme digestion as previously described. 
Purified but non digested DNA plasmid was used as  control. The vectors with cloned 
inserts were sent to MWG-Biotech for sequencing. 
For the preparation of large-scale plasmid DNA, a pre-culture of 5 ml, with a positive 
transformed colony, was grown overnight and then transferred to 100 ml of LB/ampicillin 
medium, which was grown overnight at 37°C under shaking. The culture was spun and the 
bacterial  pellet  processed  using  a  Qiagen  Plasmid  Maxiprep  Kit  according  to  the 
manufacturer’s specification. The yield and quality of the plasmid DNA was also assessed 
by the NanoDrop® ND-1000 UV-Vis Spectrophotometer. 
2.6  Northern Blot Analysis 
Northern hybridization is used to measure the amount and size of RNAs transcribed from a 
particular  gene.  RNA  samples  were  separated  according  to  size  using  1% 
agarose/formaldehyde gel electrophoresis for at least 4 hr at 70 V. The gel contained 1% 
agarose, 12% formaldehyde, and 2 X northern gel buffer (1 X MOPS, Appendix 8.10). 
RNA samples were prepared by adding the RNA (4 µg) to RNA loading mix consisting of 
12.5% formaldehyde, 50% formamide and sterile water to 20 µl. Formamide is used to 
assist the denaturation of RNA before electrophoresis through the gel. RNA mix was then 
heated briefly at 65˚C for 15 min. RNA was transferred to a nylon membrane (Hybond N, 
Amersham) by capillary transfer under 20 X SSC – a technique similar to that used in 
Southern blotting (Sambrook & Russell, 2001), that involves transfer of nucleic acids from 
gel to membrane in an upward flow of buffer. After transfer the RNA was UV cross-linked 
to the membrane, using a Stratalinker apparatus set at “optimal cross-link.” The membrane 
was then air dried and is now ready for hybridisation, and can be stored in a sealed plastic 
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2.7  Probe Labelling 
Prehybridisation of the membrane was carried out for a minimum of 2 hr at 65˚C in 50% 
formamide,  6  X  SSC,  5  X  Denhardt’s  solution,  1%  SDS,  and  0.1  mg/ml  denatured 
sonicated salmon sperm DNA. Purified PCR product was labelled using α
32P (Amersham). 
Random priming of PCR product was done using the Prime It II Kit (Stratagene). Briefly, 
10 µl of random oligonucleotide primers were added to 25 ng of DNA in a total reaction 
volume of 34 µl. The mixture was denatured by boiling for 5 min and then snap-cooled on 
ice. 10 µl of 5 X dATP primer buffer, 50 µCi α
32dATP and 1 µl of Exo-Klenow enzyme (5 
U/µl;  Stratagene)  were  added  and  incubated  at  37˚C  for  10  min.  The  Exo-Klenow 
Fragment is the large fragment of DNA Polymerase I (obtained from E. coli). It exhibits 
5’-3’ polymerase activity, but lacks the 3’-5’ and 5’-3’ exonuclease activities of DNA 
Polymerase  I.  The  labelled  probe  was  finally  denatured  by  boiling  for  5  min  before 
addition to the membrane and hybridization buffer. Hybridization was performed overnight 
at 42˚C in the same prehybridisation solution lacking Denhardt’s solution but containing 
50  %  formamide  and  the  denatured  probe.  After  overnight  hybridization,  blots  were 
washed once in 10 X SSC, 1% SDS for 30 min at room temperature, once in prewarmed 1 
X SSC, 0.5 % SDS for 45 min at 42˚C, and once in prewarmed 0.1 X SSC, 0.2 % SDS for 
30 min at 42ºC. Blots were then dried, covered with a sheet of saran wrap and exposed to 
X-ray film for at least 16 h at -80ºC then developed using Compact X4 X-ograph (Imaging 
systems). 
Nylon  membranes  containing  either  genomic  DNA  or  RNA  can  be  stripped  and 
rehybridised up to 4 times. Hybridized probes can be stripped by immersing the membrane 
in  boiling  SDS  solution  (0.1%),  repeated  twice  with  a  fresh  batch  of  boiling  solution. 
Membrane was then dried and prehybridised before hybridization with a second probe. 
2.8  RNA Interference in T. brucei 
RNA interference (RNAi) refers to the introduction of homologous double stranded RNA 
(dsRNA) to specifically target a gene product of interest, resulting in an apparent “null” 
phenotype caused by the ablation of mRNA (chapter 1.9). Charles E. Ebikeme, 2007     Chapter 2, 56 
 
Figure 2-1: RNAi vector p2T7Ti. 
 
The RNAi vector (Figure 2-1) used in this study (p2T7Ti) is based on the strategy of 
placing the sequence of interest between opposing T7 promoters (La Count et al., 2000). 
The vectors contain a rRNA spacer for integration into the rRNA locus of the parasite’s 
genome, a tetracycline inducible operator, as well as a drug resistance gene for selection 
(phleomycin). The vector must be used in specially derived T. brucei cell lines (29-13), 
which express bacteriophage T7 RNA polymerase and the tet repressor from bacteriophage 
λ. The T7 polymerase and the tetracycline repressor constructs were maintained in the 29-
13  cell  line  (La  Count  et  al.,  2000)  by  the  addition  of  15  µg/ml  G418  and  25  µg/ml 
Hygromycin B to the medium. To induce the RNAi effect, tetracycline was added at a 
concentration of 100 ng/ml. Without tetracycline, the tet repressor expressed in the cells 
binds to the tet operator to inhibit transcription from the integrated construct. With the 
addition  of  tetracycline,  the  repressor  is  bound  and  its  action  prevents  binding  to  the 
operator allowing transcription to occur. 
2.9  Plasmid Construction 
For the RNAi constructs, gene fragments of around 400-600 bp in size were amplified by 
PCR of gDNA using specific primers containing appropriate restriction enzyme linkers. 
Isolated, purified PCR products were cloned firstly into the pGEM-T vector following a 
cloning  strategy  as  previously  described.  Following  digestion  and  isolation  from  the 
pGEM-T vector, the  PCR  generated fragments  were cloned into the appropriate RNAi 
vector, transfected into competent E. coli bacteria and positive transformed colonies grown 
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2.10   Transfection of Trypanosomes 
For stable transfection of the procyclic host strain 29-13 via integration into an rDNA 
spacer region, the RNAi constructs were linearised by NotI digestion (Wirtz, 1995). The 
digestion of plasmid DNA was carried out in a volume of 40 µl using 1 unit of the enzyme, 
4 µl of 10X buffer and 10 µg of plasmid DNA and incubated at 37°C for two hours. After 
the addition of 1 unit of the enzyme, the reaction was re-incubated overnight, with the final 
digest checked by agarose gel electrophoresis. 
The linearised DNA plasmid was sterilized, by ethanol precipitation after an inactivation of 
the enzyme at 65°C for 20 minutes, then air dried in a sterile hood and resuspended in 20 
µl of sterile water. Agarose gel electrophoresis was used to assess proper linearization of 
the vector. 
For the transfection, PCF 29-13 cells were grown to mid-log phase (5 x 10
6 cells/ml). 5 x 
10
7  cells  were  collected  by  centrifugation  at  1,500g  for  10  min  at  room  temperature, 
washed twice in 10 ml of ZPFM buffer (Appendix 8.11) and then resuspended in 0.5 ml of 
the buffer. To minimise the possibility of degradation, linearised plasmid DNA was added 
to the cells just before electroporation. Cells were electroporated by using a Biorad Gene 
Pulser  set  at  1.4  kV  and  25  µF  in  0.4-cm-gap  cuvettes  using  two  pulses  delivered  10 
seconds apart. Immediately following transfection, cells were transferred into 10 ml of 
fresh  pre-warmed  SDM79  medium  with  10%  heat  inactivated  foetal  calf  serum 
supplemented  with  neomycin,  hygromycin.  Drug  selection  was  started  after  overnight 
recovery to allow the build up of resistant proteins. 
After  one  day  the  10  ml  culture  of  cells  was  split  into  the  top  6  wells  of  a  24-well 
microtitre plate, and diluted down stepwise by doubling dilution. Drug resistant cells were 
selected between 7 to 14 days and then cloned by limiting dilution in 96-well plates. 
2.11   Analysis of Growth Rates 
Growth  rate  analysis  was  also  used  to  assess  the  effect  of  trypanocidal  drugs  on  BSF 
trypanosomes, growth of RNAi cell lines upon tetracycline induction, and the effect of 
different carbon sources for growth of PCF trypanosomes. PCF cultures were commonly 
initiated  at  a  starting  density  of  5  x  10
5  cells/ml.  For  RNAi  cell  lines  growth  was 
determined in the presence and absence of tetracycline. Cells were grown in 24 well plates, 
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supplemented  with  proline  or  glucose  individually  at  10  mM  (other  supplements  were 
added at concentration specified in the results section). 
In general, master cultures were propagated in SDM79 (strain 427) or CM (strain 927). 
Differing medium conditions employed a general strategy of centrifugation of aliquots of 
the  master  cultures  (1,250  rcf  for  10  mins)  and  resuspending  cells  to  the  desired  cell 
density.  Experimental  counts  involving  SDM80  based  medium  (with  or  without 
supplementation) involved an overnight recovery in SDM80. 
BSF cultures were typically started at a density of 2 x 10
4 cells/ml, in HMI-9 medium in 
the presence and absence of drug. Parasite numbers were measured by counting with an 
improved Neubauer haemocytometer (Weber Scientific). 
2.12   Radiolabeled Uptake Assays 
Parasites  were  harvested  during  the  mid-log  phase  of  growth,  at  indicated  times  post-
induction, by centrifugation at 1,250 rcf (2,500 rpm) for 10 minutes and washed three 
times with assay buffer (CBSS or PBS; Appendix 8.3, 8.12) by centrifugation at 1,250 rpm 
at 4ºC. Parasites were resuspended in assay buffer at the density of 2 x 10
8 cells/ml and 
kept  on  ice,  and  brought  up  to  room  temperature  when  the  experiment  was  about  to 
proceed. 
Uptake of radiolabelled compounds was determined using a derivation of the rapid oil/stop 
spin protocol, as previously described (Carter & Fairlamb, 1993). Transport was initiated 
with  100  µl  of  cells  being  mixed  with  100  µl  assay  buffer,  containing  radiolabelled 
compounds (Amersham), at a specific concentration of (see relevant results section) plus or 
minus other test compounds, at the concentrations specified in the Results sections. Uptake 
was left to proceed over time points specified in the results section. 
To separate trypanosome cells from radiolabelled amino acid solution, oil was used (1-
Bromodo-decane, density: 1.066 gcm
-3). The buffer was layered over a 90 µl cushion of 
oil.  The  oil’s  density,  upon  centrifugation,  separates  the  trypanosome  cells  from  the 
radioactive medium containing labelled amino acid. The tube was flash frozen in liquid 
nitrogen, and the pellet was separated from the remnants of the tube with a tube cutter, and 
lysed in 200 µl SDS (2%) and mixed with 3 ml scintillation fluid (Ecoscint A, National 
Diagnostics) and incorporated activity counted after 24 hrs (to avoid luminescence) using a 
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1450 Microbeta). All experiments (at each time point for each substrate) were carried out, 
at least, in duplicate, and three times independently. 
Non-transported  radiolabeled  compounds,  associated  with  cells  or  in  interstitial  spaces, 
were measured by performing control uptake determinations on ice (by commencing the 
reaction at a zero time point using cells, and buffer kept on ice to ensure, essentially, no 
uptake).  
2.13   Metabolomic Profiling 
Metabolomics requires special approaches for sample preparation, separation, and mass 
spectrometric analysis (Dettmer et al., 2007). Rapid quenching of metabolism with hot 
ethanol has proven to be an effective method of identifying metabolites (D. Wildridge, 
personal communication). It is necessary to also analyse culture medium without cells in 
order to generate spectra of medium associated metabolites to subtract from the metabolic 
profile.  Sample  preparation  involves  bringing  the  large  quantity  of  cells  grown  into  a 
format that is compatible with the analytical technique used, while removing components 
(serum proteins) that will interfere with the analysis (Dettmer et al., 2007; M Kamleh, 
personal communication). The procedure includes a pre-concentration step to achieve the 
detection limits required. The large volume of cells grown are pelleted by centrifugation at 
1,250 rpm at 4ºC and resuspended at a concentration of 2 x 10
8 cells/ml in serum-free 
medium  and  incubated  at  room  temperature  for  30  mins.  Cells  were  separated  from 
medium by spinning down at 6,000 rpm for 5 mins at 4ºC. 0.75 ml of 80% EtOH/20 mM 
HEPES (pH 7) at 80ºC was quickly added to separated medium and cell pellet, cooled on 
ice for 5 mins, vortexed, and then the supernatant recovered by centrifugation at 13,000 
rpm for 5 mins. Recovered supernatant was frozen in liquid nitrogen and stored at -80ºC 
for further analysis. 
Samples were processed using an Orbitrap Mass Spectrometer (Kamleh M & Watson D, 
University  of  Strathclyde).  Metabolites  were  separated  on  a  ZIC-HILIC  (Sequant) 
chromatographic column over a period of 55 minutes by eluting 10 µl of sample with 80% 
Acetonitrile/20% water (0.1% formic acid), gradually increasing the concentration of the 
aqueous component to 60%, and then returning to 20%. The Orbitrap mass spectrometry, 
employed here, is not strictly quantitative (in the absence of an authenticated standard). 
However, the data generated is quantitative in a relative sense. The increase or decrease in 
size  of  a  given  peak  is  related  to  the  changes  in  abundance  of  that  metabolite  across 
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putative formulae using an algorithm that sums all possible combinations of the elements 
C,  H,  O,  P,  N,  S.  Although  for  a  given  mass  there  may  be  many  possible  elemental 
combinations, in practice many of these can be eliminated as improbable. 
2.14   Bioinformatic Analyses 
The data was analysed using the GraFit 5.0 data analysis software (Erithacus). Kinetic 
constants were determined by non-linear regression analysis using the Michaelis-Menten 
equation.  Vector  NTI  was  used  to  analyse  DNA  and  protein  sequences.  Sequence 
alignments were studied using Clustal W (www.ebi.ac.uk). Clustal W is a general purpose 
multiple  sequence  alignment  program  for  DNA  or  proteins,  which  calculates  the  best 
match for the selected sequences, and lines them up so that the identities, similarities and 
differences can be seen, and apparent evolutionary relationships can be seen via viewing 
Cladograms  or  Phylograms.  Prediction  of  transmembrane  domains  within  amino  acid 
sequences  was  done  by  TMpred  (www.ch.embnet.org).  The  TMpred  program  makes 
predictions  on  membrane-spanning  regions  and  their  orientation.  The  following  web 
resources were used to analyse nucleic acid and amino acid sequences. Metabolomic data 
was analysed using the Cytoscape software (chapter 5). 
Databases: 
TIGR database: www.tigr.org 
NCBI database: www.ncbi.nlm.nih.gov 
GeneDB: www.genedb.org 
KEGG: www.genome.jp/kegg 61 
3  RNAi Knock-down Approaches to Characterising 
Candidate Amino Acid Transporter Genes in 
Trypanosoma brucei Charles E. Ebikeme, 2007     Chapter 3, 62 
3.1  Introduction 
3.1.1 Amino Acid Usage in Trypanosomes 
The completion of the  T. brucei  genome sequence (Berriman  et al., 2005) highlighted 
several interesting characteristics of trypanosome amino acid metabolism. It revealed that 
most  of  the  enzymes  of  the  classical  pathways  for  aromatic  amino  acid  oxidation  are 
missing. Conversion of phenylalanine to tyrosine does not occur in T. brucei, due to the 
fact  that  it  does  not  have  the  enzyme  phenylalanine-4-hydroxylase.  All  trypanosome 
species have genes for transamination and reduction to the corresponding aromatic lactate 
derivative. Branched chain amino acids can be converted to acetyl-CoA derivatives within 
the mitochondria. In T. brucei threonine is apparently not oxidised via the 2-oxobutyrate 
pathway, instead being degraded to acetyl-CoA and glycine by a mitochondrial specific 
threonine dehydrogenase. Catabolism of histidine is absent in T. brucei and a functional 
urea cycle is missing across the trypanosomes. 
In spite of the extrapolation possible from genome analysis, little is known about amino 
acid usage and consumption in BSF trypanosomes. Cysteine is an essential amino acid for 
in  vitro  cultures  (Duszenko  et  al.,  1992).  The  enzyme  L-threonine  3-dehydrogenase  is 
important  in  metabolising  threonine.  L-threonine  metabolism  takes  place  in  the 
mitochondrion producing  glycine and acetyl CoA. BSF trypanosomes,  however, lack a 
complete  functional  mitochondrion,  and  nothing  is  known  so  far  about  the  subcellular 
localization  of  the  threonine  metabolism  in  this  life  form.  Recently,  Nano  LC-MS/MS 
proteomic  analysis  has  revealed  the  presence  of  an  L-threonine  3-dehydrogenase 
(Tb927.6.2790) enzyme in the glycosome of BSF trypanosomes (Colasante et al., 2006), 
suggesting that BSF trypanosomes do metabolise threonine. However, the authors were 
unable to postulate a reason why this enzyme is localised in the glycosome of the BSF 
trypanosome. 
One important use of amino acids is in the regulation of cell osmolarity. Osmoregulation is 
the active regulation of the osmotic pressure of fluids to maintain the homeostasis of water 
content, which, in trypanosomes is closely linked to amino acid accumulation and release. 
The  mechanics  of  osmoregulation  has  been  more  closely  studied  in  Leishmania. 
Accumulated  amino  acids  provide  the  cell  with  an  osmotic  reservoir,  which  is  readily 
utilised  for  osmoregulation.  When  Leishmania  promastigotes  are  exposed  to  a  sudden 
decrease  in  osmolality,  they  initially  swell  but  subsequently  undergo  shrinkage  to 
compensate  (Blum  et  al.,  1999).  This  regulatory  volume  decrease  (RVD)  response Charles E. Ebikeme, 2007     Chapter 3, 63 
mechanism involves  anionic amino acid channels (HAAC – hypotonic-activated amino 
acid anion channel), which allow neutral and acidic amino acids to be released from the 
cells. The HAAC system has been likened to volume activated anion channels at work in 
mammalian cells that mediate the efflux of small organic osmolytes. 
In a hypotonic environment, osmosis causes water to flow into the cell, leading to swollen 
cell morphology. The release of amino acids by Leishmania promastigotes has been shown 
to be proportional to the osmotic stress placed on the cell (Blum et al., 1999). That is to 
say,  that  the  proportionality  was  independent  of  ionic  strength  and  proportional  to  the 
imposed osmotic gradient. Alanine, proline and glutamate (among others) are the principal 
amino acids implicated in osmoregulation in Leishmania. 
Other  cell  species  use  the  dissipation  of  potassium  and  chloride  ions  (linked  to  water 
release) for correcting volume changes (Vieira et al., 1996). The use of osmotic reservoirs 
of  organic  solutes  means  adaptive  regulation  of  volume  changes.  Leishmania 
promastigotes swell in hypotonic media but recover their resting shape and volume within 
15–20  mins.  In  T.  brucei  swelling  of  cells  by  decreasing  the  osmotic  strength  of  the 
extracellular  medium  has  been  used  for  membrane  permeability  experiments  and  as  a 
method  for  incorporating  non-penetrating  (non-transported)  low  molecular  weight 
molecules into cells (Voorheis et al., 1980). 
3.1.2 Genes of the Amino Acid Transporter Family 
Large amino acid transporter gene families have been identified from the tritryp genome 
sequences (Berriman et al., 2005; Jackson, 2007). Across the 11 megabase chromosome of 
the African trypanosome, 6 chromosomes contain repetoires of amino acid transporters. 
Chromosome 8 of the T. brucei genome is rich in amino acid transporter genes and two 
transporter islands were located – one containing Tb927.8.4700 (AATP6, AAT5) and the 
other  containing  Tb927.8.7610  (AATP1,  AAT7),  Tb927.8.7600  (AATP2,  AAT7)  and 
Tb927.8.7680 (AATP4, AAT7) in a tandem array (Figure 3-1). AATP6 and AATP1 were 
chosen for knock-down functionality investigations. At the same time, a candidate amino 
acid transporter that showed the most sequence divergence within the family was chosen 
(Figure 3-2). Charles E. Ebikeme, 2007     Chapter 3, 64 
 
Figure 3-1: Amino Acid Transporter location (TbAATP6 and TbAATP1). 
All  11  megabase  chromosomes  of  the  T.  brucei  genome,  showing  relative  amino  acid 
transporter densities (A). Chromosomal location of two identified amino acid transporter 
islands along chromosome 8. Gene arrays of individual transporter islands (B), showing 
TbAATP6  five  gene  array  (red  box)  and  the  downstream  array  containing  TbAATP1 
(AAT7), TbAATP2 (AAT7) and TbAATP4 (AAT7). 
 Charles E. Ebikeme, 2007     Chapter 3, 65 
 
Figure 3-2: Amino Acid Transporter location (TbAATP12). 
All  11  megabase  chromosomes  of  the  T.  brucei  genome,  showing  relative  amino  acid 
transporter  densities  (A).  Chromosomal  location  of  TbAATP12  (AAT13)  along 
chromosome 10 (B). 
 
Of the three gene groups selected AATP1 has no homeologs in Leishmania or T. cruzi 
genomes, whereas AATP12 is present in all three species and an AATP6 homolog is only 
found in T. cruzi (Jackson, 2007). In general, TbAATP1 shows a ≥95% similarity within 
the group, TbAATP2 shows a ≥85% similarity within the group, TbAATP4 genes are 99% 
similar to one another, and TbAATP6 genes show a ≥98% similarity within the group. 
TbAATP1 is most closely related to TbAATP2 (>70%) and least to TbAATP6 (~40%). It 
was  hoped  that  these  investigations  would  provide  information  into  the  function  and 
regulation  of  closely  related,  co-located  transporters.  Genetic  modification  of 
trypanosomes  (removal  of  transporter  genes  via  gene  knock  out  or  knock  down  of 
transcripts  by  RNAi-based  systems)  should  help  to  clarify  the  role  of  individual 
transporters to net measured uptake of amino acids in these cells. As well as evaluating the 
function of T. brucei AATP genes. 
Previously, Dr. I. Accoceberry amplified segments of the T. brucei TbAATP1 gene, from 
T. brucei strain 427 genomic DNA using the following primers: Charles E. Ebikeme, 2007     Chapter 3, 66 
5’-ATATGGATCCAACATCGGATCAACTACCATTG-3’,  sense  from  position  201  to 
223 of the TbAATP1 coding region, including a BamHI site (underlined). 
5’-ACATAAGCTTACCAAAGAAGGCTGTCAGTGCA-3’antisense  complementary  to 
positions from 915 to 936, including a HindIII site (underlined), for amplification of 735 
bp (N terminal region). 
The construct carrying a 606 bp fragment of TbAATP1 gene was cloned into the p2T7Ti 
vector (LaCount et al.,  2000) for use in RNAi experiments. Two cloned lines of PCF 
trypanosomes generated for RNAi-based experiments were selected by Dr. I Accoceberry 
– the lines were named IC8 and 4E8. Preliminary experiments indicated that the TbAATP1 
transporter is a carrier of small, uncharged amino acids with specificity for L-serine, L-
threonine, L-alanine, glycine, L-cysteine and L-asparagine. Here, I set out to confirm L-
threonine  uptake  via  TbAATP1  as  well  as  search  for  a  functional  role  of  this  newly 
characterised amino acid transporter. 
TbAATP6  is  one  of  the  three  groups  of  amino  acid  transporter  genes  upregulated  in 
procyclic forms (Tb927.4.4730, Tb927.8.4700, and Tb927.4.3990) (Brems et al., 2004). In 
all, RNAs from BSF and PCF trypanosomes were used as templates for the generation of 
fluorescent cDNA probes. The resulting probes were hybridised to the generated genomic 
arrays,  revealing  differentially  regulated  genes.  AATP6  was  chosen  for  knock-down 
functionality investigations. 
TbAATP12 was chosen under the basis of it being an ‘orphan’ (one that bears the least 
similarity to any of its neighbours). This ‘orphan’ amino acid transporter (Figure 3-2), 
located  on  chromosome  10,  was  termed  TbAATP12.  TbAATP12  shows  only  a  15% 
homology to the other amino acid transporter along the chromosome (Tb10.6k15.0450, 
AAT14) and a 36% homology to its closest related amino acid transporter (Tb927.4.4860, 
AAT4). 
Genetic modification of trypanosomes (removal of genes via knock-out or knock-down of 
transcripts) can help identify the roles of amino acid transporter genes in trypanosomes. I 
report here the use of RNAi to evaluate the function of candidate amino acid transporter 
genes from T. brucei. Charles E. Ebikeme, 2007     Chapter 3, 67 
3.2  Results 
3.2.1 Identification of Genes 
The GeneDB Trypanosoma brucei database was screened using the name  “amino acid 
transporter.” From the database 46 genes with the molecular function, biological process 
and cellular component corresponding to amino acid transport were revealed (Table 2). 
The GeneDB annotations of amino acid transporter gene products are based on inferred 
electronic annotation (annotations based on "hits" in sequence similarity searches), and 
inferred from sequence or structural similarity to known amino acid transporters. 
 
Figure 3-3: Dendogram of aligned AATP genes. 
DNA sequence alignment of all 46 putative amino acid transporter genes as annotated by 
the T. brucei genome database. 
 
All 46 genes were aligned using Clustal W and grouped based on homology, as a guide to 
the level of relationship exhibited by all genes, with a view to later functional expression 
experiments to find a phenotype. From the alignments, close clustering of gene groups Charles E. Ebikeme, 2007     Chapter 3, 68 
emerged (Figure 3-3). Closely related genes, showing a sequence identity greater than 75% 
were classed into AATP groups and given new AATP numbers (Table 2). 
Parallel Classification 
Gene I.D. 
AATP# 
(from GeneDB) 
New AATP# 
(by alignments) 
AAT 
Locus 
Tb927.8.7610  AATP1    AAT7 
Tb927.8.7620  AATP1    AAT7 
Tb927.8.7630  AATP1    AAT7 
Tb927.8.7640  AATP1    AAT7 
Tb927.8.7660  AATP1    AAT7 
Tb927.8.7600    AATP2  AAT7 
Tb927.8.7650    AATP2  AAT7 
Tb927.8.7670    AATP2  AAT7 
Tb927.8.7690    AATP2  AAT7 
Tb927.8.7680    AATP4  AAT7 
Tb927.8.7700    AATP4  AAT7 
Tb927.4.4830    AATP3  AAT4 
Tb927.4.4850    AATP3  AAT4 
Tb927.4.4870    AATP3  AAT4 
Tb927.4.4840  AATP7    AAT4 
Tb927.4.4820  AATP10    AAT4 
Tb927.4.4860  AATP8    AAT4 
Tb927.4.3990    AATP13  AAT2 
Tb927.4.4000    AATP13  AAT2 
Tb927.4.4010    AATP13  AAT2 
Tb927.4.4020    AATP5  AAT2 
Tb927.8.8290  AATP5  AATP5  AAT10 
Tb927.8.8300    AATP9  AAT10 
Tb11.017590    AATP14  AAT17 
Tb11.01.7600    AATP14  AAT17 
Tb927.6.4660  CAATP  ATP15  - 
Tb927.8.5450    AATP16  AAT6 
Tb09.211.1760    AATP17  AAT11 
Tb10.6k15.0450    AATP18  AAT14 
Tb927.8.7740    AATP11  AAT8 
Tb927.4.4730  AATP11  AATP11  AAT3 
Tb927.4.3930    AATP20  AAT1 
Tb927.8.4700  AATP6  AATP6  AAT5 
Tb927.8.4710    AATP6  AAT5 
Tb927.8.4720    AATP6  AAT5 
Tb927.8.4730    AATP6  AAT5 
Tb927.8.4740    AATP6  AAT5 
Tb927.8.4750    AATP6  AAT5 
Tb11.01.7500    AATP21  AAT16 
Tb11.01.7520    AATP21  AAT16 
Tb927.8.8220    AATP22  AAT9 
Tb927.8.8230    AATP22  AAT9 
Tb927.8.8240    AATP22  AAT9 
Tb927.8.8250    AATP22  AAT9 
Tb927.8.8260    AATP22  AAT9 
Tb10.70.1170      AAT12 
Tb11.02.4520      AAT15 
Tb10.70.0300    AATP12  AAT13 
Table 2: Amino acid transporter genes from T. brucei. Charles E. Ebikeme, 2007     Chapter 3, 69 
 
In general, closely located genes (along the same chromosome) show a high similarity to 
each  other.  For  example,  AATP1  (Tb927.8.7610/20/30/40/60)  and  AATP2 
(Tb927.8.7650/70/90)  show  a  ≥70%  identity  to  each  other.  The  identity  found  among 
tandem  copies  (see  later)  indicates  that  duplication  of  these  genes  constitutes  a  recent 
dynamic event. It is possible that gene duplication resulted in close forms of co-located 
transporters and over time the slight divergence in sequence emerged. 
The advantage of indexing amino acid transporter genes by sequence homology rather than 
genomic position (Jackson, 2007) means individual  genes with related function can be 
grouped, leading to easier and more efficient downstream functional genomic strategies. 
With the amount of genetic redundancy in amino acid transporter genes, it is hard to assess 
what level of homology is required between genes that would translate to function. 
3.2.2 TbAATP1 & Growth of PCF trypanosomes 
TbAATP1  RNAi  cell  lines  were  used  to  explore  a  role  for  this  transporter  system  in 
growth. Cells of the 4E8 clone (previously derived by Dr Accoceberry) were grown in the 
presence  and  absence  of  tetracycline.  Furthermore,  loss  of  threonine  was  explored  in 
differing  medium  conditions.  When  D-glucose  is  not  the  main  carbon  source  PCF 
trypanosomes  have  more  reliance  on  proline  for  growth  (Lamour  et  al.,  2005).  It  is 
possible  that  other  amino  acids  become  more  essential  for  growth  in  the  absence  of 
glucose. Charles E. Ebikeme, 2007     Chapter 3, 70 
Day
0 2 4 6
C
e
l
l
 
N
u
m
b
e
r
s
 
(
p
e
r
 
m
l
)
5 10
6 10
SDM80 (-tet)
SDM80 (+tet)
Day
0 2 4 6
C
e
l
l
 
N
u
m
b
e
r
s
 
(
p
e
r
 
m
l
)
5 10
6 10
Glucose (-tet)
Glucose (+tet)
Day
0 2 4 6
C
e
l
l
 
N
u
m
b
e
r
s
 
(
p
e
r
 
m
l
)
5 10
6 10
7 10 Proline (-tet)
Proline (+tet)
Day
0 2 4 6
C
e
l
l
 
N
u
m
b
e
r
s
 
(
p
e
r
 
m
l
)
5 10
6 10
7 10
SDM79 (-tet)
SDM79 (+tet)
A B
C D
 
Figure 3-4: Growth of TbAATP1 4E8 RNAi cell lines. 
Tetracycline induced an uninduced, grown in SDM80 (panel A), SDM80 plus 10 mM D-
glucose (panel B), SDM80 plus 10 mM L-proline (panel C), and SDM79 (panel D). 
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Figure 3-5: Growth of PCF trypanosomes (strain 427) in threonine deficient medium. 
SDM80 deficient of L-threonine supplemented with 10 mM threonine and 10 mM proline 
and 10 mM glucose. 
 
It seems apparent here that, for the ∆TbAATP1-i cell line, there is no significant difference 
in growth when cells are utilising differing carbon sources. However, with RNAi knock-
down, total protein loss of function is seldom attained. With this in mind I wanted to test 
threonine’s contribution to cell growth by using a more robust control. Wild type PCF 
trypanosomes were grown in threonine deficient medium to ascertain if PCF trypanosomes 
were capable of growing without the amino acid. It was found that there is no growth 
defect seen when growing wild type PCF trypanosomes in L-threonine deficient medium 
with L-proline or D-glucose as the primary carbon source. Cells grown in L-threonine Charles E. Ebikeme, 2007     Chapter 3, 71 
deficient medium showed no growth disadvantage over controls, even in the absence of 
glucose.  Growth  during  mid-log  phase  of  RNAi  cell  lines  was  explored  by  systematic 
passaging of cells.  
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Figure 3-6: Growth counts of TbAATP1 4E8 RNAi cell lines. 
Induced and uninduced cell lines (SDM79). 
 
Induced cells showed stunted growth over time (after the first passage). In comparison with 
non-induced  cell  lines,  they  fail  to  reach  comparable  numbers.  With  RNAi  non-
responsiveness to tetracycline can occur after prolonged tetracycline exposure (La Count, 
personal communication). With the growth defect seen (Figure 3-6) it was important to 
determine TbAATP1 transporter activity through measuring threonine uptake. Charles E. Ebikeme, 2007     Chapter 3, 72 
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Figure 3-7: Growth and measure of threonine uptake. 
Tetracycline induced and uninduced TbAATP1 4E8 RNAi cell lines (this result represents 
data from 3 similar repeats). 
 
By day 5, threonine uptake shows a ~70% reduction and remained reduced by day 10, 
however, only at ~40%. It is possible that it is the initial loss of transporter activity that 
results in the stunted growth. Although, a role for threonine in growth has been ruled out, a 
role for TbAATP1 in growth has not been ruled out. It is possible that the cumulative 
reduction of six amino acids (threonine, cysteine, glycine, serine, asparagine, and alanine) 
is what leads to the growth defect seen, but the effect is time dependent. Trypanosomes 
contain high intracellular pools of amino acids which they utilise for cellular processes 
(such as osmoregulation). It is possible that with TbAATP1 not-functioning, the cells are 
able to use their intracellular pools to compensate. However, once the pool is exhausted, 
defective growth is seen. 
L-threonine’s role in acetate formation and downstream lipid metabolism is a potential 
avenue that needs further investigation. L-threonine has been proposed as a major supply 
of  acetyl-CoA  for  fatty  acid  biosynthesis  (Cross  et  al.,  1975).  Investigations  into  the 
changes  in  the  lipid  profile  of  knock-down  cell  lines  are  ongoing  (Dr  Terry  Smith, 
University of Dundee). By diminishing threonine uptake the cells might end up altering 
their lipid profiles by shifting dependency on synthesised versus acquired fatty acids. Charles E. Ebikeme, 2007     Chapter 3, 73 
3.2.3 L-threonine Transport in T. brucei 
Time dependence of L-threonine uptake was studied in tetracycline induced and uninduced 
∆TbAATP1-i cells (96 hour induction); by incubating cells for different time periods in 
CBSS buffer (Appendix 8.3) containing 10 µM [
3H] L-threonine. 
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Figure 3-8: Threonine uptake. 
Uptake of 10 µM L-[
3H] Threonine in TbAATP1 4E8 RNAi cell lines (plus and minus tet 
induction) over a 2 minute time period (n=3, Error bars = ±SEM). 
 
Measured  internalised  threonine  is  significantly  reduced  in  induced  ∆TbAATP1-i  cell 
lines, showing a 60-70% reduction in uptake over the 2 min incubation period. Reduction 
of threonine uptake is never total probably due to the fact that RNAi knock-down is never 
total. It was previously shown that uptake of radiolabeled serine was inhibited by excess of 
unlabelled  serine,  L-threonine,  L-alanine,  glycine,  L-cysteine,  and  L-asparagine 
(Accoceberry,  unpublished).  Therefore,  TbAATP1  substrate  specificity  was  further 
examined by measuring uptake of radiolabelled L-threonine (at 10 µM) in the presence of 
10 mM of each of the 20 non-radiolabelled amino acids (Figure 3-9). Charles E. Ebikeme, 2007     Chapter 3, 74 
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Figure 3-9: Threonine inhibition. 
Inhibition of L-[
3H] Threonine uptake. Uptake in PCF trypanosomes of 10 µM threonine in 
the  presence  of  all  20  amino  acids  at  a  concentration  of  10  mM.  Uptake  shown  as  a 
percentage of control with no inhibitor (L-Tyrosine is not soluble at a concentration of 10 
mM under the conditions required for this experiment. Consequently inhibition of uptake 
was not determined in the presence of tyrosine) (n=4, Error bars = ±SEM). 
 
Results represent the percentage of L-threonine uptake over a time period of 30 sec against 
a  control  containing  only  L-[
3H]  threonine.  All  amino  acids  show  some  degree  of 
inhibition but maximal  inhibition of uptake of  radiolabelled  L-threonine is seen in the 
presence of cold L-serine, L-threonine, glycine, L-cysteine, L-alanine and L-asparagine. 
Biochemically, this suggests a common route of entry for these six amino acids. 
I wanted to ascertain the order of preference of substrate for TbAATP1. I measured uptake 
of radiolabeled serine in the presence of unlabelled serine and threonine (up to 1 mM) to 
find out which inhibited to a greater degree. Charles E. Ebikeme, 2007     Chapter 3, 75 
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Figure 3-10: Serine inhibition. 
Uptake of 10 µM L-[
3H] Serine in the presence of increasing concentrations of cold serine 
and threonine (no inhibitor, 10 µM, 50 µM, 100 µM, 500 µM, and 1 mM) (n=1). 
 
Inhibition gave IC50 values in the micro molar range, with serine giving an IC50 value of 
147.1  µM  ±  82.3  and  threonine  giving  an  IC50  value  of  26.7  µM  ±  1.5.  Inhibition  of 
radiolabeled serine is more complete and to a greater degree in the presence of threonine. 
This suggests that TbAATP1 has a higher affinity for threonine than it does for serine. 
In order to ascertain affinities for each substrate that uses the threonine-specific transporter 
system  a  more  detailed  inhibition  assay  was  performed.  L-threonine  was  used  as  the 
primary radiolabel due to the fact that it was the most specific for this transporter system 
(uptake of cold L-threonine inhibited radiolabelled L-serine by a greater degree at the same 
concentration). Uptake of radiolabelled L-threonine (10 µM), in the presence of 0-10 mM 
of each of the inhibiting amino acids, was studied using a single 30 sec time point. Charles E. Ebikeme, 2007     Chapter 3, 76 
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Figure 3-11: Threonine inhibition by AATP1 specific amino acids. 
Inhibition of 10 µM L-[3H] Threonine using cold threonine (A), serine (B), asparagine (C), 
alanine (D), glycine (E), and cysteine (F) over a range of concentrations (no inhibitor, 1 
µM, 10 µM, 50 µM, 100 µM, 500 µM, 1 mM, 2 mM and 4 mM). Uptake shown as a 
percentage of control with no inhibitor (n=3, Error bars = ±SEM). 
 
Using a range of concentrations can distinguish between ‘weak’ and ‘partial’ inhibition. In 
each case these amino acids gave a progressive dose-dependent inhibition. Suggesting the 
order  of  affinity  for  AATP1  being  L-threonine>>L-serine>>Glycine>>L-alanine>>L-
cysteine>>L-asparagine. 
  IC50  SEM 
Threonine  27.9 µM  5.3 
Serine  197.3 µM  91.9 
Glycine  296.2 µM  71.4 
Cysteine  5.74 mM  4.91 
Asparagine  9.57 mM  5.35 
Alanine  1.17 mM  0.335 
Table 3: Calculated IC50 for the TbAATP1 specific amino acids. Charles E. Ebikeme, 2007     Chapter 3, 77 
 
L-threonine, L-serine and glycine have the highest affinities for TbAATP1, showing IC50 
values in the micro molar range. The calculated IC50 values refer to the amount of inhibitor 
required to inhibit uptake of a particular amino acid by 50%. 
Kinetic parameters for the mode of threonine uptake were determined. Measuring initial 
velocity  of  L-threonine  transport  against  substrate  concentration  (starting  at  200  µM 
threonine)  for  the  TbAATP1  cell  line  grown  with  and  without  tetracycline  revealed  a 
typically  hyperbolic  curve,  and  Vmax  and  Km  values  were  calculated  by  non-linear 
regression. 
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Figure 3-12: Kinetics of threonine uptake in uninduced TbAATP1 RNAi cell lines. 
Uptake of L-[
3H] Threonine over a range of concentrations at a single 30 sec time point 
(n=3). 
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Figure 3-13: Kinetics of threonine uptake in tetracycline induced TbAATP1 RNAi cell lines. 
Uptake of L-[
3H] Threonine over a range of concentrations at a single 30 sec time point 
(n=3). 
 
The  apparent  kinetic  behaviour  of  L-threonine  uptake  is  comparable  to  the  inhibition 
constant (IC50) previously found. Inhibition of uptake of radiolabelled L-threonine by cold 
L-threonine over a range of concentrations gave an inhibition constant of 27.96 µM. Here, 
kinetic  constants  were  calculated  by  non-linear  regression  using  the  Michelis-Menten 
equation.  For  the  uninduced  cell  line  a  Km  value  of  73.925  µM  and  a  Vmax  of  35.3 
picomols/sec/10
7 cells were calculated, whereas for the induced cell line a Km value of 
86.967 µM and a Vmax of 14.8 picomols/sec/10
7 cells were calculated. 
3.2.4 Osmoregulation 
When  L.  donovani  are  challenged  with  an  acute  decrease  in  osmolarity,  the  parasites 
rapidly release amino acids of which Ala, the major osmolyte in cells, accounted for half of 
the total amino acid loss (Darling & Blum, 1990). Osmoregulation in PCF trypanosomes 
was tested here in the context of the RNAi cell line TbAATP1. TbAATP1 is a transporter 
of small, uncharged neutral amino acids (alanine, glycine, cysteine, serine, threonine and 
asparagine). The proposition is that with transporter availability cells will be unable to 
regulate cell volume and shape under hypotonic stress. All observations for this cell line 
were done at 72 hrs post tetracycline induction. Charles E. Ebikeme, 2007     Chapter 3, 79 
Three different hypotonic conditions was used, simply differing in water content (0, 25% 
and 50% water). Cells were monitored by microscopy after a 30 min time period to judge 
the level of swelling that initially occurred and the change in cell shape. 
Overrall,  there  was  no  difference  in  the  amount  of  general  swelling  when  comparing 
induced and uninduced cell lines. It is entirely possible that the length of time needed for 
TbAATP1 induced cells to recover resting shape within hypotonic media is altered. Hence, 
no difference in swell shape is seen between the two cell lines. This could be due to the 
fact that although there is a common transport route for these amino acids, other general 
amino  acid  transport  mechanisms  could  contribute.  As  well  as  the  fact  that  release  of 
alanine to compensate for swelling could easily be substituted with another amino acid 
pool. Although, the TbAATP1 transporter has here not been shown to be implicated in 
osmoregulation, other systems could be at play. 
3.2.5 Cloning of TbAATP6 & TbAATP12 RNAi Constructs 
In this study I tested the ability of the p2T7Ti vector to generate, by RNAi knockdown, 
mutant  phenotypes  for  TbAATP12  and  the  TbAATP6  set  of  genes  not  previously 
characterised in T. brucei. I attempted to inhibit expression of the T. brucei TbAATP6 and 
TbAATP12 genes in PCF trypanosomes. A previously developed T. brucei cell line 29-13, 
engineered to express T7 RNA polymerase and the tetracycline repressor, was used. A 600 
bp  fragment  from  the  TbAATP6  open  reading  frame  was  inserted  between  the  two 
opposing  T7  promoters  of  the  p2T7Ti  vector  that  are  both  regulated  by  tetracycline 
repressors. A 554 bp fragment and a 620 bp fragment from the TbAATP12 open reading 
frame was inserted between the two opposing T7 promoters of the p2T7Ti vector that are 
both regulated by tetracycline repressors. 
A 3’end segment of the T. brucei “TbAATP6” gene was amplified from T. brucei strain 
427 genomic DNA using the following primers: 
5’- ATATGGATCCATTGTCAATCTTCATGTTTTC-3’, sense from position 980 to 1001 
of  the  TbAATP6  coding  region,  including  a  BamHI  site  (underlined),  and  5’- 
ACATCTCGAGATTGAGGCAGCCGTACCAAAC-3’,  antisense  complementary  to 
positions from 1559 to 1580, including a XhoI site (underlined), for amplification of 600 
bp (C terminal region) (Figure 3-14). Charles E. Ebikeme, 2007     Chapter 3, 80 
Purified PCR product
Lane 1: 1 kb Ladder Marker
Lane 2: TbAATP6 purified PCR product
250
500
750
1 2
 
Figure  3-14:  Ethidium  bromide  stained  gel  showing  PCR  amplification  of  a  segment  of 
TbAATP6. 
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Figure  3-15:  Ethidium  bromide  stained  gel  showing  excision  of  p2T7Ti  ligated  TbAATP6 
insert. 
 
5’end and 3’end segments of the T. brucei “TbAATP12” gene were amplified from T. 
brucei strain 427 genomic DNA using the following primers: 
5’- ATATGGATCCATGGTTGTGAATTCTGATGGG-3’, sense from position 1 to 21 of 
the  TbAATP12  coding  region,  including  a  BamHI  site  (underlined),  and  5’- 
ACATCTCGAGAAAAATGTTGTTAGGCGGACA-3’,  antisense  complementary  to 
positions from 533 to 554, including a XhoI site (underlined), for amplification of 554 bp 
(N terminal region) (Figure 3-17). Charles E. Ebikeme, 2007     Chapter 3, 81 
5’- ATATGGATCCGGGATTTGGTATTTTTATCTT-3’, sense from position 740 to 761 
of  the  TbAATP12  coding  region,  including  a  BamHI  site  (underlined),  and  5’- 
ACATCTCGAGATTGATAATCGCATAAATCGT-3’,  antisense  complementary  to 
positions from 1518 to 1539, including a XhoI site (underlined), for amplification of 620 
bp (C terminal region) (Figure 3-16). 
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Figure 3-16: Ethidium bromide stained gel showing both fragments of TbAATP12 amplified 
by PCR. 
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Figure 3-17: Ethidium bromide stained gel showing excision of p2T7Ti ligated TbAATP12a 
insert. 
 
Transfection  of  the  PCF  cell  line  29-13  with  the  RNAi  constructs  directed  against 
TbAATP6  and  TbAATP12  proved  moderately  efficient.  The  cells  survived  14  day 
phleomycin selection (0.1 µg/ml) and were subsequently cloned out by limiting dilution. Charles E. Ebikeme, 2007     Chapter 3, 82 
However, for TbAATP6, viable cells grew very slowly initially even in the presence of up 
to 75% conditioned medium. 
3.2.6 Northern Blot Analysis 
The  effectiveness  of  RNAi  on  mRNA  levels  and  the  correlation  between  the  growth 
defects and mRNA levels was examined. RNA was extracted from clonal lines before and 
after  induction  with  tetracycline.  Total  isolated  RNA  was  then  subjected  to  Northern 
analysis with a probe derived from the coding region of TbAATP6 and TbAATP12. 
 
Figure 3-18: Northern blot analysis of RNA from TbAATP6 RNAi cell lines. 
Northern blot was probed with a fragment from the TbAATP6 gene and a ß tubulin gene 
was used as a control. Lanes 1-4 indicate days post tet induction (T0, 0 hr; T1, 24 hr; T2, 
48 hr; T3, 72 hr). 
 
Northern  analysis  of  RNA  from  ∆TbAATP6-i  (Figure  3-18)  shows  that  the  target 
TbAATP6 mRNA was readily detectable in transfected cells in the absence of the inducer 
tetracycline (Lane 1: T0). However, analysis indicated that degradation of the TbAATP6 
mRNA was not efficient. At time points up to 72 hours no loss of mRNA was seen, with 
only a significant loss of mRNA after 24 hours (Lane 2: T1). This means that RNAi gene 
silencing  of  TbAATP6  is  not  operating  in  an  efficient  and  inducible  manner  in  this 
instance. RNAi is powerful tool for selective interference of gene expression in PCF but 
experiments presented here didn’t demonstrate its effectiveness. Charles E. Ebikeme, 2007     Chapter 3, 83 
 
Figure 3-19: Northern blot analysis of RNA from TbAATP12 RNAi cell lines. 
Northern blot was probed with a fragment from the TbAATP12 gene and a ß tubulin gene 
was used as a control. Lanes 1-4 indicate days post tet induction. 
 
Northern  analysis  shows  that  the  target  TbAATP12  mRNA  was  readily  detectable  in 
transfected  cells  in  the absence  of  the  inducer  tetracycline  and  that  degradation  of  the 
TbAATP12 mRNA was efficient, even after 24 hours post tetracycline induction (Figure 3-
19). 
3.2.7 Tetracycline Induction and Growth Curves 
The growth of clonal cells carrying the RNAi construct upon tetracycline induction was 
compared  uninduced  cells.  Growth  was  determined  in  normal  medium  as  well  as  in 
medium containing single carbon sources (SDM80 plus proline or glucose at 10 mM). In 
∆TbAAT6-i PCF clones, tetracycline induction caused a dramatic growth phenotype, not 
only  in  SDM79,  but  also  in  SDM80  supplemented  with  10  mM  L-proline.  Growth  of 
induced  cell  lines  in  SDM80  plus  D-glucose  (10  mM)  showed  no  difference  from 
uninduced cell lines. Charles E. Ebikeme, 2007     Chapter 3, 84 
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Figure 3-20: Growth of TbAATP6 RNAi cell lines. 
Tetracycline induced and uninduced cell lines grown in SDM80 (panel A), SDM80 plus 10 
mM L-proline (panel B), SDM80 plus 10 mM D-glucose (panel C) and SDM79 medium 
(panel D) (this result represents data from 3 similar repeats). 
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Figure 3-21: Growth of TbAATP12 RNAi cell lines. 
Tetracycline induced and uninduced cell lines grown in SDM80 (panel A), SDM80 plus 10 
mM L-proline (panel B), SDM80 plus 10 mM D-glucose (panel C) and SDM79 medium 
(panel D) (this result represents data from 3 similar repeats). 
 Charles E. Ebikeme, 2007     Chapter 3, 85 
For ∆TbAATP6-i, a decrease in the growth rate of induced culture in SDM79 medium was 
evident within 24 hours of tetracycline induction. The uninduced cells grew at much higher 
rate than the induced cells (Figure 3-20 D), exhibiting a reduced doubling time in normal 
medium and proline only medium. Microscopic inspection of the cells showed no major 
changes in cell morphology upon the addition of tetracycline. L-proline is the only amino 
acid that can serve as a carbon source (Lamour et al., 2005). It is possible that TbAATP6 
has a role in proline transport due to the fact that a reduction of growth upon tetracycline 
induction is associated with  growing  cells in proline only  medium. However,  with the 
northern  blot  analysis  showing  ineffective  knock-down  of  the  gene  transcript,  the 
significance of this is most likely be due to abarrent effects of the RNAi mechanism and 
not due to the TbAATP6 gene. 
In  ∆TbAATP12-i  PCF  clones,  tetracycline  induction  caused  no  significant  growth 
phenotype. Growth of ∆TbAATP12-i induced cell lines in SDM80 plus D-glucose (10 
mM), SDM79, SDM80 plus L-proline (10 mM) showed no difference from uninduced cell 
lines.  Moreover,  microscopic  inspection  of  the  cells  showed  no  major  changes  in  cell 
morphology upon the addition of tetracycline. 
3.2.8 TbAATP6 Transporter Phenotype 
I  wanted  to  test  a  possible  transporter  phenotype  to  see  if  TbAATP6  knock-down 
corresponds  to  reduced  uptake  of  a  particular  amino  acid.  Since  TbAATP6  showed  a 
growth phenotype, particularly in proline only medium, I assessed TbAATP6 as a possible 
proline transporter. Charles E. Ebikeme, 2007     Chapter 3, 86 
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Figure 3-22: Proline uptake in TbAATP6 RNAi cell lines. 
Uptake  of  100  µM  L-[
3H]  Proline  in  TbAATP6  RNAi  cell  lines  (plus  and  minus  tet 
induction) over a 1 hour time period (n=3, Error bars = ±SEM). 
 
TbAATP6 RNAi cell lines showed no reduced accumulation of proline over the one hour 
time period, suggesting that this transporter is not involved in proline uptake. However, in 
the absence of a working RNAi mechanism (as shown by northern blots) a phenotype for 
TbAATP6 cannot be postulated. 
3.3  Discussion 
Why the redundancy in amino acid transporter genes? It is possible that in addition to the 
fact that genes correspond to a given/particular structure-activity relationship, amino acid 
transporter genes could have evolved out of a particular need for a particular metabolic 
pathway. It is possible that important metabolites involved in the same pathway could be 
co-transported together, resulting in different transporters for different amino acid groups, 
of which the groups are not based on structural relationships. 
3.3.1 TbAATP1 
Previous studies involving the use of a number of amino acids to competitively inhibit the 
uptake  of  others  have  allowed  the  differentiation  of  several  separate  amino  acid 
transporters  (Voorheis,  1971).  Four  amino  acid  transport  systems  were  defined;  first 
neutral  amino  acid  carrier  (transporting  glycine,  alanine,  serine  and  threonine),  second Charles E. Ebikeme, 2007     Chapter 3, 87 
neutral amino acid carrier (transporting valine, leucine, proline and methionine), first acid 
amino acid carrier (transporting  glutamate only), and the first basic amino acid carrier 
(transporting lysine only). However, it is now evident from the vast number of amino acid 
transport  genes  identified  from  the  genome  database  as  well  as  the  biochemical 
characterisations of transport of certain amino acids that a more complex story is at play. 
Voorheis  (1971)  reported  the  existence  of  a  neutral  amino  acid  transport  system  in 
bloodstream form trypanosomes (questionable since no data was presented). Here I report, 
through  RNAi,  a  similar  transport  system  that  exists  in  PCF  trypanosomes.  TbAATP1 
(AAT7)  mediates  the  transport  of  alanine,  threonine,  serine,  glycine,  cysteine  and 
asparagine. This genomic locus seems unique to T. brucei as no homeologs are found in 
Leishmania or T. cruzi. This suggests that only T. brucei has a transporter system unique 
for the amino acids transported by TbAATP1 (ser, gly, cys, ala, asn, thr). 
Acetate  derived  from  threonine  has  a  role  as  a  precursor  for  lipid  biosynthesis  and 
inhibition  of  threonine  metabolism  via  the  enzyme  aldehyde  dehydrogenase  showed  a 
marked growth phenotype (Voorheis et al., 1975). Here, with TbAATP1, I show some 
indication to a growth phenotype when downregulation of this transporter system is in 
play. However, this growth phenotype has not been linked exclusively to reduced threonine 
uptake. 
The  segment  of  TbAATP1  amplified  for  creation  of  the  RNAi  construct  shows  high 
sequence  homology  to  the  three  unannotated  genes  flanking  TbAATP1  (termed 
TbAATP2). TbAATP1 and TbAATP2 show >80% sequence identity (with 70% usually 
needed for knock down experiments). Therefore, it is a certainty that the RNAi phenotype 
is also as a result of TbAATP2  knock down. Most amino acid transporters have been 
biochemically characterised but few have been related to a specific genomic locus. Here, 
uptake  of  L-serine,  glycine,  L-cysteine,  L-asparagine,  L-alanine  and  L-threonine  is 
specifically linked to the AAT7 genomic locus of T. brucei. This genomic locus seems to 
play a role in cell growth as seen by stunted growth of cell lines exposed to tetracycline for 
prolonged  periods.  However,  this  growth  phenotype  does  not  seem  to  be  related  to 
immediate transporter activity, yet seems more of a delayed effect of initial amino acid 
depletion. 
I have shown an order of affinity for the TbAATP1 transport system (L-threonine>>L-
serine>>Glycine>>L-alanine>>L-cysteine>>L-asparagine).  Does  the  order  of  preference 
relate to downstream metabolic requirement? Only few studies into amino acid usage in Charles E. Ebikeme, 2007     Chapter 3, 88 
trypanosomes have been performed, and most focus on a few. Apart from use in protein 
synthesis  the  most  biologically  relevant  of  the  TbAATP1  specific  amino  acids  are  L-
threonine  and  L-cysteine.  Cysteine  is  an  essential  growth  factor  for  bloodstream  form 
trypanosomes  and  is  involved  in  protein  biosynthesis  as  well  as  in  the  production  of 
glutathione and trypanothione (Duszenko et al., 1992). Dr I. Accoceberry has suggested at 
least one other route of entry for L-cysteine (unlabelled cysteine was unable to inhibit 
radiolabelled cysteine). 
L-threonine usage by African trypanosomes has previously been studied and been found to 
be a precursor for acetate (which feeds into lipid biosynthesis) in T. brucei (Cross et al., 
1975).  There  is  cleavage  of  L-threonine  to  form  glycine  and  acetate  within  the 
mitochondrial compartment. Preliminary examination of changes in medium amino acid 
levels  during  growth  of  Trypanosoma  brucei  revealed  complete  metabolisation  of  L-
threonine (Cross et al., 1975). BSF and PCF trypanosomes were reported previously to be 
able to catabolise L-threonine (Colasante et al., 2006). In PCF trypanosomes threonine 
metabolism has been shown to occur exclusively in the mitochondrion: here threonine is 
converted to acetyl-CoA and glycine by the enzymes L-threonine 3-dehydrogenase (EC 
1.1.1.103) and acetyl-CoA:glycine C-acetyltransferase (Opperdoes et al., 1981). 
Here  I  have  shown  no  essentiality  for  L-threonine  in  PCF  trypanosomes.  Removal  of 
threonine from the growth medium showed no disadvantage for growth of wild type cells 
whether proline or glucose was used as the primary carbon source. This suggests that the 
acetate units provided by acetyl-CoA from the catabolism of threonine can be compensated 
for by another source (pyruvate when glucose is metabolised and fatty acid metabolism 
when  glucose  is  absent).  It  is  also  possible  that  the  internal  threonine  pool  can  be 
supplemented by another source. Lack of threonine essentiality suggests that the growth 
defect of ∆TbAATP1-i cell lines is not as a result of threonine alone and most likely due to 
the other TbAATP1 specific amino acids, either individually or cumumulatively. Salvage 
of these six amino acids in trypanosomes occurs via transport processes as well as from 
side products of other metabolic processes with the exception of glycine and serine, of 
which biosynthesis does not seem to occur from another metabolic pathway (KEGG). The 
essentiality of all AATP1 specific amino acids (individually and in combination) will need 
to be investigated much in the same way threonine was investigated. 
The six amino acids specific for TbAATP1 give more insight into the structural specificity 
of the transporter. Asparagine is the only TbAATP1 specific amino acid with a hydrophilic 
side group and, consequently, is the least specific for TbAATP1. However, its side group is Charles E. Ebikeme, 2007     Chapter 3, 89 
small enough to be recognised by the transporter. Other amino acids with hydrophilic side 
groups contain a charged group or are too large to be recognised by the transporter. The 
rest of the TbAATP1 specific amino acids share common neutrality and a small side chain 
of two carbon units or less.  
There is a consistency shown among the uptake of currently characterised amino acids by 
their various systems. Modes of entry of amino acids have affinities in the micro molar 
range, reflecting the relative abundance of these substances the parasite encounters. Here I 
have determined the kinetic constants of threonine transport by ∆TbAATP1-i cell lines. A 
Km value of 73.925 µM and a Vmax of 21.18 nanomols/min/10
8 cells were calculated. L-
methionine transport in both PCF and BSF parasites were measured in the presence of 
various methionine concentrations (Hasne & Barrett, 2000). The kinetic constants were 
determined by non-linear regression analysis using the Michaelis–Menten equation. A Km 
value of 30.99 +/-7.6 µM and a Vmax of 16.29 +/- 0.01 nmol/min/10
8 cells were calculated. 
For uptake in bloodstream forms, a Km value of 32.89 +/-3.4 µM and a Vmax of 28.89 +/-
0.1  nmol/min/10
8  cells  were  calculated  (Hasne  &  Barrett,  2000).  Proline  uptake  in 
procyclic trypanosomes has been shown to be carrier mediated with an apparent Km of 21 
+/-2.9 µM and a Vmax of 7.0 nanomoles/min/10
8 cells. This level of uptake is modulated by 
the presence or absence of glucose in the growth media (Lamour et al., 2005). 
Cell  survival  is  dependent  on  the  ability  of  cells  to  maintain  a  chemically  stable 
intracellular  milieu  (for  optimal  enzyme  activity)  and  to  regulate  their  volume.  Cells 
exposed  to  a  medium  of  reduced  osmolarity  swell  initially,  but  subsequently  undergo 
compensatory shrinkage by a regulatory volume decrease (RVD) response. Different types 
of osmolytes have been implicated in the RVD process, from amino acids such as alanine, 
glutamine, glycine, proline, and glutamate, to sugars (Viera et al., 1998). The ability of 
Leishmania to regulate its volume has been studied. When L. donovani are challenged with 
an acute decrease in osmolarity, the parasites rapidly release amino acids of which Ala, the 
major osmolytes in cells, accounted for half of the total amino acid loss (Darling & Blum, 
1990). Charles E. Ebikeme, 2007     Chapter 3, 90 
 
Figure 3-23: Volume regulation in trypanosomatid parasites under hypotonic shock (taken 
from Viera et al., 1998). 
AAs, amino acids (neutral and negatively charged); N, nucleus; RVD, regulatory volume 
decrease. 
 
Here,  I  have  shown  the  TbAATP1  transporter  system  not  to  be  implicated  in 
osmoregulation. However, other systems could be at play. It is entirely possible that the 
length  of  time  needed  for  ∆TbAATP1-i  induced  cells  to  recover  resting  shape  within 
hypotonic media is altered. Hence, no difference in swell shape is seen between both cell 
lines. 
The kinetics of release of amino acids from the intracellular pool can be explored much in 
the way it has been previously (Voorheis & Martin, 1980). Cells previously incubated with 
a metabolically inert amino acid (2-amino [1-
14C] isobutyric acid) were then exposed to 
varying osmotic strengths, with the release of radioactivity measured over time. 
The  amino  acid  analogue  glycine  chloromethyl  ketone  (1-amino  3-chloropropan-2-one) 
has been shown to act as a specific irreversible inhibitor of the neutral amino acid transport 
system  (Owen  &  Voorheis,  1975).  Pre-incubation  of  cells  with  the  analogue  and  then 
subjecting them to hypotonic stress would be a way to ascertain if this transport system is 
involved in osmoregulation. Charles E. Ebikeme, 2007     Chapter 3, 91 
3.3.2 TbAATP6 & TbAATP12 
The  RNAi  technique  was  used  to  study  the  physiological  role  of  two  other  genes 
(TbAATP6 and TbAATP12) in T. brucei PCF trypanosomes. Elimination of transcripts in 
cell lines transfected with the P2T7Ti vector carrying a fragment of the AATP gene was 
evaluated by Northern blot analysis. With TbAATP6 significant degradation of transcript 
was  not  seen  in  tetracycline  induced  cell  lines  up  to  72  hours  post  induction.  With 
TbAATP12  loss  of  mRNA  was  seen  as  early  as  24  hours  post  induction.  Lack  of  an 
effective  RNAi  mechanism  at  work  in  ∆TbAATP6-i  cell  lines  could  be  as  a  result  of 
sequence similarity to a related AATP gene. Tb11.01.7500 and Tb11.01.7520 (AAT16 and 
AAT17) are the closest related AATP and show a ~50% sequence identity to TbAATP6. 
That identity is spread throughout the gene sequence and not limited to a particular part of 
the  open  reading  frame.  It  is  possible  that  the  RNAi  mechanism,  in  this  case  is  not 
operating in a gene specific manner. The RNAi construct created for TbAATP6 takes a 
gene fragment from the C-terminal end of the protein (3’ end of the open reading frame). 
With  RNAi  sometimes  C-terminal  RNAi  targeting  is  ineffective  (Dr.  Alibu,  personal 
communication) and most of the time, N-terminal targeting works out better. Hence, for 
efficient targeting of TbAATP6, a gene fragment towards the N-terminal of the gene and 
one that will provide less crosstalk between related gene products is needed in the design 
of future RNAi experiments. 
The  fact  that  ∆TbAATP6-i  cell  lines  showed  reduced  growth  in  normal  medium  and 
proline only medium suggested a possible role for the transporter associated with proline 
metabolism.  Proline  uptake  in  tetracycline  induced  cell  lines  showed  no  significant 
difference from uninduced cell lines. However, this experiment was performed after 72 
hours tetracycline induction; a time shown by Northern analysis to have no significant 
degradation of mRNA transcript. It is possible that cross-reaction of the RNAi mechanism 
to another related gene results in stable down-regulation of that transcript. However, with 
no reduction in proline uptake we must assume that neither TbAATP6 nor a related similar 
AATP acts as a proline transporter. Another possibility exists; one that involves another 
amino acid or group of amino acids that are under regulation by glucose. Proline regulation 
by glucose availability has been shown (Lamour et al., 2005; chapter 4). Increased reliance 
of other amino acids in the absence of glucose is a possibility that has yet to be explored. It 
is  important  to  note  that  any  suggested  phenotype  is  inadmissible  in  the  absence  of  a 
working RNAi mechanism. Charles E. Ebikeme, 2007     Chapter 3, 92 
TbAATP12  RNAi  cell  lines  showed  no  growth  defect  with  tetracycline  induction 
regardless  of  primary  carbon  source  in  the  growth  medium,  ruling  out  a  role  for 
TbAATP12 in cell growth. A transport phenotype still remains to be determined for this 
cell line. Uptake assays using all 20 radiolabelled amino acids will need to be performed in 
order to ascertain if uptake of any amino acid is effected. 
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4  Proline Transport Regulation as a Result of a 
Metabolic Shift Induced by N-Acetyl D-Glucosamine Charles E. Ebikeme, 2007     Chapter 4, 94 
4.1  Introduction 
The T. brucei lifecycle is complex, and the parasite adapts to life in both its insect host 
(tsetse fly) and in the mammalian hosts. These distinct environments require the parasite to 
remodel its metabolism to thrive within each (Besteiro et al., 2005). In the D-glucose-rich 
environment  of  the  mammalian  bloodstream  the  parasite  relies  solely  on  D-glucose  to 
produce energy. D-glucose can be metabolised by either the glycolytic pathway or the 
pentose  phosphate  pathway  (Barrett,  1997).  The  first  seven  steps  of  glycolysis  occur 
sequestered in the peroxisome-like organelle, the glycosome (Opperdoes & Borst, 1977; 
Michels et al., 2006). 
In PCF trypanosomes, the mitochondrion has traditionally been held to produce the major 
proportion of the cell’s ATP (Bochud-Allemann & Schneider, 2002). This is largely due to 
the  use  of  alternative  carbon  sources  like  L-proline  as  the  input  for  mitochondrial 
metabolism (Besteiro et al., 2005). ATP can be generated by oxidative phosphorylation 
(electron transport chain), or by substrate-level phosphorylation, with an unusual reaction 
catalysed by succinyl-CoA synthase, and coupled to acetate formation being key (Bochud-
Allemann & Schneider, 2002; van Hellemond et al., 1998; Rivière et al., 2005). Recently, 
the exact contribution of the Kreb’s cycle to energy generation has been looked at in detail 
(Van Weelden et al., 2003; Van Weelden et al., 2005), and it appears that in spite of most 
Kreb’s cycle enzymes being present, the flux of substrates through these enzymes does not 
occur in the classical sense. However, these studies – as with many related to procyclic 
metabolism  –  were  performed  on  trypanosomes  grown  in  D-glucose-rich  medium.  D-
glucose apparently represses L-proline metabolism in procyclic trypanosomes (Lamour et 
al.,  2005;  Evans  &  Brown,  1972).  In  these  conditions  the  parasite  appears  capable  of 
fulfilling energy needs without using the Kreb’s cycle or electron transport chain and by 
producing ATP primarily by substrate level phosphorylation (oxidative phosphorylation is 
not essential). 
In the mammalian host, trypanosomes divide as long slender bloodstream forms, covered 
by a dense coat of variant surface glycoproteins (VSG) (Cross, 1975; Roditi, 1996). When 
ingested by the fly in the blood meal, the short stumpy bloodstream forms which are cell-
cycle  arrested  and  are  pre-adapted  to  life  within  the  tsetse  fly  (Roditi  et  al.,  1989), 
differentiate into procyclic form trypanosomes that are able to colonise the midgut of the 
fly (Roditi et al., 1989). Parasite differentiation is accompanied by the replacement of the 
VSG coat by an invariant coat of EP or GPEET procyclins (Roditi et al., 1989; Roditi et Charles E. Ebikeme, 2007     Chapter 4, 95 
al., 1998). EP expression continues throughout the fly stage of the procyclic form whereas 
GPEET  expression  is  downregulated  in  late  procyclics  (Vassella  et  al.,  2000;  Acosta-
Serrano  et  al.,  2001).  In  culture,  however,  GPEET  expression  can  be  modulated  by 
glycerol or D-glucose (Vassella et al., 2000). RNAi silencing of the first step of glycolysis, 
hexokinase, caused a dramatic switch from EP-procyclins to GPEET-procyclin expressed 
on the outer coat (Morris et al., 2002); suggesting that removal of D-glucose enhances 
GPEET-procyclin  expression.  Regulation  of  expression  of  EP-  and  GPEET-procyclin 
isoforms appears to be controlled by mitochondrial enzymes of the acetate:succinate CoA-
transferase (ASCT) cycle (Vassella et al., 2004). Silencing of the hexose transporter and 
the phosphofructokinase enzyme also upregulated GPEET-procyclin expression, indicating 
that a reduction in glycolytic flux correlates with EP to GPEET switch.  
L-proline metabolism too is modulated by D-glucose availability (Lamour et al., 2005). 
Whether one or more metabolites act to trigger such a switch is not known. For instance, it 
was proposed that D-glucose (or its analogue 2-DOG) alone was capable of inducing the 
repression of L-proline metabolism (Lamour et al., 2005), since the presence of the non-
metabolisable analogue (2-DOG) is sufficient to block growth of parasites using proline as 
an energy source. It is possible that 2-DOG affects cells in a way that is independent of a 
down-regulation  of  proline  metabolism  when  glucose  is  absent.  However,  it  is  also 
possible that glucose and 2-DOG act allosterically to bring about proline down-regulation. 
In  addition  to  profound  differences  between  BSF  and  PCF  trypanosomes  in  glucose 
metabolism, uptake of this carbohydrate also differs in BSF and PCF Trypanosoma brucei 
brucei.  Different  transporter  isoforms  make  the  major  contribution  to  uptake.  The 
Trypanosome Hexose Transporter 1 (THT1) is expressed in bloodstream forms at a level 
40 times that of THT2, while procyclic form trypanosomes express only the THT2 isoform 
(Bringaud  et  al.,  1992;  Barrett  et  al.,  1995).  The  C2  substituents  of  D-glucose,  D-
glucosamine (GlcN) and N-acetyl D-glucosamine (GlcNAc) have previously been shown 
to interact with the hexose transporter of bloodstream form trypanosomes (Eisenthal et al., 
1989). D-glucose and GlcN uptake has been shown. However, in the case of GlcNAc there 
was no apparent uptake in bloodstream forms (Azema et al., 2004) although an interaction 
with the hexose transporter was noted, since GlcNAc inhibits uptake of 2-DOG and GlcN. 
The ability of PCF to accumulate GlcNAc has not been studied. 
Establishment  of  trypanosome  infection  is  as  complicated  in  the  fly  as  it  is  in  the 
mammalian system. The parasite must establish itself as a dividing procyclic population 
before development can progress. Natural infection rates are low and attributed to many Charles E. Ebikeme, 2007     Chapter 4, 96 
environmental and intrinsic fly factors (Welburn & Maudlin, 1999; Dale & Welburn, 2001; 
Welburn et al., 1993). Like other insects, the tsetse fly has an effective innate immune 
system  and  several  components,  including  midgut  lectins,  have  been  implicated  in 
trypanosome killing, playing a role in determining vector susceptibility (Welburn et al., 
1989;  Welburn  &  Maudlin,  1990).  Lectins,  a  class  of  proteins  that  bind  certain 
carbohydrates noncovalently, found in the midgut of Glossina morsitans (Ibrahim et al., 
1984) mediate the lysis of trypanosomes and at the same time have been postulated to 
provide the signal for the parasites to mature (Welburn & Maudlin, 1989).  The role of 
lectins in preventing trypanosome infection was inferred from enhanced infection rates 
after feeding the lectin-inhibitory amino sugars GlcN and GlcNAc. The amino sugars GlcN 
and GlcNAc have multiple effects in establishing parasite midgut infection. Both sugars 
occur naturally in the gut of some flies through the action of chitinase produced by the 
non-obligatory endosymbiont Sodalis glossinidius (Dale &  Welburn, 2001). The sugars 
block lectin-mediated trypanosome killing as well as inhibiting trypsin activity (Osir et al., 
1993, Abubakar et al., 2006). This is proposed to underlie the increase in infection rates 
(Mihok et al., 1992). Recently, it was proposed that these sugars may have anti-oxidant 
function that aids in establishing infection (Macleod et al., 2007). 
It has been shown that GlcNAc also stimulated trypanosome growth in vivo in the fly gut 
and also in vitro in the absence of fly derived factors (Peacock et al., 2006). We have 
investigated  the  underlying  basis  for  this  effect.  Given  that  bloodstream  form 
trypanosomes do not show any apparent uptake of GlcNAc (Azema et al., 2004), we aimed 
here  to  determine  whether  procyclic  forms  could  accumulate  GlcNAc,  or  whether  its 
effects might be due to other mechanisms. For example, either as a simple direct growth 
factor  or  alternatively,  through  inhibition  of  D-glucose  uptake  leading  to  an  induced 
metabolic shift that enhances growth. 
Repression  of  proline  catabolism  seems  to  be  directed  at  both  the  transporter  and  the 
proline  dehydrogenase  enzyme  (PRODH).  Differential  expression  of  amino  acid 
transporters, as a result of the duality of the life cycle of these parasites, is expected and 
requires that changes in its surrounding environment be observed in the different life cycle 
stages. Within individual life cycle stages we also get differential expression of amino acid 
transporters as a result of differing extracellular conditions. Proline regulation as a function 
of glucose availability has been shown in PCF trypanosomes (Lamour et al., 2005). It is 
possible that regulation of other amino acid transporters occur as a result of glucose or 
other factors, whether in PCF or BSF trypanosomes; and this regulation might play a role 
in the development of the parasite. Charles E. Ebikeme, 2007     Chapter 4, 97 
4.2  Results 
4.2.1 GlcNAc Stimulates Growth of PCF Trypanosomes 
GlcNAc has previously been show to stimulate growth of procyclic form trypanosomes 
(strain  J10)  in  vitro  using  Cunningham’s  medium  (CM)  (Peacock  et  al.,  2006).  To 
determine whether a similar effect was seen using other T. brucei strains we investigated 
growth of T. brucei strain TREU 927. 
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Figure 4-1: Cell counts of PCF trypanosomes (strain TREU 927). 
A starting density of 5 x 10
5 cells per ml, grown in CM and CM supplemented with 60 mM 
GlcNAc (this represents data from 3 similar repeats, error bars = ±SEM). 
 
60 mM GlcNAc enhanced survival and increased final density, with an increase in growth 
rate after 2 days (Figure 4-1). GlcNAc enhancement of growth could be as a direct result of 
its  usage  as  a  potent  energy  source.  To  test  whether  GlcNAc  itself  was  capable  of 
supporting growth, we tested the ability of trypanosomes to grow in medium containing 
this amino sugar but no D-glucose or L-proline (SDM80, Appendix 8.2). Charles E. Ebikeme, 2007     Chapter 4, 98 
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Figure 4-2: Cell counts of PCF trypanosomes (strain TREU 927) grown in SDM80 medium. 
A starting density of 5 x 10
5 cells per ml, grown in SDM80 (D-glucose- L-proline-depleted 
medium) supplemented independently with 60 mM GlcNAc, 10 mM L-Proline, 10 mM D-
Glucose or 10 mM L-Proline and 10 mM D-Glucose (this represents data from 3 similar 
repeats, error bars = ±SEM). 
 
While either L-proline or D-glucose supported robust growth, GlcNAc failed to do so, 
ruling out a role for GlcNAc as an energy source for these parasites (Figure 4-2). L-proline 
metabolism too is modulated by D-glucose availability (Lamour et al., 2005). Glucose is 
the preferred carbon source and down-regulates proline metabolism. It is possible that non-
internalised GlcNAc prevents glucose utilisation by blocking of the hexose transporter, 
thereby releasing proline from inhibition, resulting in a metabolic switch from  glucose 
metabolism to proline metabolism. Charles E. Ebikeme, 2007     Chapter 4, 99 
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Figure 4-3: Alamar Blue assay using PCF trypanosomes grown in SDM80. 
SDM80 medium supplemented with 10 mM of each of the 20 amino acids and D-glucose 
individually (n=3, error bars = ±SEM). 
 
The Alamar blue assay (Figure 4-3) shows that proline as principal carbon source yields a 
more significant growth of trypanosomes than glucose or any other amino acid (data not 
shown for the amino acids aspartate and glutamate). The apparent increase in fluorescence 
seen by the amino acids glutamate and aspartate is anomalous, as the non metabolised D-
isomers  of  these  amino  acids  do  not  support  growth  as  seen  from  the  cell  count  data 
(Figure 4-4). It is possible that the acidic nature of these amino acids interferes with the 
resazurin giving a false positive. The Alamar Blue method is relatively insensitive when 
trying to  assess the exact level of  growth  exhibited. To assess the exact nature of the 
increased growth stimulus provided by proline over glucose cell counts were done. Charles E. Ebikeme, 2007     Chapter 4, 100 
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Figure 4-4: Cell counts of PCF trypanosomes (strain TREU 927) grown in SDM80. 
A starting density of 5 x 10
5 cells per ml, grown in SDM80 (D-glucose- L-proline-depleted 
medium)  supplemented  independently  with  D-glucose,  L-proline,  L-glutamate,  L-
aspartate, D-glutamate, D-aspartate at 10 mM concentrations (this represents data from 3 
similar repeats, error bars = ±SEM). 
 
As previously reported, the D-glucose and L-proline-depleted medium (SDM80) fails to 
support  robust  growth  of  procyclic  form  trypanosomes  (Lamour  et  al.,  2005). 
Supplementation with L-proline or with D-glucose allows growth, while other amino acids 
do not. In fact, L-proline supports more robust growth than D-glucose (Figure 4-4). 
4.2.2 GlcNAc is not Internalised by PCF Trypanosomes 
To  verify  further  its  inability  to  act  as  a  carbon  source,  we  investigated  GlcNAc  as  a 
possible substrate for the PCF hexose transporter. Interaction of GlcNAc with the hexose 
transporter without uptake has previously been reported in BSF trypanosomes (Azema et 
al., 2004) and we investigated whether this was also the case in PCF trypanosomes. The 
ability of the procyclic hexose transporter to recognise GlcNAc and GlcN was assessed by 
determining  the  ability  of  each  to  inhibit  uptake  of  radiolabelled  2-DOG  (2-DOG  has 
previously been shown to be a suitable probe to study D-glucose uptake in procyclic form 
trypanosomes, Barrett et al., 1995). Charles E. Ebikeme, 2007     Chapter 4, 101 
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Figure 4-5: 2-Deoxy-D-glucose inhibition. 
Inhibition of uptake of 10 µM [6-
14C] 2-DOG with cold GlcNAc (open squares), GlcN 
(closed circles) and 2-DOG (open circles) over a range of concentrations (10 µM, 50 µM, 
100 µM, 500 µM, 1 mM, 5 mM, 10 mM). IC50 values were calculated for each inhibitor 
(n=3, error bars = ±SEM). 
 
IC50 values (Table 1) were calculated for each inhibitor (2-DOG = 16.5 µM ± 9.3, GlcNAc 
= 176.18 µM ± 65.28, GlcN = 443.96 µM ± 18.39). This suggests that GlcNAc and GlcN 
do  exhibit  interaction  with  the  procyclic  hexose  transporter,  although  they  show  a 
relatively low affinity (10- and 30-fold lower than 2-DOG, respectively). 
Inhibitor  IC50 (µM)  SEM 
2-Deoxy-D-glucose  16.5  9.3 
Glucosamine  443.96  18.39 
N-Acetyl D-Glucosamine  176.18  65.28 
Table 4: Calculated IC50 values for analogue inhibitors. 
 
However, interaction with the transporter does not necessarily mean internalisation of the 
analogue,  and  accumulation  of  the  analogues  was  tested  using  uptake  assays  of 
radiolabelled sugars (Figure 4-6). Charles E. Ebikeme, 2007     Chapter 4, 102 
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Figure 4-6: Uptake of Glucose analogues. 
Uptake of 1 mM [6-
14C] -2-DOG (open circles), [1-
14C] GlcN and [
3H] GlcNAc (n=3, error 
bars = ±SEM). 
 
As  previously  shown  with  the  bloodstream  form  hexose  transporter,  there  was  no 
internalisation of GlcNAc into PCF trypanosomes. In comparison, the D-glucose analogues 
2-DOG and GlcN were both recognised and internalised by the parasite. Thus GlcNAc 
neither acts as a carbon source nor enters trypanosomes, although it does interact with the 
hexose  transporter  and  thereby  inhibits  D-glucose  uptake,  by  competing  with  the 
transporter. 
4.2.3 Presence of GlcNAc Causes a Switch to Proline Metabolism 
GlcNAc inhibits D-glucose uptake without itself being internalised by PCF trypanosomes. 
To address the question as to whether the effect of GlcNAc is related to its capacity to 
diminish D-glucose uptake  and to induce  a  metabolic shift we analysed the D-glucose 
present in the medium after 24 hrs during log phase growth of trypanosomes (strain TREU 
927).  Glucose  is  quantified  spectrophotometrically  using  the  Glucose  (GO)  Assay  Kit 
(Sigma).  The  kit  employs  enzymatic  reactions  to  produce  a  coloured  end-product,  
proportional  to  the  original  glucose  concentration,  which  can  be  measured  at  540  nm. 
Briefly, D-glucose is oxidized to gluconic acid and hydrogen peroxide by glucose oxidase, 
with hydrogen peroxide reacting with o-dianisidine in the presence of peroxidase to form a 
coloured product. Oxidized o-dianisidine reacts with sulfuric acid to form the measurable 
end-product Charles E. Ebikeme, 2007     Chapter 4, 103 
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Figure 4-7: Glucose utilisation in presence of GlcNAc. 
Residual D-glucose concentration in culture medium during log phase growth of procyclic 
form trypanosomes (strain 927) in the presence and absence of GlcNAc (n=3, error bars = 
±SEM). 
 
With  GlcNAc  present  in  the  medium,  D-glucose  is  consumed  at  a  lower  rate  by  the 
parasites (Figure 4-7). The quantity of L-proline consumed by the procyclic trypanosomes 
has previously been shown to be decreased when D-glucose is available as the principal 
carbon source (Lamour et al., 2005). To assess if GlcNAc supplemented in the medium 
can stimulate this switch to increase proline utilisation, PCF trypanosomes were grown in 
Cunningham’s medium (approx. 4 mM D-glucose and 60 mM L-proline; Appendix 8.4) 
plus or minus GlcNAc (60 mM), SDM80 supplemented with D-glucose (10 mM), or L-
proline (10 mM) and then assayed for L-proline uptake. Charles E. Ebikeme, 2007     Chapter 4, 104 
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Figure 4-8: L-proline uptake. 
Procyclic  form  trypanosomes  pre-adapted  to  different  medium  concentrations  and  then 
assayed for L-proline uptake. Uptake of [
3H] L-proline into procyclic (strain TREU 927) 
trypanosomes grown in Cunningham’s medium (CM containing 4 mM D-glucose and 60 
mM  L-proline)  (white  square),  SDM80  supplemented  with  10  mM  D-glucose  (black 
circles),  SDM80  supplemented  with  10  mM  L-proline  (white  circles)  and  CM 
supplemented with 60 mM GlcNAc (black squares). Uptake was measured at a single 30 s 
time point over a range of concentrations (up to 200 µM) (n=3, error bars = ±SEM). 
 
Pre-adaptation to D-glucose deficient conditions (in SDM80 based medium) increased L-
proline uptake in procyclic form trypanosomes, to a rate twice that in cells grown in high 
D-glucose conditions (Figure 4-8). Cells grown in CM showed an even further reduction in 
L-proline uptake. However, addition of GlcNAc to the medium induced L-proline uptake 
to levels comparable to cells grown in high L-proline medium. It thus appears that the 
presence of GlcNAc induced increased L-proline consumption, probably as a consequence 
of its capacity to diminish uptake of D-glucose. 
4.2.4 Oligomycin Sensitivity 
Oligomycin is the most sensitive known inhibitor of the F0/F1 ATPase enzyme, which is 
critical in ATP generation using the mitochondrial respiratory chain, but not when cells 
produce  ATP  by  substrate  level  phosphorylation.  It  has  been  reported  that  PCF 
trypanosomes growing in a D-glucose-rich media are over 1000 times less sensitive to 
oligomycin than parasites growing in D-glucose-depleted medium (Coustou et al., 2003; 
Lamour et al., 2005). Oligomycin at a concentration of 0.1 ng/ml has been shown to kill all Charles E. Ebikeme, 2007     Chapter 4, 105 
cells  utilising  proline  as  the  principal  carbon  source  whereas  with  glucose  that  value 
increases to 10 µg/ml. 
A modified Alamar Blue method was employed, where procyclic trypanosomes (strain 
TREU 927) were grown in the presence of oligomycin (0.1 ng/ml) and L-proline (5 mM) 
and  the  D-glucose  concentration  was  titred  in  doubling  dilutions  (5  mM  starting 
concentration). 
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Figure 4-9: Oligomycin sensitivity. 
Alamar Blue of PCF trypanosomes exposed to 0.1 ng/ml oligomycin in the presence of 5 
mM proline and decreasing concentrations of glucose (5 mM starting concentration), in the 
presence and absence of GlcNAc (n=3, error bars = ±SEM). 
 
The D-glucose IC50 value for oligomycin sensitivity significantly increases by more than 
ten fold from 48.6 µM to 674.5 µM in the presence of GlcNAc. The metabolic switch 
appears to be a graded response, with oligomycin sensitivity increasing as D-glucose levels 
decrease, indicating a tightly regulated balance. From this, it is evident that, the same link 
between  D-glucose  availability,  L-proline  consumption  and  oligomycin  sensitivity  is 
observed. 
4.2.5 GlcNAc Protects Against Death by 2-Deoxy D-glucose 
The non-metabolised glucose analogue 2-DOG has been shown to lead to the death of PCF 
trypanosomes using proline as the sole carbon source (Lamour et al., 2005; Kessler & 
Parsons, 2005). This killing effect was suggested to be related to the repression of proline Charles E. Ebikeme, 2007     Chapter 4, 106 
usage that glucose (and 2-DOG) exerts (Lamour et al., 2005). This effect of 2-DOG is 
ameliorated  by  increasing  concentrations  of  glucose  in  the  media  (Kessler  &  Parsons, 
2005). Here we examine quantitatively how 2-DOG exerts an effect on proline utilisation, 
and whether GlcNAc offers any protection to the toxic effects of 2-DOG. 
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Figure 4-10: 2-Deoxy-D-glucose sensitivity. 
Alamar Blue of procyclic form trypanosomes grown in the presence of 5 mM L-proline 
and decreasing concentrations of 2-DOG (10 mM starting concentration), in the presence 
and absence of GlcNAc (n=3, error bars = ±SEM). 
 
The effects of 2-DOG are dependent on concentration. Limiting concentrations of 2-DOG 
give an IC50 of 93.9 µM. GlcNAc at a concentration of 60 mM is able to protect against the 
effect of 2-DOG, due to its capacity to diminish 2-DOG entering the cell, significantly 
increasing the IC50 to 953.2 µM. 
4.2.6 Proline  Regulation  as  a  Result  of  the  Overall  Metabolic 
Status of the Cell 
In PCF trypanosome proline consumption is tightly linked to glucose availability. Proline 
consumption as a function of glucose concentration shows a dose dependent response to 
glucose, indicating a gradual replacement of glucose metabolism by proline metabolism – 
rather  than  an  “on-off”  switch  stimulated  by  glucose  reaching  a  critical  limiting 
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The ability of these parasites to adapt to glucose depleted conditions may be altered by 
long-term in vitro culturing in glucose rich medium (Bringaud et al., 2006). The general 
lab strains T. brucei PCF 427 and T. brucei PCF 927 have generally  been cultured in 
standard high glucose medium (SDM79, Cunningham’s Medium). We posed the question 
as to how long is necessary for cells to be exposed to glucose for it to exert its repression 
on proline metabolism? Does glucose entering the cell exert repression directly? To answer 
this question cells were grown in high proline, no glucose and then assayed for proline 
uptake over a 6 hour period in the presence or absence of 10 mM glucose. 
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Figure 4-11: Proline uptake in presence of D-glucose. 
Uptake  of  100  µM  [
3H]  L-Proline  in  proline  adapted  cell  lines  in  the  absence  (white 
circles) and presence (black circles) of 10 mM Glucose, over a 6 hour time period (n=1). 
 
There seems to be no difference in proline uptake between proline adapted cells in the 
presence and absence of 10 mM glucose. Proline uptake reaches a maximum point at 5 – 
10 mins, with apparent efflux after that. This suggests that glucose repression is not a result 
of glucose itself, but rather the adaptational processes that result from glucose availability. 
This  also  suggests  that  proline  regulation  is  probably  not  regulated  at  the  glucose 
transporter level. Because if simple entry of glucose into the cell was all that was required 
to reduce the uptake of proline we would expect to see reduced consumption of proline 
over time. This all gives more weight to glycolysis and glycolytic enzymes in control of 
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However, this does not tell us how much time is needed for glucose to exert its effect, only 
that the glucose entering the cell is not immediately exerting its repression over proline. To 
answer  the  time  dependency  question,  we  adapted  PCF  trypanosomes  to  proline  only 
conditions by growing in SDM80 plus 10 mM proline. At time zero we split cell cultures 
and added 10 mM glucose to one of the flasks and assayed for proline uptake, at a single 
30 second time point, over a 24 hour period. 
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Figure 4-12: Proline uptake after long term D-glucose exposure. 
Uptake of 100 µM [
3H] L-Proline in PCF trypanosomes after a 24 hour period exposure to 
10 mM D-glucose (n=3, error bars = ±SEM). 
 
It is evident that after 24 hours in the presence of D-glucose proline uptake repression is 
beginning to take effect. Proline uptake shows a ~40% reduction after 24 hours in the 
presence of D-glucose. This, together with the previous experiment on proline uptake in 
the  presence  of  D-glucose  in  the  assay  buffer  shows  that  the  repressive  effects  of  D-
glucose on proline are not as a direct result of the entering glucose. Yet, it seems the entire 
metabolic status of the cell (i.e. glycolytic flux) is more likely to be the determinant for 
proline repression. 
4.3  Discussion 
It has been long established that GlcNAc enhances colonisation of tsetse by trypanosomes, 
which  has  been  causally  linked  to  GlcNAc  inhibition  of  midgut  trypanocidal  lectins 
(Abubakar et al., 2006; Mihok et al., 1992; Osir et al., 1993; Welburn & Maudlin, 1999). 
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derived factors was surprising (Peacock et al., 2006). With the fact that GlcNAc is not 
internalised by BSF trypanosomes (Azema et al., 2004) and D-glucose exerts repressive 
effects on proline consumption we investigated the possibility that the in vitro effects of 
GlcNAc was brought about by the ability of the analogue to block glucose entry to the cell 
via the hexose transporter, thereby resulting in a switch to L-proline metabolism, which 
provides a better growth effect. 
We show here that the stimulation of growth is not as a direct result of GlcNAc utilisation 
as a carbon source, because GlcNAc is not internalised by the parasite and cannot replace 
D-glucose or L-proline as a carbon source for energy. However, there is interaction with 
the hexose transporter, demonstrated by GlcNAc inhibition of uptake of 2-DOG. 
We therefore propose that GlcNAc, through blocking of the procyclic hexose transporter, 
promotes  a  metabolic  shift  in  procyclic  form  trypanosomes  leading  to  an  increased 
consumption of L-proline, as previously noted when procyclic form trypanosomes were 
grown  in  glucose-depleted  media  (Lamour  et  al.,  2005).  L-proline  metabolism  in  PCF 
trypanosomes is more efficient than D-glucose metabolism. When D-glucose and L-proline 
are both present in the growth medium, however, the procyclic form trypanosome will 
preferentially use D-glucose as the main carbon source (Bringaud et al., 2006; Cross et al., 
1975). 
It appears, therefore, that the in vitro growth stimulatory effect of GlcNAc relates to the 
switch  from  D-glucose  to  L-proline  catabolism,  leading  to  an  increase  in  L-proline 
consumption. This is correlated to increased oligomycin sensitivity. The switch is a graded 
response,  rather  than  a  binary  distinction,  since  L-proline  consumption  is  gradually 
reduced  as  D-glucose  levels  rise,  and  there  is  a  corresponding  gradual  decrease  in 
susceptibility to oligomycin. The repressive effect of D-glucose on L-proline metabolism 
seems to be related to the overall metabolic status of the cell rather than any allosteric 
action of D-glucose on its own, since cells adapted to growth without D-glucose retain 
high levels of L-proline uptake rates for many hours even when D-glucose is added. 
This up-regulation of proline consumption seems to be at the transporter and enzymatic 
level (PRODH enzyme; Lamour et al., 2005). Whether one or more metabolites act to 
trigger  such  a  switch  is  not  known,  however,  the  switch  is  as  a  result  of  glucose 
metabolism (down stream metabolites). It is possible that D-glucose itself does not act 
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adaptation exists. It is evident that the cell up-regulates proline transport. Whether this up-
regulation involves a single transporter or several transporters is still to be elucidated. 
In spite of the metabolic shift that accompanies growth in L-proline, procyclics using L-
proline as the main carbon source show no infectivity advantage to tsetse flies over control 
procyclics  grown  in  normal  D-glucose-rich  medium  (W.C.  Gibson,  personal 
communication). This suggests that the in vivo effects of GlcNAc are not a result of any 
metabolic advantage of the trypanosomes, but rather are a consequence of reduction in fly 
anti-microbial defences such as inhibition of lectins (Welburn & Maudlin, 1999). 
In addition to its impact on L-proline catabolism, D-glucose exerts an influence on other 
aspects  of  procyclic  trypanosome  biology,  including  procyclin  expression  as  well  as 
mitochondrial energy generation (Butikofer et al., 1997; Morris et al., 2002; Vassella et 
al.,  2001).  The  reason  for  the  negative  regulation  exerted  by  D-glucose  on  L-proline 
metabolism is far from clear, especially in the light of the fact that L-proline provides a 
markedly better growth stimulus than D-glucose. A possible explanation could be linked to 
the  developmental  cues  associated  with  reduced  D-glucose  availability.  When  BSF 
trypanosomes  are  taken  up  by  the  tsetse  vector,  presumably  glucose  availability  drops 
rapidly during digestion of the bloodmeal in the tsetse midgut. It is possible that D-glucose 
availability is one marker involved in life cycle progression of the parasite. It will therefore 
be of interest to determine whether the response of procyclics to D-glucose with regard to 
L-proline catabolism is linked to the response in expression of particular procyclin surface 
membrane  protein  isoforms  or  is  related  to  processes  leading  to  developmental 
differentiation of the parasite. 111 
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5.1  Introduction 
It is evident that PCF trypanosomes exhibit metabolic adaptational processes (Lamour et 
al.,  2005;  chapter  4).  We  have  shown  that  a  switch  to  proline  metabolism  occurs  (as 
indicated by oligomycin sensitivity and proline uptake) (chapter 4). This switch is a graded 
response  to  glucose  availability  and  can  be  mimicked  by  blocking  of  the  PCF  hexose 
transporter by GlcNAc. However, what is not known is how far reaching this metabolic 
switch goes. It is our intent to investigate, through metabolic profiling, what other markers 
emerge as a result of this metabolic shift. 
Metabolic changes, as a result of differing primary carbon source usage detected in the 
Orbitrap  visible  metabolome  will  be  particularly  informative  when  comparing  with 
previous studies using these targeted approaches to investigate parts of the metabolome. 
With this in mind, we decided to investigate the metabolome of PCF trypanosomes with 
regard to the metabolic adaptation as a result of differing carbon source usage. 
Systems  biology  is  a  rapidly  emerging  field.  Technological  advances  have  allowed 
metabolomics, the study of all metabolites within a given system, to emerge as a research 
area (Breitling et al., 2006). Individual metabolites, and their relative abundance within 
cells can be assessed by a range of techniques (Breitling et al., 2006; Goodacre, 2004; 
Dettmer et al., 2007), one of which involves Fourier transform ion cyclotron resonance 
mass spectrometry (FT-ICR-MS) (Brown et al., 2005; Hirai et al., 2004; Marshall et al., 
1998). Fourier transform mass spectrometry determines the mass-to-charge ratio (m/z) of 
ions based on the cyclotron frequency of the ions in a fixed magnetic field. The signal (free 
induction decay) detected as an image current is transformed to its mass spectrum using the 
Fourier equation. 
The recently introduced Orbitrap mass analyser (Hu et al., 2005) offers resolution and 
accuracy close to that of classical high field FT-ICR-MS or FTMS (Breitling et al., 2006). 
However, the Orbitrap operates using electrostatic rather than magnetic fields and hence 
by-passes the requirement of a large, super-cooled magnet. This allows it to be linked to 
chromatographic columns and thus avoids the risk of ion suppression effects which can 
occur  with  directly  infused  complex  samples.  This  technique  can  resolve  thousands  of 
metabolites,  in  the  molecular  mass  range  of  100–1500,  with  extreme  mass  accuracy 
(routinely  <2  ppm).  This  technique  has  been  employed  to  build  ab  initio  networks  of 
metabolites  whose  masses  can  be  linked  by  common  biochemical  transformations  in 
trypanosomes  (Breitling  et  al.,  2006).  Exact  mass  can  also  be  used  to  predict  likely Charles E. Ebikeme, 2007     Chapter 5, 113 
formulae for metabolites and tentatively to identify compounds based on comparison to 
databases of known metabolites. The fact that multiple formulae can yield masses within 2 
ppm (Kind & Fiehn, 2006) means that different approaches are also required to confirm 
identity. 
In FTMS (including Orbitrap analysis), ions, generated from soft ionisation methods (e.g. 
electrospray) are excited into cyclotron resonances that are a function of mass and charge. 
The frequency of gyration of these ions is detected in the mass spectrometer and then 
converted to high accuracy masses using the Fourier transform. The determined mass is as 
a result of several different physical principles within the analyser (Hu et al., 2005). The 
ionised metabolite mixture is trapped in an orbital trajectory of which the frequency of the 
orbit depends on mass/charge ratio. 
In the case of the orbitrap, the trapping is achieved without the need of a magnetic field, 
with ions trapped in a radial electric field between a central and outer cylindrical electrode. 
The ultra-high resolution enables simultaneous identification of ions that would not be 
resolved using less accurate mass determination approaches. The combined advantage of 
accurate mass determination and resoultion makes it possible to restrict the number of 
possible molecular formulae that represent an individual molecular mass (Hu et al., 2005; 
Breitling et al., 2006).  
The number of metabolites present in trypanosomes is sufficiently small to ensure very 
good resolution using high resolution, high mass accuracy mass spectrometry without the 
need for subcellular fractionation. Metabolomics requires special approaches for sample 
preparation,  separation,  and  mass  spectrometric  analysis  (Dettmer  et  al.,  2007).  The 
metabolome represents a vast number of components belonging to a wide variety of classes 
of  compounds  (amino  acids,  lipids,  organic  acids,  nucleotides,  etc).  Such  diversity  of 
compounds have reflecting diversity in their physical and chemical properties and occur in 
a wide range of abundances. To this effect, a careful experimental design is needed for the 
success of metabolomic investigations (Dettmer et al., 2007). While processing samples, 
formation and degradation of metabolites due to remaining enzyme activity or oxidation 
processes  is  a  possibility  (Dettmer  et  al.,  2007).  Therefore,  rapid  quenching  and 
metabolism  inhibition  is  required.  Rapid  quenching  of  metabolism  with  hot  HEPES-
buffered  ethanol  with  subsequent  freezing  in  liquid  nitrogen  has  proven  an  effective 
method of identifying metabolites in our lab (D. Wildridge, personal communication). Any 
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example, aqueous extraction results in poor recovery of very polar compounds as well as 
the loss of volatile organic compounds (Dettmer et al., 2007). 
Within  the  field  of  metabolomics  three  distinct  types  of  investigation  exist;  metabolic 
profiling,  metabolic  fingerprinting  and  metabolic  footprinting  (Dettmer  et  al.,  2007). 
Profiling  involves  quantitative  targeted  metabolite  analysis  of  metabolites  of  a  specific 
class or related to a selected pathway. The disadvantage of profiling is the fact that targeted 
analysis is a hypothesis-driven approach rather than a hypothesis-generating one, and that 
the data generated is not a global view of occurrences within the metabolome. Metabolic 
fingerprinting  involves  an  unbiased  global  screening  approach.  The  intention  is  not  to 
identify each observed metabolite but allows comparison of patterns or “fingerprints” as a 
result of cellular perturbations. Fingerprinting observes the true phenotype, however, the 
causal  metabolites  of  the  observed  phenotype  must  be  identified  if  any  biochemical 
understanding  is  to  be  gained  from  the  data.  This  means  that  assignment  of  chemical 
formulae to masses must be made. The high resolution, unique to the Orbitrap processor, 
allows the potential to indentify large numbers of metabolites. 
With  this  in  mind,  metabolomic  fingerprinting  can  be  used  to  classify  or  diagnose  a 
particular perturbation. Metabolomic  footprinting involves the analysis  of extra-cellular 
metabolites in cell culture medium, which is a reflection of metabolites used or excreted by 
cellular  processes.  These  three  different  metabolomic  investigative  methods  shall  be 
employed to address the question of metabolic adaptation in PCF trypanosomes. 
Exact mass, used to predict likely formulae for metabolites, can be used to tentatively  
identify  compounds  based  on  comparison  to  databases  of  known  metabolites  (Kyoto 
Encyclopaedia of Genes and Genomes, www.genome.jp/kegg). Metabolic changes, as a 
result  of  differing  primary  carbon  source  usage  detected  in  the  Orbitrap  visible 
metabolome will be particularly informative when compared with previous studies using 
these targeted approaches to investigate parts of the metabolome. 
A complete representation of any cell, any organism, and any biosphere, which will enable 
computational prediction of higher-level complexity of cellular processes and organism 
behaviours from genomic and molecular information, is an area of research receiving much 
attention.  Several  widely-available  databases  have  emerged  to  address  this  specific 
problem. KEGG is one of the most in-depth and comprehensive databases that exist for the 
identification of compounds and known metabolites. The KEGG pathway database is a 
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(Kanehisa et al., 2006). However, it is presently impossible to view global networks. To 
this end, several software packages have been developed for modelling of biomolecular 
interactions. An example is Cytoscape, which is an open source software package that 
allows  the  modelling  of  thousands  of  cellular  components  and  interactions 
(www.cytoscape.org), either actual (in vivo) or hypothetical (ab initio). Dynamic states on 
molecules  and  molecular  interactions  are  handled  as  attributes  on  nodes  and  edges 
(respectively), whereas static hierarchical data, such as protein-functional ontologies, are 
supported by use of annotations (Shannon et al., 2003). 
“MettaNetter” is a software plug-in developed for Cytoscape that allows inference and 
visualisation of the kind of high-resolution mass spectrometry data obtained directly from 
the Orbitrap processing (Fabien Jourdan, University of Toulouse). Inference requires a list 
of potential biochemical transformations, which are generated from commonly available 
biochemistry data as well as data sets from a range of databases, such as KEGG. The data 
extracted  from  the  Orbitrap  process  is  a  list  of  masses  (metabolites)  and  their 
corresponding  intensities  (qualitative).  Each  metabolite  can  be  theoretically  linked  to 
another metabolite via a hypothetical biochemical transformation, and in turn more and 
more  metabolites  can  be  linked  together;  resulting  in  a  global  ab  initio  metabolomic 
network to be built (Figure 5-2). The Cytoscape program represents metabolites and their 
biochemical transformations as nodes and edges, respectively (Figure 5-1). 
 
Figure 5-1: Nodes and edges. 
Cytoscape representation of metabolites and biochemical interactions as nodes and edges, 
respectively. Nodes represented as circles and edges represented as joining lines. 
 
The  KEGG  database  contains  approximately  488  trypanosome-specific  metabolites  and 
their  resulting  interactions  (biochemical  transformations).  In  collaboration  with  Fabien 
Jordan, their interactions and biochemical transformations were extracted to form a global Charles E. Ebikeme, 2007     Chapter 5, 116 
metabolomic  network  built  using  Cytoscape.  The  global  network  (Figure  5-2)  is  a 
representation of the different trypanosome pathways that exist within the KEGG database. 
 
Figure 5-2: KEGG Network of T. brucei metabolites. 
Cytoscape representation of trypanosomes specific metabolites from the KEGG database. 
Insert: shows particular metabolites and interactions in zoom. 
 
The KEGG database contains 488 trypanosome specific metabolites and their resulting 
interactions (biochemical transformations). The global network (Figure 5-2) represents the 
inherent complementarity of the metabolic pathway within trypanosomes, and does not 
take into account any enzymatic data. 
5.2  Results 
5.2.1 Global View of the Metabolome 
PCF trypanosomes were adapted to various conditions by growing in different medium for 
7  days;  Cunningham’s  medium  (CM,  Appendix  8.4),  CM  supplemented  with  60  mM 
GlcNAc  (NA),  SDM80  medium  (Appendix  8.2)  supplemented  with  10  mM  D-glucose 
(GL), or 10 mM L-proline (PR). Parasites, at mid-log phase of growth, were harvested by Charles E. Ebikeme, 2007     Chapter 5, 117 
centrifugation (chapter 2.13) and resuspended in 1 ml of serum-free medium. Cell numbers 
attained  were  enough  for  3  individual  extractions.  Cells  were  then  incubated  at  room 
temperature for 30 mins. The intention being to allow metabolism to re-attain homeostasis 
but  with  a  greatly  concentrated  cell  density.  Cells  were  separated  from  medium  by 
spinning down at 6,000 rpm for 5 mins at 4ºC. 0.75 ml of 80% EtOH/20 mM HEPES (pH 
7.0) was quickly added to separated medium and cell pellet, cooled on ice for 5 mins, 
vortexed, and then the supernatant recovered by centrifugation at 13,000 rpm for 5 mins. 
Recovered  supernatant  was  frozen  in  liquid  nitrogen  and  stored  at  -80ºC  for  further 
analysis. 
Samples  were  processed  using  an  Orbitrap  MS  (chapter  2.13).  The  Orbitrap  mass 
spectrometry,  employed  here,  is  not  quantitative  (in  the  absence  of  an  authenticated 
standard). However, the data generated is quantitative in a relative sense. The increase or 
decrease in size of a given peak is related to the changes in abundance of that metabolite 
across conditions. The exact masses derived from the Orbitrap mass spectrum are assigned 
putative formulae using an algorithm that sums all possible combinations of the elements 
C,  H,  O,  P,  N,  S.  Although  for  a  given  mass  there  may  be  many  possible  elemental 
combinations, in practice many of these can be eliminated as improbable. 
Results presented here are from one culture subjected to 3 separate ethanol extractions. The 
final list of masses obtained from the Orbitrap mass spectrum were masses found in at least 
two of the three ethanol extractions. 
The data extracted from the Orbitrap mass spectrum for each state was built into an ab 
initio metabolomic network. Metabolites, theoretically linked to other metabolites via a 
hypothetical  biochemical  transformation,  using  a  list  of  common  biochemical 
transformations  (Appendix  8.16)  within  the  mettanetter  software  allowed  the  global 
metabolome to be viewed for each metabolic state. Charles E. Ebikeme, 2007     Chapter 5, 118 
 
Figure 5-3: CM state network. 
Cytoscape representation of extracted metabolites and their relevant ab initio biochemical 
interactions. Metabolites that show no interactions with any other metabolites are shown as 
individual “orphans” at the bottom. 
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Figure 5-4: GlcNAc state network. 
Cytoscape representation of extracted metabolites and their relevant ab initio biochemical 
interactions. Metabolites that show no interactions with any other metabolites are shown as 
individual “orphans” at the bottom. 
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Figure 5-5: Glucose state network. 
Cytoscape representation of extracted metabolites and their relevant ab initio biochemical 
interactions. Metabolites that show no interactions with any other metabolites are shown as 
individual “orphans” at the bottom. 
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Figure 5-6: Proline state network. 
Cytoscape representation of extracted metabolites and their relevant ab initio biochemical 
interactions. Metabolites that show no interactions with any other metabolites are shown as 
individual “orphans” at the bottom. 
 
In comparing metabolic states (Table 5), the CM state showed 1085 nodes (metabolites) 
and 1711 edges (interactions) whereas the GlcNAc showed 1113 nodes and 1794 edges. 
The GL state showed 1011 nodes and 1386 edges whereas the PR state showed 1021 nodes 
and 1389 edges. In general, the global view of the metabolome constructed by Cytoscape 
has all linking metabolites forming a network and orphan metabolites (ones that show no 
interaction with any others) displayed individually. 
  Nodes  Edges 
CM  1085  1711 
NA  1113  1794 
GL  1011  1386 
PR  1021  1389 
Table 5: Total nodes and edges across the metabolic states 
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Primary investigations took a metabolomic fingerprinting approach. An unbiased global 
network,  built  using  filtered  masses  from  the  Orbitrap  data  set  was  then  subjected  to 
principal  component  analysis  (M  Kamleh,  University  of  Strathclyde).  The  principal 
component analysis (PCA) allows representation of complex data in lower dimensional 
space, defined by the principal components (PCs) (Stoyanova & Brown, 2001). The focus 
of PCA is pattern recognition, identifying directions of large variations in the data via the 
principal  components  (Stoyanova  &  Brown,  2001).  In  the  case  of  spectral  data,  the 
principal component is amplitude regardless of a lineshape, whereas the other PCs are 
indications of what other kind of variations are in the data. 
 
Figure 5-7: Principal Component Analysis. 
Principal component analysis scores of the filtered dataset. Cunningham’s medium grown 
samples (CM), Cunningham’s medium supplemented with GlcNAc grown samples (NA), 
proline only medium grown samples (PR), and glucose only medium grown samples (GL). 
Metabolites extracted from cell pellet (A) or supernatant (S). 
 
The thousands of discrete data points obtained from each sample examined represents the 
action of many known and unknown variables within the system (Kemsley et al., 2007). 
The PCA generated is a score plot, with the score a presumed value expressing how close 
one sample is to the others. Samples behaving in the same way will exhibit close scores. Charles E. Ebikeme, 2007     Chapter 5, 123 
PCA  showed  distinct  grouping  of  metabolites  derived  from  cells  grown  in  specific 
medium, with CM and NA samples (CM based) grouping together and PR and GL samples 
(SDM80 based) grouping together. It was hypothesised that NA samples should mimic the 
PR state, considering addition of GlcNAc causes a switch to proline metabolism (chapter 
4). However, when viewing the global metabolome, many more factors are at play. And 
considering the subtle switches in metabolic adaptation which are evident (chapter 4), the 
full metabolite profile will never be a complete mimic of PR state. Moreover, differences 
in  medium  composition  play  a  part,  as  they  determine  the  resulting  metabolic  profile. 
Cunningham’s medium is much richer in component mix, exhibiting many more individual 
components, whereas SDM80 reflects a more restrictive and basic medium composition 
(Appendix 8.2). The greater the number of starting metabolites available mean the more 
metabolites  as  a  result  of  metabolism  we  are  likely  to  see.  Indeed,  when  viewing  the 
metabolome,  more  metabolites  are  seen  within  the  CM  network  as  compared  to  the 
network  based  upon  SDM80  medium  (GL  and  PR).  With  this  in  mind,  the  only  two 
conditions  which  are  directly  comparable  are  the  GL  and  PR  growth  states.  The 
metabolites seen in these two states will reflect a much truer picture of the adaptational 
processes at play. 
5.2.2 Metabolic Fingerprint 
The next step was a direct comparison of the metabolites found in the CM state with the 
NA state as well as between GL and PR states. Comparing the PR and GL states should 
reveal differences in metabolites as a result of the usage of differing carbon sources. The 
metabolites that appear as a result of PR usage as compared with GL usage may provide 
insight into global metabolic state. Moreover, the appearance of metabolites seen in the 
GlcNAc  state  as  compared  with  the  CM  state  may  reveal  metabolites  linked  to  the 
metabolic shift as seen in comparing the GL and PR state. Also, it is important to focus on 
appearing metabolites that form networks as that will highlight new pathways and patterns. Charles E. Ebikeme, 2007     Chapter 5, 124 
 
Figure 5-8: Metabolites unique to proline metabolism (comparing GL and PR states). 
Cytoscape representation of extracted metabolites and their relevant ab initio biochemical 
interactions. Metabolites that show no interactions with any other metabolites are shown as 
individual “orphans” at the bottom. 
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Figure 5-9: Metabolites unique to GlcNAc supplementation (comparing CM and NA states). 
Cytoscape representation of extracted metabolites and their relevant ab initio biochemical 
interactions. Metabolites that show no interactions with any other metabolites are shown as 
individual “orphans” at the bottom. 
 
Identified from the PR state were 166 metabolites unique to proline metabolism (Figure 5-
8). In comparison, GlcNAc supplementation of CM showed 277 metabolites unique to that 
particular growth condition (Figure 5-9). Of the 277 metabolites that appear as a result of 
GlcNAc supplementation, 28 (~10%) were common to PR state (Table 6), suggesting that 
these metabolites are associated with proline metabolism. 
Conversely,  we  wanted  to  apply  the  same  characterisation  to  the  GL  and  CM  state 
respectively in comparison to the PR and NA state, showing metabolites unique to glucose 
metabolism. Charles E. Ebikeme, 2007     Chapter 5, 126 
 
Figure 5-10: Glucose specific metabolites (comparing PR and GL states). 
Cytoscape representation of extracted metabolites and their relevant ab initio biochemical 
interactions. Metabolites that show no interactions with any other metabolites are shown as 
individual “orphans” at the bottom. 
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Figure 5-11: Glucose specific metabolites (comparing NA and CM states). 
Cytoscape representation of extracted metabolites and their relevant ab initio biochemical 
interactions. Metabolites that show no interactions with any other metabolites are shown as 
individual “orphans” at the bottom. 
Identified from the GL state were 159 metabolites unique to glucose metabolism (Figure 6-
10). In comparison, the CM state showed 207 metabolites unique to that particular growth 
condition (Figure 6-11). Of the 159 metabolites associated with glucose metabolism, 37 
(~23%) were common to the CM state (Table 6). 
metabolites unique to 
proline metabolism 
metabolites unique to glucose 
metabolism 
115.190  221.089  681.356  114.079  237.670  298.036  545.392 
174.145  238.115  703.571  119.219  237.830  299.085  661.694 
174.212  238.529  728.555  140.951  238.117  299.085  761.310 
180.098  281.897  730.571  165.071  238.259  400.133  899.292 
200.692  287.282  751.499  165.316  238.528  412.258  1040.322 
200.694  317.233  753.515  174.118  239.101  412.258   
200.696  390.277  784.128  208.734  260.067  417.194   
200.776  415.665  1883.769  209.184  260.570  417.771   
200.793  488.165    209.204  281.272  419.097   
208.719  640.211    209.292  298.036  482.089   
Table 6: Carbon source specific metabolites (pellet). 
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The generated list of metabolites specific for glucose and proline associated metabolism 
represents, essentially, a list of biomarkers for metabolism. The exact masses derived from 
the  pellet  are  assigned  putative  formulae  using  an  algorithm  that  sums  all  possible 
combinations of the elements C, H, O, P, N, S, Cl, allowing possible putative compounds 
to be postulated. 
Pellet 
Proline State  Glucose State 
Mass  Formula  Mass  Formula 
174.212  C5H14O4N3  114.079  C5 H10 O1 N2 
221.089  C7H9O1N8  165.070  C5H15N2P2 
238.115  C6H16O5N5  238.117  C9H14O2N6 
281.897  C7H4O4CL1P1S2  239.101  C9H13O3N5 
287.282  C17H37O2N1  260.067  C4H16O4N5P2 
317.233  C17H33O5  281.272  C18H35O3N5 
390.277  C24H38O4  298.036  C7H14O6N3P2 
488.164  C24H35O4CL2P1  299.085  C9H17O10N1 
640.211  C27H38O4N8CL2S1  299.085  C9H17O10N1 
681.356  C29H53O14N4  400.133  C19H22N6CL1P1 
    412.258  C18H35O2N7P1 
    412.258  C18H35O2N7P1 
    417.194  C22H30O4N2P1 
    419.097  C7H20O7N10P1S1 
    482.089  C21H18O3N7CL1P1 
    545.392  C29H55O8N1 
    761.310  C29H48O13N9P1 
    899.292  C28H57O15N10P2S2 
Table 7: Putative formula generated from pellet metabolites. 
 
Not all metabolites could be assigned putative formula within an appropriate range of error 
(2 ppm). The range of error (in parts per million) refers to how far the detected mass 
deviates from the standard predicted mass. The metabolites that could be assigned putative 
formula could not be identified by PubChem. However, the biomarkers generated here can 
provide a phenotype for metabolic adaptation. 
5.2.3 Metabolic Footprint 
Metabolomic footprinting involves the analysis of extra-cellular metabolites in cell culture 
medium, which is a reflection of metabolites taken up or excreted by cellular processes. 
We  further  wanted  to  characterise  each  metabolic  state  by  identifying  metabolites  that 
appear as a result of differing carbon source usage. A total of 175 metabolites were found 
to be unique to the PR state and 123 to the GL state (in comparison to the GL state and PR 
state, respectively). Whereas 223 metabolites were found to be unique to the NA state and 
191 to the CM state (in comparison to the CM state and NA state, respectively). Charles E. Ebikeme, 2007     Chapter 5, 129 
metabolites unique to proline 
metabolism 
metabolites unique 
to glucose 
metabolism 
73.026056  174.2125  417.1982  105.0426  650.3568 
83.037048  200.6972  419.0934  120.0706  878.3125 
83.952363  200.7767  473.8264  149.0477  910.2836 
114.92541  200.7824  498.157  151.0289   
115.00889  208.8514  589.4192  165.234   
115.20142  237.9377  748.2686  208.9397   
115.42682  238.082  782.2394  417.8282   
117.06744  238.1123  877.813  418.461   
150.05031  260.096    431.273   
165.07378  390.277    473.187   
Table 8: Carbon source specific metabolites (supernatant). 
 
This identified, as a product of glucose metabolism, 13 unique metabolites. Conversely, 
proline metabolism showed 28 unique metabolites. Of all the metabolites identified only 
one could be assigned chemical formula. The glucose-specific metabolite of mass 105.042 
corresponds to a chemical formula of C3H7NO3 (Serine). It is possible that there is a 
greater need for serine when proline is being used as the main carbon source, leading to a 
greater consumption of the metabolite from the surrounding medium. 
The exact masses derived are assigned putative formulae using an algorithm that sums all 
possible combinations of the elements C, H, O, P, N, S, Cl, allowing possible putative 
compounds to be postulated. 
Supernatant 
Proline  Glucose 
Mass  Formula  Mass  Formula 
83.037  C4H5O1N1  208.939  C2H1O5N3P2 
150.050  C9H10S1  431.273  C17H35O5N8 
165.073  C2H9O3N6  473.187  C17H27O9N7 
238.112  C13H19O2P1  650.356  C27H54O7N7P2 
260.095  C17H12O1N2     
390.277  C24H38O4     
417.198  C27H30O2P1     
498.156  C21H30O7N3P2     
589.419  C30H53O4N8     
748.268  C29H45O15N6P1     
Table 9: Putative formula generated from supernatant metabolites. 
 
Not all metabolites could be assigned putative formula within an appropriate range of error 
(2 ppm). The metabolites that could be assigned putative formula could not be identified 
by  PubChem.  However,  the  biomarkers  generated  here  can  provide  a  phenotype  for 
metabolic adaptation. Charles E. Ebikeme, 2007     Chapter 5, 130 
5.2.4 Metabolic Profile 
Metabolites of the glycolytic pathway and key mitochondrial metabolites were searched 
for. This was relevant since previous work (chapter 4) had indicated differences in energy 
metabolism related to these pathways. It was important; first of all, to find out if we could 
view all the relevant metabolites (glycolysis and Kreb’s cycle intermediates) under the 
conditions  used  (extraction  of  metabolites  and  Orbitrap  processing  technique).  The 
molecules with the same mass but distinct structures (dihydroxyacetone phosphate and 
glyceraldehyde-3-phosphate) can only be discriminated with additional information, and is 
beyond the scope of what is investigated here. Of all the glycolytic and mitochondrial 
intermediate  metabolites  only  pyruvate  (Figure  5-12)  and  the  amino  acids  (proline, 
threonine, glutamine and glutamate) (Figure 5-13) could be identified within the dataset. 
Pyruvate is the ultimate end product when glucose is being used as the primary carbon 
source (Figure 1-4). However, when proline is being used, pyruvate is further metabolised 
within  the  mitochondrion.  We  would  therefore  expect  to  see  a  greater  abundance  of 
pyruvate in GL and CM states as compared to NA and PR states. 
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Figure 5-12: Pyruvate abundance within the cell pellet and supernatant. 
Relative intensity of pyruvate found in the cell pellet and supernatant from cells grown in 
differing conditions; Cunninghm’s medium (CM), CM supplemented with GlcNAc (NA), 
SDM80 plus Glucose (GL), SDM80 plus Proline (PR). 
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Within the cell pellet no pyruvate was identified, where as high amounts of pyruvate could 
be seen in the supernatant extract of the CM and NA conditions. SDM80 contains twice as 
much pyruvate as Cunningham’s medium (100 mg/L vs 200 mg/L; Appendix 8.2, 8.4) 
Here, comparing pyruvate abundances across the four states does not give any insight into 
the metabolic status of the cell. 
Continuing the metabolic profiling approach we wanted to investigate other branches of 
the metabolome. More specifically, the amino acid complement (as analysed by targeted 
metabolite analysis) of PCF trypanosomes with regard to the metabolic adaptation as a 
result of differing carbon source usage. Amino acid usage regulation has already been seen 
with  proline  (chapter  4).  However  it  is  not  known  if  glucose  exerts  effects  (whether 
repressive or not) on other amino acids, or if other amino acids become more essential in 
the  absence  of  glucose.  The  full  conventional  20  amino  acid  complement  along  with 
related compounds (taurine, ornithine homocysteine, and citrulline) was sought within the 
data generated from the Orbitrap process (Table 10). 
Pellet  Supernatant 
  CM  NA  GL  PR  CM  NA  GL  PR 
Glycine  0.000  0.000  0.000  0.000  0.000  0.000  0.000  0.000 
Alanine  7.434  6.641  7.384  7.390  6.573  7.186  7.321  7.311 
Serine  5.832  5.609  5.923  5.551  5.434  0.000  5.519  0.000 
Proline  8.627  8.647  7.761  8.332  8.630  8.658  7.311  8.319 
Threonine  7.063  7.132  7.399  7.439  7.063  6.950  7.345  7.364 
Cysteine  0.000  0.000  0.000  0.000  0.000  0.000  0.000  0.000 
Taurine  7.290  7.319  7.496  7.466  7.303  7.319  7.549  7.507 
Leucine  8.062  8.072  8.085  8.096  8.057  8.063  8.044  8.050 
Asparagine  6.439  6.996  5.556  5.628  6.512  6.869  0.000  0.000 
Ornithine  7.378  7.430  7.197  7.142  7.415  7.449  7.186  7.121 
Aspartic acid  6.230  6.531  0.000  0.000  5.863  6.242  0.000  0.000 
Homocysteine  0.000  0.000  0.000  0.000  0.000  0.000  0.000  0.000 
Glutamine  7.218  7.182  6.090  6.077  7.231  7.374  6.023  6.769 
Lysine  7.701  7.687  7.615  7.658  7.727  7.700  7.578  7.609 
Glutamate  6.991  7.060  6.660  6.806  6.981  7.046  6.650  6.681 
Methionine  7.940  7.985  8.021  8.039  7.967  7.991  8.020  8.012 
Histidine  8.115  8.105  7.907  7.976  8.134  8.116  7.886  7.926 
Phenylalanine  8.558  8.395  8.541  8.584  8.585  8.389  8.543  8.546 
Arginine  8.680  8.649  8.650  8.712  8.548  8.655  8.633  8.509 
Citrulline  0.000  0.000  0.000  0.000  0.000  0.000  0.000  0.000 
Tryptophan  7.214  7.305  6.679  6.673  7.210  7.314  6.618  6.626 
Tyrosine  8.043  8.054  8.205  8.143  8.083  8.075  8.219  8.159 
Valine  7.557  7.578  7.689  7.604  7.415  7.561  7.644  7.552 
Isoleucine  0.000  0.000  0.000  0.000  0.000  0.000  0.000  0.000 
Table 10: Targeted amino acid analysis. 
Relative intensities of amino acids found in cell pellet and supernatant of cells grown in 
differing conditions; Cunningham’s medium (CM), CM supplemented with GlcNAc (NA), 
SDM80 plus Glucose (GL), SDM80 plus Proline (PR). 
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Figure 5-13: Targeted amino acid analysis. 
Relative intensities of serine (top) and aspartate (bottom) as found in the cell pellet and 
supernatant of cells grown in differing conditions. 
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Of the 20 amino acids only glycine, cysteine and isoleucine could not be identified from 
the list of masses, and only serine and aspartate showed any significant differences (Figure 
5-13).  Most  amino  acids  showed  no  considerable  changes  across  the  differing  growth 
conditions. Within the cell pellet no aspartate was found in either the GL or PR states in 
comparison to the CM and NA states (despite aspartate being a medium component in 
both). This was also mimicked in the profile seen from the supernatant. This could possibly 
be explained by the fact that CM contains 110 mg/L of aspartate whereas SDM80 contains 
only 13.3 mg/L, and the fact we do not see any aspartate in the GL  and PR states is 
because the little aspartate that is present is quickly metabolised. 
Interestingly, serine was present only in the supernatant of the CM and GL states (absent in 
the NA and PR states). This variance was not mimicked in the profile seen from the cell 
pellet. It is possible that there is a greater need for serine when proline is being used as the 
main  carbon  source,  leading  to  a  greater  consumption  of  the  metabolite  from  the 
surrounding medium. The fact that a greater amount of serine within the cell pellet was not 
seen does not refute that possibility as an increase in serine metabolism could remove the 
metabolite from the profile seen, leaving us with an interior metabolite abundance similar 
to the GL state. 
5.3  Discussion 
Systems biology offers an attractive method of investigating cellular processes at a global 
level. The advantage of global metabolomic approaches is that it highlights various cellular 
processes that can be investigated further by classical biochemical targeted techniques. 
Indeed, that was our intention here. We aimed to use metabolomic approaches not only to 
visualise the metabolome of the trypanosome as a result of differing carbon source usage, 
but also identify biomarkers that appear as a result of the metabolic adaptations already 
characterised (Lamour et al., 2005; chapter 4). 
Metabolomics  technologies  are  embryonic.  Refinements  are  required,  not  only  to  the 
sample processing techniques (to allow more metabolites to be seen) but also to the data 
analysis. This study represents one of very few performed on any organism and it is the 
eventual  goal  to  develop  methodologies  adapted  to  the  investigation  of  the  T.  brucei 
metabolome. This preliminary data highlights areas that need further confirmation in terms 
of reproducibility and areas of methodology to troubleshoot. Whether metabolomics will 
prove an effective tool for the characterisation and analysis of cellular processes remains to 
be seen. Charles E. Ebikeme, 2007     Chapter 5, 134 
Our  initial  assumption was that the  metabolic  adaptations involved in  differing  carbon 
source usage would be an easy event to observe in trypanosomes when viewing the global 
metabolome. There is a switch from the glycosome to the mitochondrion as the major 
source  of  energy  production  that  occurs  with  the  metabolic  adaptation.  It  was  our 
assumption  that  we  would  observe  more  intermediates  specific  for  each  pathway 
depending on the carbon source in use. This was not the case. For example, proline was 
seen  in  equal  amounts  irrespective  of  primary  carbon  source.  The  same  was  true  for 
glutamate, a key intermediate in proline metabolism. 
What  global  metabolomics  offers  is  a  snapshot  of  the  processes  ongoing.  It  has  the 
disadvantage  of  not  being  able  to  show  flux  through  a  specific  pathway.  Varying  and 
having more incubation time points might allow for metabolic flux to be seen. It is possible 
that the metabolites not seen from the data could be simply because they have been used up 
quickly. Moreover, metabolites not seen can be as a result the extraction process. The use 
of more than one extraction process will undoubtedly identify metabolites not common to 
another extraction process. For example, extraction of cells into boiling water is a method 
commoly  employed  as  complementary  to  boiling  ethanol.  A  greater  portion  of 
phospholipids might be precipitated in EtOH extraction as compared with water extraction 
(M  Kamleh,  personal  communication).  The  methodology  employed  consists  of  a 
centrifugation step that separates cells from spent medium. This centrifugation step can be 
eliminated  as  it  perturbs  cellular  metabolism  by  creating  an  anoxic  (depleted  oxygen) 
environment. Immediate addition of boiling EtOH will give a much truer snapshot of the 
metabolome. 
The orbitrap process can also be altered to allow more metabolites to be seen. During the 
process, metabolites are ionised by the addition of a proton. It is also possible to run the 
process in reverse by stripping away a proton. This means that metabolites that do not 
favour  proton  addition  might  be  more  amenable  to  subtraction  (sugar  phosphate 
compounds), allowing them to be identified (M Kamleh, personal communication). With 
all  these  improvements  to  the  methodology  in  mind,  it  is  still  possible  that  targeted 
metabolic  profiling  will  support  the  hypothesis  already  confirmed  by  traditional 
biochemical techniques. 
Targeted amino acid analysis highlighted serine as a metabolite that differs as a result of 
metabolic adaptation. Serine was absent from supernatant extracts in both the PR and NA 
state, suggesting that when cells are using proline as the principal carbon source there is a Charles E. Ebikeme, 2007     Chapter 5, 135 
greater  metabolic  requirement.  This  might  translate  into  upregulation  of  transporter 
processes (e.g. TbAATP1; chapter 3) and/or target enzyme relevant to serine metabolism. 
Metabolic fingerprinting involves an unbiased global screening approach. The intention is 
not  to  identify  each  observed  metabolite  but  allows  comparison  of  patterns  or 
“fingerprints”  as  a  result  of  cellular  perturbations.  Fingerprinting  observes  the  true 
phenotype, however, the causal metabolites of the observed phenotype must be identified if 
any biochemical understanding is to be gained from the data. Identified from metabolomic 
fingerprinting investigation was essentially a list of metbolites unique to either L-proline or 
D-glucose  metabolism.  Of  the  159  metabolites  associated  with  glucose  metabolism 
(SDM80  plus  glucose),  37  (~23%)  were  found  in  the  CM  state;  whereas  of  the  277 
metabolites that appear as a result of GlcNAc supplementation, 28 (~10%) were common 
to PR state. These handful of metabolites represent biomarkers for metabolism. However, 
these  biomarkers  could  not  be  assigned  putative  chemical  formula,  and  hence,  the 
metabolite could not be identified. This is possibly due to the fact that metabolites appear 
in a range of different forms. Some metabolites appear associated with sodium ions. Many 
others forms of adducts exist, K adduct, Ca adduct, CH3CN adduct, NH4 adduct, HCOOH 
adduct, clusters of 2 or more molecules, as well as triple and quadrable charged species. At 
present these cannot be easily be deciphered. What needs to be done is to extend the simple 
putative formula analysis to include all other permutations and combinations that might 
exist for any given mass. 
There is no doubt that metabolomics offers new areas of trypanosome biology to explore. 
With only half the genome annotated there is potential for new biochemical pathways to be 
identified, whether they are trypanosome-specific or not. Further investigations need to 
confirm these biomarkers as well as confirm if these metabolites appear as a result of other 
conditions that cause a metabolic shift. 136 
6  Uptake and Effects of Trypanotoxic Amino Acid 
Analogues Charles E. Ebikeme, 2007     Chapter 6, 137 
6.1  Introduction 
The precedent set by work with the P2 transporter, with regards to targeting toxins to 
trypanosomes via nutrient transporters (chapter 1.11), inspired a search for several amino 
acid  analogues  with  trypanocidal  activity.  Some  amino  acid  transporters  fulfil  similar 
criteria  to  purine  transporters  with  regard  to  their  transport  characteristics  (Hasne  & 
Barrett,  2000).  In  some  cases,  the  transporters’  natural  substrates  are  of  low  plasma 
abundance,  so  these  transporters  should  have  correspondingly  high  affinities  for  their 
substrate (and hence maybe also substrate analogues). A drug using such a carrier will also 
have relatively low competition from natural substrate. Several amino acid analogues that 
kill  trypanosomes  are  known.  Some  thiazine-linked  amino  acids  showed  good  in  vitro 
activity  against  T.  brucei  and  also  led  to  temporary  reduction  of  parasitaemia  in  mice 
(Vanbogaert et al., 1993). These compounds had been designed as putative inhibitors of 
trypanothione  biosynthesis,  although  it  appears  that  this  was  not  their  mode  of  action, 
which remains uncertain. Most recently, Acivicin and 6-diazo-5-oxo-l-norleucine (DON); 
which are glutamine analogues that can kill trypanosomes in vitro (Hofer et al., 2001). 
These  glutamine  analogues  only  arrest  the  proliferation  of  the  parasites.  A  functional 
immune  response  is  then  required  to  eradicate  the  static  trypanosomes  (Fijolek  et  al., 
2007). Also, the methionine analogue buthionine sulphoxamine (BSO) has been identified 
as potential trypanocides (Huynh TT et al., 2003; Arrick et al., 1981) giving a 50 µM IC50 
against  PCF  trypanosomes.  BSO  mode  of  action  seems  to  involve  inhibition  of  γ-
Glutamylcysteine synthetase (γ-GCS) resulting in trypanolytic effects. However, γ-GCS 
inhibition was not conclusively shown to be the sole target for BSO. 
6.1.1 Azaserine 
Compounds affecting the utilisation of the amino acid L-glutamine have a comparatively 
long history in the field of cancer chemotherapy (Livingston et al., 1970). At one time the 
glutamine agonists were undergoing clinical trials, but lack of effectiveness has caused a 
decline  in  interest.  Glutamine,  in  trypanosomes,  is  essential  for  several  biosynthetic 
pathways as well as DNA replication. Azaserine is of similar structure to glutamine and is 
an irreversible inhibitor of glutamine amidotransferases (Livingston et al., 1970), which 
catalyze the ATP-dependent transfer of the amido nitrogen of glutamine to an acceptor – in 
this case GMP (Figure 6-1). Charles E. Ebikeme, 2007     Chapter 6, 138 
 
Figure 6-1: Schematic representation of DNA synthesis showing L-glutamine usage in T. 
brucei (A) and the specific chemical reaction (B). 
Enzymatic steps are represented by arrows with enzymes represented by red numbers (1, 
GMP synthase; 2, guanylate kinase; 3, nucleoside diphosphatase; 4, pyruvate kinase; 5, 
ribonucleotide-diphosphate  reductase  large  chain;  6,  nucleoside  diphosphate  kinase) 
Abbreviations: XMP, xanthosine monophosphate; GMP, guanosine monophosphate; GDP, 
guanosine  diphosphate;  GTP,  guanosine  triphosphate;  dGDP,  deoxyguanosine 
diphosphate; dGTP, deoxyguanosine triphosphate; PPi, diphosphate. 
 
Azaserine  is  the  most  thoroughly  studied  compound  within  the  diazo-analogues  of 
glutamine. In mammalian cells, it has been shown that azaserine interferes with several 
reactions that involve glutamine. The reaction most sensitive to inhibition by azaserine is 
the  conversion  of  formyglycinamide  ribotide  (FGAR)  to  formylglycinamidine  ribotide 
(FGAM), a reaction within the biosynthetic pathway of purines (Hartman et al., 1955). The 
mechanism of inhibition still remains unclear, but what is clear is the irreversibility of the 
azaserine effect. De novo inhibition of purine biosynthesis is not the only cellular affect of 
azaserine. There has also been evidence shown for inhibition of cytidine biosynthesis and 
binding to DNA to interferes with its template function (Livingston et al., 1970). 
Azaserine has been shown to have some antibiotic properties (Bennett et al., 1956). In 
prokaryotes,  azaserine  is  transported  by  the  aromatic  transport  system.  In  Salmonella 
typhimurium, resistance seems to be as a result of a mutation in a gene whose product 
transports general aromatic amino acids (Williams et al., 1980). Sensitivity is regained by 
another mutation in a gene involved in histidine transport, suggesting that the antibiotic 
may be transported by multiple transport systems. Charles E. Ebikeme, 2007     Chapter 6, 139 
Azaserine action on Escherichia coli is similar to that of mammalian cells. The aromatic 
amino acids are the most effective in blocking the inhibition by azaserine on growth of E. 
coli. However, the ability of the aromatic amino acids to antagonise azaserine action may 
be due to non-specific effects and is not related to the action of azaserine on the aromatic 
acid biosynthesis pathway (Kaplan et al., 1959). The results of their investigation suggest 
that  the  penetration  of  the  antibiotic  through  the  cell  membrane  is  prevented  by  the 
aromatic amino acids. Hypotheses proposed have been supported by the fact that azaserine 
has been shown to be under the control of the amino acid transport system (Jacquez et al., 
1957). However, azaserine action on the utilisation of aromatic amino acids in E. coli has 
not been investigated and cannot be ruled out. 
Trypanosomes lack  aromatic  amino  acid biosynthesis pathways as well as most of the 
enzymes  of  the  classical  pathways  for  aromatic  amino  acid  oxidation.  Conversion  of 
phenylalanine to tyrosine by phenylalanine-4-hydroxylase does not occur in T. brucei. All 
trypanosome species have genes for transamination and reduction to the corresponding 
aromatic lactate derivative (Berriman et al., 2005). This suggests that action of azaserine 
does  not  involve  aromatic  amino  acid  pathways,  leaving  competition  for  glutamine  in 
GMP and CTP synthesis as the key candidate for azaserine’s trypanocidal action, as de 
novo purine biosynthesis does not occur in trypanosomes. 
 
Figure 6-2: Schematic representation of CTP synthesis  showing L-glutamine usage in T. 
brucei (A) and the specific chemical reaction (B). 
Enzymatic steps are represented by arrows with enzymes represented by red numbers (1, 
CTP synthase; 2, nucleoside diphosphate kinase; 3, ribonucleoside-diphosphate reductase 
large chain; 4, nucleoside diphosphate kinase. Abbreviations: UTP, uridine triphosphate; 
CTP,  cytosine  triphosphate;  CDP,  cytosine  diphosphate;  dCDP,  deoxycytosine 
diphosphate; dCTP, deoxycytosine triphosphate; Pi, inorganic phosphate. 
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In early studies, azaserine was noted to have an effect on the incorporation of purines and 
pyrimidines in Trypanosoma equiperdum (Momparler & Jaffe, 1964). The amino acids 
glutamine, tryptophan, tyrosine and leucine partially prevented the inhibition produced by 
azaserine.  Results  presented  by  Momparler  &  Jaffe  (1964)  suggest  that  the  effect  of 
azaserine is to inhibit the conversion of UMP to CMP, resulting in a depletion of cytosine-
containing nucleotides (Figure 6-2). More recently, CTP synthetase has been shown to be a 
potential drug target in BSF trypanosomes (Hofer et al., 2001; Fijolek et al., 2007). With 
CTP levels in BSF trypanosomes controlled by synthesis rather than by degradation, and 
no  apparent  salvaging  of  cytidine  or  cytosine  by  the  parasite,  the  inhibition  of  CTP 
synthesis has been shown to have a dramatic effect on CTP levels and cell growth. 
6.1.2 Levodopa 
Potential trypanocidal amino acid analogues may be hampered by size of the side chain to 
allow targeting via an amino acid transporter. Aromatic amino acid analogues provide a 
level of complexity that can be built into a molecule and still be targeted through an amino 
acid transporter. The tyrosine analogue L-Dopa, along with other catecholamines, have 
been  shown  to  have  high  trypanocidal  activity  (Owolabi  et  al.,  1989).  Various 
catecholamines (dopamine and tryptamine analogues) were tested against trypanosomes 
using  a  feeder  layer  culture  system  (Microtus  agrestis  embryonic  fibroblasts). 
Catecholamines are compounds derived from tyrosine containing the catechol and amine 
structure. In vitro tests showed as little as 1 µM cleared all trypanosomes at a starting 
density of 10
5 cells per ml after 24 hours. L-Dopa and other catecholamines are subject to 
auto-oxidation  and  are  potent  producers  of  hydrogen  peroxides,  quinones,  and  free 
radicals. 
The  discovery  of  L-Dopa’s  trypanocidal  activity  together  with  the  fact  that  certain 
catecholamines have been shown to have high trypanocidal activity (Owolabi et al., 1989) 
lead the investigation into the possibility of metabolic activation. Two pathways exist in 
mammalian  cells  for  the  metabolism  of  aromatic  amino  acids.  The  tyrosine  pathway 
converts  tyrosine  to  noradrenalin  via  L-Dopa  and  dopamine  (Figure  6-3),  whereas 
tryptophan is converted to melatonin via serotonin (Figure 6-4). 
L-Dopa  can  cross  the  blood-brain  barrier  and  is  commonly  used  in  the  treatment  of 
Parkinson’s disease (PD). PD is a chronic disease of the central nervous system caused by 
lowered levels of the inhibitory neurotransmitter dopamine. Symptoms include muscular 
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most common human degenerative disorders (Schapira, 2005). L-Dopa is the drug most 
commonly used to address the dopaminergic features of the disease, leaving the long term 
progression  unaffected.  The  use  of  dopaminergic  drugs  improves  motor  function,  and 
significantly reduces both the morbidity and mortality in sufferers – leading to an overall 
improvement in quality of life. Progression of the disease is still ongoing, and because of 
that, the effects of L-Dopa are modified due to the fact that the dopaminergic cells required 
to store and release dopamine are still in decline. 
Two different types of dopamine receptors are found in the brain (D1-like and D2-like 
receptors) and mediate different actions when stimulated by dopamine. Both are G-protein-
coupled,  D1-like  receptors  stimulate  adenylyl  cyclase  whereas  D2-like  receptors  inhibit 
adenylyl  cyclase  (Mercuri  &  Bernardi,  2005).  Despite  the  fact  that  D2-like  receptor 
agonists are more effective anti-parkinsonian drugs, the use of mixed D1 and D2 receptor 
agonists provide the best control over PD symptoms. 
 
Figure 6-3: Tyrosine pathway. 
Schematic representation of L-tyrosine metabolism in mammalian cells. Enzymatic steps 
are  represented  by  arrows  with  enzymes  represented  by  red  numbers  (1,  tyrosine 
hydroxylase; 2, dopa decarboxylase; 3, dopamine beta-hydroxylase). 
 
In dopaminergic neurons, accumulated tyrosine in converted to L-Dopa by addition of an 
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decarboxylase follows. Vesicles within the neuron store and release dopamine; and when a 
dopaminergic nerve is stimulated the vesicles fuse with the outer membrane of the nerve 
(Kostrzewa  et  al.,  2005).  Within  the  synaptic  and  extra-synaptic  spaces  dopamine  is 
converted into inactive metabolites by the enzymes monoamine oxidase and catechol-O-
methyltransferase  (Mercuri  &  Bernardi,  2005).  Clearance  is  also  controlled  by  the 
dopamine  transporter.  In  PD  there  are  fewer  dopaminergic  nerves,  meaning  that  fewer 
dopamine molecules re-enter nerve cells. Treatment involves giving exogenous L-Dopa 
which  generates  a  high  intraneuronal  L-Dopa  content,  thereby  elevating  levels  of 
dopamine. Combination therapy is common with L-Dopa treatment. L-Dopa is typically 
administered  in  conjunction  with  a  decarboxylase  inhibitor  that  is  unable  to  cross  the 
blood-brain  barrier.  This  allows  the  exogenous  L-Dopa  to  avoid  metabolism  by  body 
tissues, leaving the most of the L-Dopa to enter the brain to produce the therapeutic effect. 
 
Figure 6-4: Schematic representation of L-tryptophan metabolism in mammalian cells. 
Enzymatic steps are represented by arrows with enzymes represented by red numbers (1, 
tryptophan  2,3  dioxygenase;  2,  arylformidase;  3,  dopa  decarboxylase;  4,  tryptophan 
hydroxylase;  5,  dopa  decarboxylase;  6,  alkalkytransferase;  7,  methyl  transferase;  8, 
acetylserotonin O-methyltransferase). 
 
Tryptophan is converted to 5-hydroxytryptophan via the enzymatic action of tryptophan 
hydroxylase  (enzyme  4),  with  subsequent  conversion  to  the  neurotransmitter  serotonin. 
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lack  the  enzyme  tyrosine  hydroxylase.  However,  despite  this  fact,  non-dopaminergic 
neurons can accumulate L-Dopa. In this case, the L-Dopa is converted dopamine by dopa 
decarboxylase. 
As highlighted earlier (chapter 1.19), the range of pathophysiological effects associated 
with the disease are linked to trypanosome involvement, possibly by reducing host levels 
of  essential  amino  acids  (El  Sawalhy  et  al.,  1995).  Another  possibility  is  the  direct 
involvement of toxic or inhibitory actions of metabolites produced from aromatic amino 
acid metabolism in trypanosomes. The aromatic α-keto acids and indole-3-pyruvic acids 
have been shown to accumulate abnormally in the urine of infected mice (El Sawalhy et 
al., 1995). This pathological symptom has been likened to other inherited disorders of 
aromatic  amino  acid  metabolism.  Indeed,  the  correlation  between  the  physiological 
manifestations of trypanosomiasis and other neurological disorders cannot be discounted. 
It is evident that the perturbations of host environment brought about by  trypanosome 
amino acid metabolism result in pathogenesis and physiology of the disease. 
6.1.3 Cell Penetrating Peptides 
Cell  penetrating  peptides  (CPPs)  have  a  maximum  length  of  ~30  amino  acids,  have  a 
positive charge (Deshayes, 2005), and have the potential to be novel antimicrobials These 
peptides are able to translocate through cell membranes without causing damage to the 
cell. Most research has focused on their potential use as delivery agents for therapeutic 
“cargo”  such  as  DNA,  peptides,  and  proteins;  while  some  research  focuses  on  their 
antimicrobial properties. 
These peptides demonstrate an ability to translocate into cells without causing damage to 
the  membrane  (Deshayes  et  al.,  2005;  Zorko  &  Langel,  2005).  Although  the  specific 
mechanism  in  which  the  peptides  cross  the  lipid  bilayer  is  currently  unknown,  such 
properties have lead to the idea of using these peptides to deliver therapeutic cargo, such as 
DNA, peptides, or even proteins, into cells to treat various conditions and diseases (Zorko 
& Langel, 2005). There are no naturally occurring CPPs, most are either derived from 
transduction domains of native proteins, or designed to mimic the structure and sequence 
of such domains. Two of the best characterized CPPs are pVEC and TP10, a deletion 
analogue of Transportan (Elmquist et al., 2001; Soomets et al., 2000). Apart from uptake 
by  mammalian  cells,  both  peptides  can  successfully  translocate  into  insect  cells, 
protoplasts and yeast cells (Palm et al., 2006; Mae et al., 2005; Parenteau et al., 2005). In 
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very  low  concentrations  (Nekhotiaeva  et  al.,  2004).  This  led  to  investigations  of  CPP 
activity on the human malaria parasite and (as outlined in this chapter) BSF trypanosomes 
(Arrighi et al., in press). 
Peptides are emerging as attractive drug delivery tools (Brooks et al., 2005). The human 
immunodeficiency virus (HIV) encodes several trans-acting regulatory proteins not present 
in other retroviruses. One of these genes, designated tat, encodes a 14 kDa nuclear protein 
that acts to trans-stimulate virus gene expression and is localised predominantly in the 
nucleus. Recently, site-directed mutagenesis has been used to identify function domains 
within  the  tat  protein  (Rubens  et  al.,  1989).  Tat  mutations  centred  on  the  stretch  of 
positively  charged  amino  acids  showed  a  retained  tat  function  although  at  diminished 
levels. Moreover, the basic residues seemed to function as a nuclear localisation signal, a 
feature common among other nuclear proteins. 
The tat-derived peptide is a small basic peptide that has been successfully shown to deliver 
a large variety of cargoes that differ in size from small particles to large nucleic acids and 
proteins  (Brooks  et  al.,  2005).  The  ‘transduction  domain’  or  region  conveying  cell 
penetrating properties appears to be confined to a small stretch of basic amino acids, with 
the sequence RKKKRRQRRR (Ruben et al., 1989). It has been shown by a structure-
activity  relationship  study  investigating  which  feature  within  the  tat  peptide  was 
responsible for the membrane translocating property, that the cationic cluster of amino 
acids is the main functional domain determining translocation (Vives et al., 1997). The 
common  sequence  determinant  in  most  studies  performed  with  the  tat  peptide  is  the 
GRKKRRQRRR sequence. 
The mechanism of cell entry by the tat peptide along with other CPPs is unknown, yet 
several  theories  have  been  postulated  from  simple  diffusion  to  an  inverted  micelle 
formation where ionic interactions between the cationic charges of the peptide and the 
anionic  charges  of  the  phosphate  groups  of  the  phospholipid  heads  of  the  membrane 
initiate  the  membrane  absorption  of  the  peptide  (Brooks  et  al.,  2005).  Membrane 
association occurs in an energy independent manner, although it seems energy is required 
for translocation across the membrane (Deshayes et al., 2005). 
6.1.4 Eflornithine 
The ornithine analogue eflornithine (diflouromethylornithine, DFMO) was synthesised in 
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inhibitor  of  polyamine  biosynthesis  acts  as  an  irreversible  inhibitor  of  ornithine 
decarboxylase (ODC), with a consequent impairment of cell division. It is thought that 
DFMO’s mode of inhibition of ODC is by the formation of covalent adducts within the 
active site of the target enzyme through specific amino acid residues (Poulin et al., 1992). 
Trypanosome  cells  are  also  sensitive  to  DFMO.  However,  the  selective  toxicity  in 
treatment stems from the fact that trypanosomes are more sensitive, possibly because of the 
fact that polyamine depletion in trypanosomes  has a  greater  effect than in mammalian 
cells. In conjunction to this, the protozoa have an ODC that is degraded and replenished 
much more slowly that its mammalian host (Phillips et al., 1987). A 36 amino acid C-
terminal region, rich in proline, glutamate, aspartate, serine and threonine residues is found 
in the amino acid sequence of mammalian but not T. brucei ODC. In eukaryotes, regions of 
protein with this amino acid composition is a marker for rapid intracellular degradation, 
meaning trypanosome ODC has a much longer half life than its mammalian counterpart 
(Phillips  et  al.,  1987).  This  is  proposed  as  a  possible  cause  of  the  selective  toxicity 
exhibited  rather  than  increased  uptake  or  greater  affinity  for  the  trypanosome  enzyme. 
Indeed, T. brucei rhodesiense shows a greater turnover rate of ODC and this subspecies is 
consequently less sensitive to DFMO action (Bacchi et al., 1990; Iten et al., 1995). 
Uptake of this analogue of ornithine has been  proposed to occur via passive diffusion 
although some evidence for energy dependent transport exists (Bacchi et al., 1983; Bitonti 
et al., 1987). Uptake of DFMO in T. brucei has previously been studied in some detail 
(Bitonti et al., 1985). The rate of accumulation of DFMO is strongly dependent on the 
extracellular concentration, which suggested simple passive diffusion at play. Saturation of 
the uptake process with extracellular DFMO concentrations between 5 µM and 10 mM 
could  not  be  demonstrated.  Apparent  uptake  did  not  show  inhibition  by  any  common 
analogues (ornithine, lysine and arginine). However, the data presented by Bitonti shows 
only accumulation of DFMO at a 60 min time point, a time point which is far too long to 
report exclusively upon transport processes, especially when a diffusion component could 
also  be  at  play.  Moreover,  inhibition  studies  only  used  concentrations  of  competition 
barely 20 times that of DFMO (56 µM DFMO vs 1 mM analogue). Net internalisation of 
compounds comprises of transport as well as downstream effects related to metabolism and 
distribution. Therefore, at the longer time points these latter effects play a larger role on net 
uptake than initial transport. Temperature sensitivity of uptake gives the most evidence for 
transport processes at play. Indeed, in PCF trypanosomes uptake has been shown to be 
temperature sensitive and, moreover, follow Michaelis-Menten kinetics with an apparent 
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Certain biochemical changes to PCF trypanosomes associated with resistance to DFMO 
have been seen (Bellofatto et al., 1987). DFMO resistant cell lines were created and uptake 
of [
3H]-DFMO was investigated in comparison to wild type cell lines. The rate of DFMO 
uptake and incorporation was found to be significantly less in resistant lines (2.5 fold less) 
with intracellular concentrations of DFMO calculated to be 47 µM in wild type cells and 
only 20 µM in resistant cell lines after 70 mins. They concluded that, in this case, the 
resistance phenotype was not a direct result of increased ODC activity, or a change to the 
inhibition profile of DFMO binding to ODC, or amplification of the ODC gene. However, 
increased levels of ODC mRNA were seen suggesting increased transcription resulting in 
the  resistance  phenotype  seen.  Although,  this  result  seems  dubious  as  protein  extracts 
showed no increase in ODC levels. 
DFMO also shows  a profound effect on  morphology of trypanosomes  as well as their 
biochemical  characteristics;  causing  rapid  depletion  of  intracellular  polyamines  with  a 
compensatory increased uptake of exogenous polyamines (Alhonen-Hongisto et al., 1980), 
blocking  of  cytokinesis  leading  to  multinucleated  cells,  alterations  in  macromolecular 
synthesis,  and  abnormal  morphology  including  a  broad  appearance  with  a  short  free 
flagellum  (Bacchi  et  al.,  1983).  DFMO  exposure  of  trypanosomes  results  in  increased 
arginine and polyamine uptake as well as increased AdoMet decarboxylase activity (Porter 
et al., 1987). Arginine is a precursor of ornithine and the increased exogenous polyamine 
uptake could be a compensatory switch for the fall in intracellular levels due to ODC 
inactivity. 
When trying to decipher a mechanism of drug resistance that doesn’t involve the target 
enzyme being modified or upregulated, transport defects frequently relate to resistance. In 
the  case  of  DFMO,  energy  dependent  and  independent  processes  have  both  been 
implicated (transport versus simple passive diffusion). Assuming that both are relevant for 
getting DFMO into the cell only the loss of a transport system would lead to a resistance 
phenotype.  Rapid  drug  efflux  doesn’t  seem  to  be  a  mechanism  in  play  in  terms  of 
resistance to DFMO (Bellofatto et al., 1987). Charles E. Ebikeme, 2007     Chapter 6, 147 
 
Figure 6-5: General scheme for polyamine pathway in trypanosomes. 
Relevant enzymes are depicted in red. Enzymatic steps are represented by arrows. Blue 
arrows  denote  levels  upon  action  of  Eflornithine.  Enzymes:  ODC,  ornithine 
decarborxylase;  SAM  DC,  S-Adenosyl-methionine  decarboxylase;  spermidine  synthase, 
spermine  synthase.  Abbreviations:  MTA,  methylthioadenosine;  S-AdoMet,  S-adenosyl 
methionine; d S-AdoMet, decarboxylated S-adenosyl methionine; Glu, L-glutamate; Cys, 
L-cysteine;  GSH,  glutathione;  N-GSH-SPD,  glutathionyl  spermidine;  T[SH]2, 
trypanothione (reduced); T[S]2, trypanothione (oxidised). 
 
Targeted metabolite analysis revealed that exposure of parasites to the drug leads to an 
increase  in  ornithine  levels  and  decreases  of  spermidine,  putrescine  and  trypanothione, 
while levels of decarboxylated S-adenosylmethionine, the aminopropyl group donor in the 
polyamine  biosynthetic  pathway,  also  increase  (Fairlamb  et  al.,  1987).  One  of  the 
biochemical  effects  of  DFMO  treatment  is  complete  elimination  of  putrescine  and  a 
significant  reduction  of  spermidine  (Bacchi  et  al.,  1983).  Fairlamb  et  al  proposed  that 
significant polyamine depletion upon DFMO treatment effects levels of trypanothione (N
1, 
N
8-bis(glutathionyl)spermidine). Studies performed investigated the levels of metabolites 
involved in the synthesis of trypanothione using  HPLC methods to detect and analyse 
separated thiols. The effect of DFMO treatment was to rapidly reduce putrescine levels, 
spermidine reduction was more gradual over the 48 hour time period, and a consequent 
increase of intracellular levels of ornithine (18-fold increase over 12 hours), SAM (75-fold Charles E. Ebikeme, 2007     Chapter 6, 148 
increase after 72 hours) and dSAM (92-fold increase after 48 hours). The consequent drop 
in polyamine levels is what leads to the subsequent reduction in thiol levels. Decreased 
levels  of  trypanothione  result  in  increased  sensitivity  to  organic  peroxides  such  as 
hydrogen peroxide. 
DFMO’s cytostatic action requires a host response for effective elimination of parasites 
(Bitonti et al., 1986). Indeed, parasite respiration decreases (Giffin et al., 1986), and DNA 
synthesis is arrested (Bacchi et al., 1983). Moreover, a number of morphological changes 
are  associated  with  DFMO  action.  BSF  trypanosomes  after  36  hour  DFMO  treatment 
displayed characteristics similar to the stumpy form of the parasite, with multi-nucleated 
parasites seen (Bacchi et al., 1983). 
6.2  Results 
6.2.1 Amino Acid Analogue Screens 
The effect of a number of amino acid analogues on PCF trypanosomes as well as BSF 
trypanosomes  was  tested.  Screening  of  96  amino  acid  analogues  have  given  several 
potential trypanocidal agents with varying degrees of efficacy (Table 10, Appendix 8.14). 
IC50  values  of  all  were  determined  for  both  the  PCF  and  BSF  of  the  parasite.  A 
comparative assay against the mammalian cell line (HEK 293T) was done as a preliminary 
for potential drug application. 
 
Figure 6-6: Structures of some of the relevant amino acid analogues used. Charles E. Ebikeme, 2007     Chapter 6, 149 
 
Lead candidate investigations proceeded to look at each in further detail by trying to follow 
the path into the cell starting at a route of uptake with respect to amino acid transporters. 
Furthermore,  a  possible  cellular  target  involving  amino  acid  usage  was  investigated. 
However, it is also important to note that, the action of certain amino acid analogues might 
be brought about by metabolic and/or extracellular activation. 
Amino Acid Analogue  IC50 (µM) 
  PCF  BSF  HEK 
Azaserine  176.46  10.85  1.52 
L-Serine ß-naphthylamide  38.60  43.71  179.50 
Tryptophan Benzyl Ester  96.54  27.54  N/A 
Levodopa  58.58  31.58  112.21 
Cycloserine  116.15  308.00  176.42 
N-Benzoyl-L-Propyl-L-Tyrosine p-nitroanilide  46.20  17.40  110.00 
L-Leucine ß-Naphthyl Amide  69.66  52.70  N/A 
3,4 Dihydrophenylacetic acid  65.20  404.00  112.40 
Tryptamine  21.90  57.83  176.42 
Dopamine  63.25  275.00  87.00 
Tri-Iodothyronine (T3)  134.44  102.17  N/D 
L-Thyroxine  N/A  56.17  N/D 
Melphalan  N/A  102.24  N/D 
Table 11: Trypanocidal activities of lead candidate amino acid analogue. 
Mean IC50 values calculated for activity against the PCF, BSF trypanosome and the HEK 
cell line (N/A = no activity up to 200 µM, N/D = not determined) (n≥3). 
 
Lead candidates chosen were those that showed an IC50 value of less than 200 µM. The 
amino acid analogues show a wide range of activities; with azaserine being the most potent 
against  the  BSF  of  the  parasite  and  tryptamine  being  the  most  effective  against  the 
procyclic form. The analogues azaserine and levodopa were chosen for further analysis. 
The protocol for the alamar blue assay used here is adapted from Raz et al. (1997), using a 
starting BSF cell density of 10
4 cells per well. However, some labs commonly employ cell 
numbers as low as 10
3 cells per well. There is some evidence that the difference in starting 
densities does result in a shift in IC50’s. This shift could be many orders of magnitude. 
With that in mind, it is possible that the moderate IC50’s shown here by some analogues 
could show higher activities under different conditions. Charles E. Ebikeme, 2007     Chapter 6, 150 
6.2.2 Trypanocidal Activities 
A killing phenotype was investigated with some of the trypanotoxic amino acid analogues. 
For this, PCF trypanosomes were incubated with 1 mM drug (azaserine, L-Dopa, serine ß-
napthylamide,  tryptophan  benzyl  ester  and  tryptamine)  and  viewed  periodically  noting 
their morphology. 
With tryptophan benzyl ester and serine ß-napthylamide, PCF trypanosomes were killed 
overnight, with no dead intact parasites seen; just disintegrated cell debris. With L-Dopa 
killing occurred over 24 hours with dead whole cells visible leading to disintegration of 
cells.  With  L-Dopa,  the  medium  colour  changes  to  a  heavy  brown,  almost  black 
appearance. With azaserine, killing occurred much more slowly. After 48 hours some live 
parasites were still visible, suggesting that azaserine has a trypanostatic effect on cells 
rather than a trypanocidal one. 
This killing phenotype was repeated for BSF trypanosomes. With tryptophan benzyl ester 
and  serine  ß-napthylamide  cells  were  all  dead  within  6  hours  of  drug  exposure.  For 
tryptophan  benzyl  ester  cell  debris  and  no  intact  parasites  were  seen.  Serine  ß-
napthylamide  showed  some  intact  dead  cell  (skeletons).  Azaserine  exposure  showed  a 
slower effect. Some cells were still alive after 6 hours and even 24 hours. Cell debris was 
seen as well as parasite skeleton. Killing due to levodopa was also within the first 6 hours 
of exposure. The killing phenotype  was the most distinct of the amino acid analogues 
tested, with all dead cells still intact. 
In  BSF  trypanosomes  we  also  wanted  to  distinguish  between  trypanostatic  and 
trypanocidal  drug  actions  for  azaserine  and  L-Dopa.  For  this,  BSF  trypanosomes  at  a 
starting density of 7 x 10
4 cells/ml were incubated in the presence of drug at twice its IC50 
concentration. Cells were monitored by microscopy periodically and cell numbers were 
determined  using  an  improved  Neubauer  haemocytometer  (counting  chamber;  Weber 
Scientific). Charles E. Ebikeme, 2007     Chapter 6, 151 
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Figure 6-7: Trypanocidal cell counts. 
BSF  trypanosomes  incubated  at  1xIC50  and  2xIC50  of  each  drug  (10  µM  and  20  µM 
azaserine; 30 µM and 60 µM L-Dopa) over a 72 hour period (this experiment represents 3 
similar repeats). 
 
With L-Dopa at 2xIC50 concentration a trypanocidal effect was seen. Cells incubated at 
1xIC50  could  overcome  the  initial  drug  exposure  and  were  seen  to  proliferate  after  24 
hours. With azaserine, a more trypanostatic effect was seen. Both concentrations of the 
drug used stopped trypanosomes from proliferating and only after day 3 was cell death 
seen. 
6.2.3 Mode of action 
With amino acid analogues showing high structural similarity to the naturally occurring 
amino acids, it is possible that a specific action involving amino acid usage is involved. 
Azaserine shows similarity with the amino acid glutamine and levodopa shows similarity 
to  tyrosine.  Here,  we  simply  incubated  bloodstream  form  trypanosomes  with  high 
concentrations of all the 20 amino acids at twice each drug’s IC50 to determine whether any 
amino acids, at high concentrations, could antagonise analogue activity. Charles E. Ebikeme, 2007     Chapter 6, 152 
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Figure 6-8: Amino acid recovery of azaserine action. 
The action of 20 µM azaserine in the presence of 10 mM of each of the 20 amino acids 
(norvaline included), with no drug used as a control (n=3, Error bars = ±SEM). 
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Figure 6-9: Amino acid recovery of L-Dopa action. 
The action of 60 µM L-Dopa in the presence of 10 mM of each of the 20 amino acids 
(norvaline included), with no drug used as a control (n=3, Error bars = ±SEM). Charles E. Ebikeme, 2007     Chapter 6, 153 
 
Results showed no difference in toxicity with increased concentrations of amino acids, 
suggesting  that  the  analogue’s  mode  of  action  does  not  involve  amino  acid  usage  by 
trypanosomes or, at the very least; the mode of action is not competitive with other amino 
acids.  The  apparent  recovery  by  L-cysteine  was  anomalous  as  viewing  of  cells  by 
microscopy showed no live parasites. 
It is possible that the high level of L-Dopa toxicity seen by Owolabi et al is simply as a 
result of metabolic activation. However, this possibility was investigated by testing all 
intermediates  and  ultimate  products  of  the  pathway  for  trypanocidal  activity  against 
trypanosomes. 
Amino Acid Analogue  IC50 (µM) 
  PCF  BSF  HEK 
5' Hydroxy-L-Tryptophan  N/A  N/A  N/A 
Serotonin  155  N/A  N/A 
Tryptamine  21.90  57.83  176.42 
Dopamine  63.25  275.00  87.00 
Kynurenine  N/A  N/A  N/A 
Noradrenaline  N/A  N/A  N/A 
Table 12: Trypanocidal activities of metabolic downstream analogues. 
Mean IC50 values calculated for activity against the PCF, BSF trypanosome and the HEK 
cell line (N/A = no activity up to 100 µM, N/D = not determined) (n≥3). 
 
Dopamine, noradrenaline, kynurenine, 5’hydroxy-tryptophan and serotonin did not show 
any  significantly  higher  toxicity  against  trypanosomes  when  compared  to  L-Dopa  and 
Tryptamine (Table 12). A mode of action for L-Dopa involving the generation of reactive 
oxygen species has already been postulated (Olowabi et al., 1989). However, it was not 
clear if its action was due to internal or exterior activity of L-Dopa itself or one or more of 
its derivatives. In trypanosomes, protection against oxidative stress is controlled partly by 
super-oxide  dismutase,  a  family  of  antioxidant  metalloenzymes  which  detoxifies 
superoxide anions (Prathalingham et al., 2007). We also tested L-Dopa for activity against 
TbSOD mutants to see  if increased  L-Dopa  activity was evident in TbSOD  knock-out 
lines. No difference was found in L-Dopa activity as compared to controls. L-Dopa alamar 
blue assays  against TbSOD  knock-out lines were performed by  Prof. John Kelly’s lab 
(LSHTM, London). Charles E. Ebikeme, 2007     Chapter 6, 154 
In order to try  and select for  resistance, BSF trypanosomes were passaged in  medium 
containing incremental amounts of drug. However, the generation of resistant lines proved 
problematic.  For  azaserine,  parasites  showing  only  a  4-fold  resistance  were  obtained, 
however, constant drug pressure reduced the doubling time of parasites and stable growth 
could not be obtained; with parasites usually dying after several passages. For levodopa, 
concentrations  used  caused  progressive  darkening  of  the  medium,  with  turbidity 
developing from the production of quinolones and other reactive oxygen species. Resistant 
cell  lines  could  not  be  generated  due  to  the  fact  that  trypanocidal  activity  may  not 
necessarily be as a result of the analogue itself, but secondary products of the analogue. 
6.2.4 Azaserine & the L-glutamine Transport System 
Internalisation of amino acid analogues via amino acid transporters was an essential area 
we wanted to investigate. For this, we tested uptake of radiolabeled amino acids in the 
presence of excess concentrations of amino acid analogues. A possible route of entry was 
discovered by inhibition of glutamine uptake (based on structural similarity) as well as a 
possible route of entry through the aromatic amino acid transport system. 
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Figure  6-10:  Glutamine  uptake  in  PCF  trypanosomes  in  the  presence  and  absence  of 
azaserine. 
Uptake of 10 µM L-[
3H] Glutamine in PCF trypanosomes over a 1 hour time period, in the 
presence and absence of 10 mM azaserine (n=3, Error bars = ±SEM). 
 Charles E. Ebikeme, 2007     Chapter 6, 155 
Glutamine uptake was studied in the presence of 10 mM azaserine over a 1 hour time 
period,  showing  a  significant  inhibition  of  uptake  over  a  short  period  of  time.  This 
inhibition was never total (~50%) and beyond 5 minutes no inhibition was apparent. Since 
multiple routes of entry for azaserine had been postulated in other organisms (Williams et 
al., 1980; Kaplan et al., 1959; Jacquez et al., 1957), we investigated a possible alternative 
route of entry for azaserine. Screening of a number of radiolabelled amino acids lead us to 
find a common route of uptake via a phenylalanine transport system. 
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Figure  6-11:  Phenylalanine  uptake  in  PCF  trypanosome  in  presence  and  absence  of 
azaserine. 
Uptake of 10 µM L-[
3H] Phenylalanine in PCF trypanosomes over a 1 hour time period, in 
the presence and absence of 10 mM azaserine (n=3, Error bars = ±SEM). 
 
Azaserine inhibition of phenylalanine uptake is more pronounced than the inhibition seen 
against glutamine. Again, this inhibition is lost over time, as at the 1 hour time point, 
incorporation  of  phenylalanine  in  the  presence  of  azaserine  shows  no  comparable 
difference. We also wanted to investigate if azaserine inhibition of glutamine and aromatic 
amino acids was also evident in BSF trypanosomes. Charles E. Ebikeme, 2007     Chapter 6, 156 
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Figure 6-12: Glutamine uptake in BSF trypanosomes in presence and absence of azaserine. 
Uptake of 10 µM L-[
3H] Glutamine in BSF trypanosomes over a 1 hour time period, in the 
presence and absence of 10 mM azaserine (n=1). 
 
Glutamine  inhibition  by  high  concentrations  of  azaserine  is  also  seen  in  BSF.  In  this 
instance, glutamine inhibition seems to be to a greater degree than the inhibition exhibited 
by PCF trypanosomes, with 10 mM azaserine able to inhibit L-glutamine accumulation to 
completion. 
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Figure 6-13: Tyrosine uptake in BSF trypanosomes in presence and absence of azaserine. 
Uptake of 10 µM L-[
3H] Tyrosine in BSF trypanosomes over a 1 hour time period, in the 
presence and absence of 10 mM azaserine (n=3, Error bars = ±SEM). Charles E. Ebikeme, 2007     Chapter 6, 157 
 
Tyrosine uptake in BSF trypanosomes shows an almost linear characteristic over the 1 
hour  time  period.  Internalisation  of  tyrosine  can  be  inhibited  by  azaserine  at  high 
concentrations. Therefore, it seems evident that azaserine, at high concentrations, inhibits 
glutamine, phenylalanine and tyrosine internalisation by trypanosomes. We used this fact 
as  a  mode  to  investigate  a  glutamine  specific  transport  system  in  PCF  trypanosomes, 
hoping that more insight can be gained into the nature of the glutamine transport system. 
Firstly, to find amino acids that may be co-transported along with glutamine, inhibition of 
glutamine  uptake  was  performed  using  all  the  20  amino  acids  individually  at  a  high 
concentration. 
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Figure 6-14: Glutamine inhibition by 20 amino acids. 
Uptake of 10 µM L-[
3H] Glutamine in the presence of all 20 amino acids at a concentration 
of 10 mM. Uptake shown as a percentage of control with no inhibitor (L-Tyrosine is not 
soluble at a concentration of 10 mM under the conditions required for this experiment. 
Consequently inhibition of uptake was not determined in the presence of tyrosine) (n=3, 
Error bars = ±SEM). 
 
Glutamine  uptake  shows  high  levels  of  competition  with  glutamate  and  methionine 
suggesting  a  shared  route  of  entry  for  these  three  amino  acids.  Structural  similarities 
proposed that this may be the case, although – functionally – glutamine shares amidic Charles E. Ebikeme, 2007     Chapter 6, 158 
properties with asparagine, which doesn’t seem to be transported along with it. Amino acid 
transporters often have a broad specificity range, which sometimes can be seen as “leaky” 
transport. In this case, uptake of glutamine is inhibited to high levels (>90%) by a few 
amino acids (glutamate and methionine) whereas tryptophan shows very weak inhibition 
(~40%). 
To determine the relative affinities of potential competitors for the transport system we 
used radiolabelled glutamine as the label in the presence of 0-10 mM of each of the other 
amino acids previously shown to inhibit glutamine uptake (Figure 6-15). Using a range of 
concentrations can distinguish between ‘weak’ and ‘partial’ inhibition, and can give an 
insight into the nature of the transport system. 
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Figure 6-15: Glutamine inhibition. 
Inhibition  of  10  µM  L-[
3H]  Glutamine  in  PCF  trypanosomes  by  cold  glutamine, 
methionine, glutamate, and azaserine over a range of concentrations (no inhibitor, 10 µM, 
50 µM, 100 µM, 500 µM, 1 mM, 2 mM, 4 mM, 5 mM, 8 mM, 10 mM) (n=3, Error bars = 
±SEM). 
  IC50 (µM)  Standard Error 
Glutamine  16.03  1.1 
Methionine  1393.8  326.4 
Glutamate  6397.3  1938.7 
Azaserine  3723.1  324.4 
Table 13: Calculated IC50 values for inhibitors of L-glutamine uptake. 
 Charles E. Ebikeme, 2007     Chapter 6, 159 
In each case these amino acids gave a progressive dose-dependent inhibition (although to 
different  degrees),  suggesting  the  order  of  affinity  for  a  supposed  transporter  being 
glutamine>>methionine>>glutamate, with azaserine showing only partial inhibition.  
The calculated IC50 values refer to the amount of inhibitor required to inhibit uptake of a 
particular amino acid by 50%. Only glutamine shows an IC50 value in the micro molar 
range, with the others in the millimolar range, suggesting that this transporter has a higher 
affinity for glutamine as compared to all the others. 
6.2.5 Levodopa & the Aromatic Transport System 
Studies here on aromatic amino acid uptake in trypanosomes have been done in the context 
of  the  amino  acids  phenylalanine  and  tyrosine,  along  with  the  tyrosine  analogue, 
Levodopa.  None  of  the  other  aromatic  amino  acid  analogues  (noradrenalin,  serotonin, 
tryptamine, or dopamine) showed any inhibition of phenylalanine uptake (Figure 6-16). 
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Figure 6-16: Phenylalanine inhibition by amino acid analogues. 
Uptake of 10 µM L-[
3H] Phenylalanine in PCF trypanosomes in the presence of a range of 
analogues at a concentration of 10 mM (L-Dopa concentration at 1 mM) (n=1). 
 Charles E. Ebikeme, 2007     Chapter 6, 160 
Levodopa’s high structural similarities to tyrosine lead us to investigate its internalisation 
through a tyrosine specific transport system. We investigated uptake of tyrosine in PCF 
trypanosomes over the course of 1 hour in the presence of 1 mM L-Dopa. 
Time (mins)
0 20 40 60
U
p
t
a
k
e
 
(
n
a
n
o
m
o
l
e
s
/
1
0
7
 
c
e
l
l
s
)
0
0.002
0.004
0.006
0.008
0.01
0.012 Tyr
+L-Dopa
 
Figure 6-17: Tyrosine uptake in PCF trypanosomes in the presence and absence of L-Dopa. 
Uptake of 10 µM L-[
3H] Tyrosine in PCF trypanosomes over a 1 hour time period, in the 
presence and absence of 1 mM L-Dopa (n=3, Error bars = ±SEM). 
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Figure 6-18: Tyrosine uptake in BSF trypanosomes in the presence and absence of L-Dopa. 
Uptake of 10 µM L-[
3H] Tyrosine in BSF trypanosomes over a 1 hour time period, in the 
presence and absence of 1 mM L-Dopa (n=3, Error bars = ±SEM). Charles E. Ebikeme, 2007     Chapter 6, 161 
 
L-tyrosine uptake was inhibited to a large degree by 1 mM L-Dopa, with uptake almost 
non-existent over the 1 hour time period. This was evident in both the PCF and BSF stage 
of the parasite. Given the fact that aromatic amino acids have no significant metabolic 
function within the cells, accumulation of amino acids within the cell seems odd. As in the 
previously  described  work  with  L-glutamine,  inhibitor  studies  might  give  insight  into 
structural specificities of a tyrosine transporter in trypanosomes. 
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Figure 6-19: Tyrosine inhibition by 20 amino acids. 
Uptake of 10 µM L-[
3H] Tyrosine in PCF trypanosomes in the presence of all 20 amino 
acids at a concentration of 10 mM. Uptake is shown as a percentage of control with no 
inhibitor (L-Tyrosine is not soluble at a concentration of 10 mM under the conditions 
required for this experiment. Consequently inhibition of uptake was not determined in the 
presence of tyrosine) (n=3, Error bars = ±SEM). 
 
Tyrosine  uptake  is  inhibited  relatively  poorly  by  the  20  amino  acids  at  10  mM,  with 
phenylalanine and tryptophan the two amino acids that inhibit the most (~20-50% uptake), 
and methionine showing ~60% inhibition. It is possible that a common route of entry exists 
for the aromatic amino acids due to structural similarity, however since inhibition is never 
total  it  is  possible  multiple  transporters  play  a  role  in  uptake.  Indeed,  previous  work 
investigating aromatic amino acid uptake in BSF trypanosomes suggested the existence of Charles E. Ebikeme, 2007     Chapter 6, 162 
several  aromatic  amino  acid  transporters  (M.P.  Hasne,  thesis).  Phenylalanine  and 
tryptophan  were  found  to  use  at  least  2  routes  of  entry  while  a  single  high  affinity 
transporter was identified for tyrosine. 
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Figure 6-20: Tyrosine inhibition. 
Inhibition  of  10  µM  L-[
3H]  Tyrosine  in  PCF  trypanosomes  by  cold  tyrosine, 
phenylalanine, tryptophan and L-Dopa over a range of concentrations (no inhibitor, 0.1 
mM, 1 mM, and 5mM). Uptake shown as a percentage of control with no inhibitor (n=3, 
Error bars = ±SEM). 
 
Inhibition  of  tyrosine  under  increasing  amounts  of  cold  tyrosine,  phenylalanine,  and 
tryptophan showed a dose dependent relationship, with tryptophan being the weakest of all 
the aromatic inhibitors. L-Dopa was only used at a highest concentration of 1 mM due to 
the limits of its solubility in water. Higher concentrations of L-Dopa can be achieved with 
dilution  in  HCl,  however,  the  hydrogen  ions  alter  the  pH  of  the  uptake  buffer  and 
subsequently alter uptake by trypanosomes. From this, it seems possible that a tyrosine-
specific transport system also shows some specificity for phenylalanine and tryptophan, 
and great specificity for L-Dopa. Charles E. Ebikeme, 2007     Chapter 6, 163 
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Figure 6-21: Phenylalanine inhibition. 
Inhibition of 10 µM L-[
3H] Phenylalanine in PCF trypanosomes by cold phenylalanine and 
L-Dopa over a range of concentrations (no inhibitor, 0.1 mM, 1 mM, and 5mM). Uptake 
shown as a percentage of control with no inhibitor (n=3, Error bars = ±SEM). 
 
Phenylalanine  self-inhibition  reaches  completion  at  5  mM.  Inhibition  of  phenylalanine 
with L-Dopa at the 1 mM concentration used inhibits phenylalanine uptake by ~40%. In 
comparing the result here with that from the tyrosine inhibition experiment it seems that L-
Dopa  does  have  specificity  for  both  the  tyrosine  and  phenylalanine  transport  systems, 
although to differing degrees. If one transport system for the aromatic amino acids was 
evident then L-Dopa inhibition of both tyrosine and phenylalanine would be to a similar 
degree. The fact that more inhibition of tyrosine uptake is seen suggests that different 
transport systems occur for the aromatic amino acids. 
6.2.6 Cell Penetrating Peptides 
 
Peptide  Sequence  Length 
pVEC  LLIILRRRIRKQAHAHSK  18 
TP10  AGYLLGKINLKALAALAKKIL  21 
Tat  GRKKRRQRRR  10 
Table 14: CPP amino acid sequence. 
 Charles E. Ebikeme, 2007     Chapter 6, 164 
Peptides compromise short amino acid chains, and there has been some interest in the 
antimicrobial activity of some peptides. Here we test three CPPs (TP10, pVEC and tat-
derived peptide) for anti-trypanosomal activity and look at the internalisation of TP10 and 
tat-derived peptide. 
The TP10 and pVEC CPPs were from Dr Romanico Arrighi (University of Stockholm) 
whereas the tat-derived peptide was from Dr Catherine Berry (University of Glasgow). We 
investigated  CPP  activity,  and  monitored  TP10,  pVEC  and  tat  peptide  activity  against 
blood stage trypanosomes in vitro. Here TP10 shows strong activity, with an IC50 value of 
2.7  µM.  In  contrast,  pVEC  was  ineffective  at  reducing  the  parasite  numbers  up  to 
concentrations of 25 µM. The tat-derived peptide failed to show any trypanocidal activity 
at concentrations up to  100 µM.  In order to determine whether TP10  was lysing BSF 
trypanosomes,  we  monitored  the  parasites  every  hour  up  to  six  hours  following  the 
addition of TP10 (Figure 6-22). 
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Figure 6-22: CPP activity against BSF trypanosomes. 
Cell numbers viewed microscopically over a 6 hour time period (this experiment represent 
data from 3 similar repeats). 
 
The  parasite  numbers  dropped  by  ~20%  within  one  hour  of  treatment  at  the  IC50 
concentration (2.7 µM). No further reductions were noted in the subsequent hours post-
treatment. However at 2xIC50 (5.4 µM), an initial drop in parasite numbers was followed Charles E. Ebikeme, 2007     Chapter 6, 165 
by a steady decline in the parasite population, with complete cell clearance after 6 hours. 
This data shows that TP10 is effective against blood stage trypanosomes. 
To shed light on the mechanism of TP10 trypanocidal activity we used FITC-conjugated 
TP10 (fluorescin isothiocyanate), and monitored potential uptake and localisation in the 
BSF trypanosome as compared with DAPI (4',6-diamidino-2-phenylindole, a fluorescent 
stain that binds strongly to DNA). BSF trypanosomes were exposed to either 10 µM or 50 
µM  drug.  Rapid  cell  death  was  seen  at  higher  concentrations,  and  even  at  these 
concentrations cell death was evident. 
The compound was seen to enter dead cells. However, live cells did not show significant 
internalisation of the compound. And few showed co-localisation with the kinetoplast and 
the nucleus and others with just the kinetoplast. It is possible that greater concentrations of 
drug  are  needed  to  show  any  significant  staining  of  the  trypanosome  cell  interior. 
However, because of trypanocidal activity of the compound, it will be hard to achieve 
without cell death. 
The  internalisation  of  the  tat  peptide  into  the  interior  of  the  trypanosome  was  also 
investigated. Internalisation of the peptide was not seen at concentrations of up to 60 µg/ml 
(~43 µM), with up to 3 hours incubation time. No staining of cell interior was seen, as 
compared to punctuate localisation with DAPI as a control. 
6.2.7 DFMO Mode of Uptake 
Here, we investigate further the mode of uptake of DFMO and its relation to other amino 
acids with respect to uptake via an amino acid transport system. Due to short supply of 
3H-
DFMO (a gift from Dr S Thomas, London), only a preliminary study of DFMO uptake was 
possible. Charles E. Ebikeme, 2007     Chapter 6, 166 
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Figure 6-23: DFMO uptake. 
Uptake of 10 µM 
3H-DFMO in BSF trypanosomes over a 2 hour time period (n=1). 
Uptake of 10 µM 
3H-DFMO over the 2 hour time period appears to be essentially linear, 
showing an approximate accumulation of drug at a rate of 10 picomoles per hour (per 10
7 
cells). 
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Figure 6-24: DFMO self-inhibition. 
Inhibition of 10 µM 
3H-DFMO in BSF trypanosomes by cold DFMO over a range of 
concentrations (no inhibitor, 30 µM, 60 µM, 125 µM, 250 µM, 500 µM, 1 mM, 10 mM). 
Inset: 0 – 250 µM (n=1). 
 Charles E. Ebikeme, 2007     Chapter 6, 167 
Next we wanted to determine if uptake of DFMO could be inhibited by increasing doses of 
unlabelled drug. Self-inhibition of DFMO never reaches a baseline level; with an apparent 
stimulation of uptake from 250 to 500 µM onwards. Increased DFMO concentrations seem 
to re-stimulate increased uptake of DFMO. An IC50 value was calculated (26.7 µM ± 4.6) 
based  on  the  concentration  which  gave  half  of  the  maximal  inhibition.  If  inhibition  is 
incomplete, this could suggest more than one route of entry for a particular substrate. In 
this case, inhibition at its maximum is only 50% complete. 
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Figure 6-25: DFMO inhibition by 20 amino acids. 
Uptake of 1 µM 
3H-DFMO in BSF trypanosomes in the presence of all 20 amino acids at a 
concentration of 500 µM. Uptake shown as a percentage of control with no inhibitor, with 
red line indicating inhibition level by cold DFMO (n=1). 
 
Inhibition of [
3H]-DFMO (1 µM) by the 20 amino acids using a 500-fold excess of cold 
inhibitor shows that lysine, arginine, threonine, glutamate and the aromatic amino acids 
can  inhibit  DFMO  uptake  beyond  50%.  Only  a  500-fold  excess  was  used  as  to  avoid 
stimulation of another possible intake mechanism at high concentrations as noted by the 
data collected on DFMO self inhibition with cold DFMO. This information provides more 
preliminary evidence for multiple routes of entry via amino acid specific transport systems. 
Inhibition greater than the level of self-inhibition exhibited by DFMO on its own is shown 
by the amino acids threonine and glutamate, as well as two amino acid groups (the basic Charles E. Ebikeme, 2007     Chapter 6, 168 
and  aromatic  amino  acids).  These  latter  two  groups  were  then  used  to  study  additive 
inhibition. 
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Figure 6-26: DFMO inhibition by basic and aromatic amino acids. 
Uptake of 1 µM 
3H-DFMO in BSF trypanosomes in the presence of 500 µM amino acid 
inhibitors  (histidine,  arginine,  lysine,  tyrosine,  phenylalanine,  tryptophan,  and 
combinations  of  both  the  basic  (arginine,  lysine  and  histidine)  and  aromatic 
(phenylalanine, tryptophan and tyrosine) amino acids at a concentration of 500 µM each) 
(n=1). 
 
The basic and aromatic groups of amino acids were used to study additive inhibition using 
the same inhibition concentrations as previously stated (500 µM inhibitor versus 1 µM 
DFMO). All amino acids used showed some level of inhibition, with lysine showing total 
inhibition of DFMO uptake. Interestingly, high concentrations of multiple amino acids did 
not completely reduce uptake of DFMO. DFMO uptake in the presence of all three basic 
amino acids showed levels comparable with histidine on its own. Similarly, high levels of 
the aromatic amino acids restore DFMO uptake. If a sole basic amino acid transporter was 
present we would expect to see total inhibition of DFMO uptake in the presence of all the 
basic amino acids. However, the fact that uptake is still seen in the presence of the basic 
amino acids points to a few possibilities. Firstly, that multiple transporters are present, the 
kinetics  and  capacity  of  which  cannot  be  distinguished  from  these  preliminary Charles E. Ebikeme, 2007     Chapter 6, 169 
experiments.  And  secondly,  it  is  possible  that  some  sort  of  trans-acceleration  effect  is 
occurring in the presence of high concentrations of the amino acids. Trans-acceleration 
refers  to  the  increased  capacity  of  a  single  transporter.  Thirdly,  the  presence  of  high 
concentrations  of  certain  amino  acids  might  stimulate  the  opening  of  another  related 
transporter. This might go some way to explaining the restored uptake of DFMO in the 
presence of the aromatic amino acids, and is consistent with the apparent re-stimulation of 
DFMO uptake (Figure 6-24). 
It seems possible that multiple routes of entry for DFMO are present. Lysine differs from 
DFMO by one CH2 unit on its side chain and an altered amino acid recognition motif, with 
the hydrogen replaced by a difluoromethyl unit (Figure 6-32). It is expected that DFMO’s 
high structural similarity to lysine will mean it shares a route of entry through a lysine 
specific transport system. We then went on to assess DFMO’s ability to inhibit tyrosine 
and lysine uptake, using radiolabeled amino acids and cold DFMO at high concentrations. 
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Figure 6-27: Lysine inhibition by DFMO and lysine. 
Uptake of 10 µM L-[
3H] Lysine in BSF trypanosomes at a single 30 sec time point in the 
presence of cold lysine and DFMO over a range of concentrations (no inhibitor, 0.1 mM, 1 
mM, 5mM). Uptake shown as a percentage of control with no inhibitor (n=3, Error bars = 
±SEM). 
 
Lysine inhibition seems dose dependent with respect to cold lysine. From the curve an 
apparent IC50 of 39 µM ± 4 was calculated. In the presence of DFMO, inhibition is seen Charles E. Ebikeme, 2007     Chapter 6, 170 
but is never total (~60% inhibition of 10 µM lysine at a 10 mM DFMO concentration). 
Lysine uptake, unlike DFMO (Figure 6-24), is not re-stimulated at higher concentrations of 
DFMO.  If  DFMO  is  targeted  through  a  lysine  specific  transporter,  the  nature  of  this 
transporter, in its capacity and kinetic behaviour, is still to be elucidated. DFMO uptake via 
another route was explored by inhibition of tyrosine uptake. 
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Figure 6-28: Tyrosine uptake in BSF trypanosomes in presence and absence of DFMO. 
Uptake of 10 µM L-[
3H] Tyrosine in BSF trypanosomes in the presence and absence of 10 
mM DFMO over a 1 hour time period (n=3, Error bars = ±SEM). 
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Figure 6-29: Tyrosine inhibition by DFMO. 
Uptake of 10 µM L-[
3H] Tyrosine in BSF trypanosomes in the presence of DFMO at a 
range of concentrations (no inhibitor, 0.1 mM, 1 mM, and 5 mM). Uptake shown as a 
percentage of control with no inhibitor (n=3, Error bars = ±SEM). 
 
Tyrosine  uptake  in  the  presence  of  high  concentrations  of  DFMO  (10  mM)  shows  no 
inhibition  of  accumulation  by  BSF  trypanosomes  over  the  1  hour  time  period.  This 
suggests that these two compounds do not share the same mode of uptake. Moreover, when 
inhibition of tyrosine was performed over a range of DFMO concentrations (up to 5 mM) 
we found no significant difference in tyrosine uptake. As previously shown tyrosine does 
inhibit DFMO uptake, however, the experiment was only carried out once. It is possible 
that with multiple repeats that inhibition seen becomes less significant. Another possibility 
is  the  fact  that  tyrosine  itself  interacts  with  a  transporter  of  DFMO  uptake  without 
necessarily being a substrate for that carrier. 
6.3  Discussion 
Amino  acid  analogues  have  a  great  potential  for  chemotherapy  of  human  African 
trypanosomiasis. The advantages include the fact that some trypanosome transporters have 
a high affinity for amino acids and a relatively low abundance of competing substrates. 
Moreover,  amino  acid  analogues  can  allow  us  to  assign  functional  characteristics  to 
transporter systems and allow us to differentiate between a one transporter and multiple-
transporter system. Charles E. Ebikeme, 2007     Chapter 6, 172 
Differences in trypanocidal activity of certain amino acid analogues between PCF and BSF 
could be as a direct result of uptake or, simply the metabolic differences between parasite 
stages.  The  discovery  of  L-Dopa’s  trypanocidal  action  led  us  to  test  other  relevant 
compounds  (e.g.  thyroxine  and  tri-iodothyronine).  These  compounds  did  show  some 
trypanocidal activity and it would be of interest to see if they are targeted through an amino 
acid transporter. Trypanosome induced hypothyroidism is a phenomenon that has been 
shown in vivo (Lomo et al., 1993). The development of anaemia coincides with the marked 
decrease in plasma concentration of both tri-iodothyronine and thyroxine, and it seems 
hormonal treatment enhanced survival of infected animals (Lomo et al., 1995). 
As well as multiple systemic features seen in the early acute stage, the late chronic stage of 
African  sleeping  sickness  is  associated  with  a  wide  range  of  neurological  features. 
Neurological features which are common to other neurological disorders associated with 
monoamine neurotransmitter availability within the brain (Daniel et al., 1976; Kennedy, 
2006).  These  neurotransmitters  are  synthesized  in  the  brain  from  aromatic  amino  acid 
precursors that have to be obtained from the circulating blood. Changes in the cerebral 
concentrations of one or more neurotransmitters are the cause of certain neuropsychiatric 
disorders (Fernstrom & Wurtman, 1971; Shoemaker &  Wurtman, 1971; Bernheimer & 
Hornykiewicz, 1973). The formation of neurotransmitters is largely determined by how the 
CNS can acquire pre-cursor aromatic amino acids from the circulating blood (Coppen et 
al., 1963; Daniel et al., 1976). More specifically, elevating brain tyrosine concentrations 
stimulates catecholamine production (Fernstrom & Fernstrom, 2007). 
6.3.1 Azaserine & Glutamine Transport 
In this study, the glutamine analogue, azaserine, was found to have differing activities 
against the two forms of the parasite, with an IC50 of 176.46 µM, 10.85 µM, and 1.52 µM 
against the  PCF, BSF,  and HEK  cell respectively.  It could be argued  that the toxicity 
shown by azaserine against the BSF of the parasite (10.85 µM) is moderate at best. For 
most compounds seeking therapeutic use, nanomolar IC50 values are more attractive. There 
is good evidence that the difference in starting trypanosome densities for these assays does 
result in a shift in IC50 values. This shift could be many orders of magnitude. With that in 
mind, it is possible that the moderate IC50 values shown here by some analogues including 
azaserine could show higher activities under different conditions. 
Previous investigations with other glutamine analogues like DON and acivicin showed that 
neither is totally active in vivo. T. brucei infected mice receiving doses of drugs showed no Charles E. Ebikeme, 2007     Chapter 6, 173 
trypanosomes in the blood (Hofer et al., 2001). However, with discontinuation of therapy 
trypanosomes  reappeared.  They  concluded  that  the  relapse  of  trypanosomes  after  drug 
removal  was  observed,  suggesting  that  the  glutamine  analogues  only  block  the 
proliferation of the parasites. A functional immune response is then required to eradicate 
the growth-arrested trypanosomes. 
High  mammalian  cell  toxicity  rules  out  any  potential  therapeutic  use,  however,  the 
simplicity of the molecule allows chemical remodelling if a drug target can be found. For 
example, DON is another glutamine analogue similar in structure to azaserine and shows 
no toxic effects against the mammalian cells used (Appendix 8.14). It would be interesting 
to test how the small differences between molecules translate to cell toxicity and drug 
target. Also, even though azaserine is more active against mammalian cells it provides a 
tool for identification and characterisation of particular amino acid transporters involved in 
its uptake. 
 
Figure 6-30: Schematic representation of a possible L-glutamine transport system in PCF 
trypanosomes. 
 
Here, like with other organisms (Kaplan et al., 1959; Brock & Brock, 1960), we have 
shown azaserine to be transported into the cell by the amino acid transport system, with 
multiple routes of entry evident (azaserine showed inhibition of glutamine, phenylalanine 
and tyrosine in both forms of the parasite, although to differing degrees). In the PCF of the 
parasite we studied this mode of inhibition in more detail, using unlabelled glutamine, 
glutamate, methionine and azaserine over a range of concentrations (0-10 mM). In each 
case  these  amino  acids  gave  a  progressive  dose-dependent  inhibition,  with  azaserine 
showing only partial inhibition at the highest concentration used (10 mM). This partial Charles E. Ebikeme, 2007     Chapter 6, 174 
inhibition  exhibited  suggests  more  than  one  glutamine  transporter  with  azaserine  only 
entering the cell via one transporter. This, coupled to the fact that glutamate inhibition is 
weak (and at the same time complete) suggests that both glutamine transport systems are 
inhibited  by  glutamate  but  at  different  concentrations  –  one  at  a  low  glutamate 
concentration  and  the  other  at  a  high  glutamate  concentration.  Complete  inhibition  of 
phenylalanine uptake shows entry via an aromatic amino acid transport system, a transport 
system which seems not to be shared by other aromatic amino acids. 
Previous work investigating the nature of methionine transport in trypanosomes (Hasne & 
Barrett, 2001) showed a single methionine transporter with high affinity for methionine 
(showing a Km value of 30.9 ± 7.6 µM and a Vmax value of 16.2 ± 0.2 nmol/min/10
8 cells 
for PCF trypanosomes). Hasne & Barrett (2001) reported the existence in PCF of a single 
methionine transporter based on the fact that competing amino acids showed weak rather 
than  partial  inhibition  of  methionine  uptake.  However,  competing  amino  acids  (e.g. 
phenylalanine)  do  not  show  any  structural  similarities  to  methionine  and  glutamine 
inhibition was only 60% at a 5 mM concentration. Here we report an L-glutamine transport 
system that has high affinity for glutamine (16 µM IC50) and shows weak inhibition by L-
methionine (1.39 mM IC50). It is possible that multiple glutamine transporters exist (Figure 
6-30), which show differing affinities for glutamate, methionine and azaserine. And that 
one of the glutamine transporters has a higher affinity for methionine than glutamine. This 
would be the methionine transporter previously characterised. Uptake of methionine would 
be poorly inhibited by  glutamine  as  glutamine  has another route of uptake. Glutamine 
uptake is inhibited by methionine, however the other glutamine transporters have a high 
capacity for glutamine. 
L-glutamine  and  L-tyrosine  uptake  is  evident  in  BSF  trypanosomes,  indicating  the 
existence of a similar transport system for these amino acids working in the mammalian 
stage  of  the  parasite.  Moreover,  glutamine  and  tyrosine  inhibition  by  azaserine  is  still 
evident.  However,  it  is  unknown  as  to  the  exact  nature  of  the  transport  system.  It  is 
possible  that  glutamine  internalisation  shows  a  different  specificity  profile  in  BSF 
trypanosomes (different apparent Ki and/or a different inhibiting set of amino acids), which 
would indicate the expression of a different gene or set of genes specific for this stage of 
the parasite. This seems likely considering the plethora of amino acid transporter genes 
found  in  the  genome,  some  of  which  show  differential  expression.  Previous  work 
investigating aromatic amino acid uptake in BSF trypanosomes suggested the existence of 
several  aromatic  amino  acid  transporters  (M.P.  Hasne,  thesis).  Phenylalanine  and Charles E. Ebikeme, 2007     Chapter 6, 175 
tryptophan  were  found  to  use  at  least  2  routes  of  entry  while  a  single  high  affinity 
transporter was identified for tyrosine 
Amino acid recovery of azaserine action is a phenomenon well documented in bacteria 
(Kaplan et al., 1959; Brock & Brock, 1960) and in T. equiperdum (Momparler & Jaffe, 
1964). Here no such recovery could be shown by the alamar blue method. This suggests 
two things; firstly that azaserine’s mode of action does not involve amino acid usage or 
that the effect on amino acid usage is irreversible; and secondly that azaserine penetration 
through  the  cell  membrane  could  not  be  prevented  by  competing  amino  acids. 
Therapeutically,  this  would  be  an  encouraging  feature  for  a  potential  drug  to  have  as 
competing amino acids in the blood plasma or cerebrospinal fluid would have little effect 
on drug efficacy. The fact that azaserine has multiple routes of entry into the trypanosome 
interior meant we could not antagonise azaserine action by simple transport competition. 
The multiple routes of entry also goes some way to explain why resistance through loss of 
transport could not be easily achieved. 
6.3.2 Levodopa & Aromatic Amino Acid Transport 
Here we show that Levodopa has toxicity against both forms of the parasite (58.58 µM 
against  PCF  and  31.58  µM  against  BSF).  Owolabi  et  al  (1989)  showed  trypanocidal 
activity  of  certain  catecholamines  (dopamine  and  tryptamine  analogues).  BSF 
trypanosomes (10
5 cells/ml) on a feeder layer culture system (Microtus agrestis embryonic 
fibroblasts)  incubated  with  drug  (1  µM)  were  completely  cleared  after  24  hours.  It  is 
possible that the high level of toxicity seen by Owolabi is simply as a result of metabolic 
activation. In vivo tests showed complete clearance of trypanosomes from the bloodstream 
of mice at a dose of 0.1 mg/kg. The possibility of metabolic activation was explored by 
testing other compounds of aromatic metabolism in mammalian cells. No other compound 
showed  any  significant  higher  toxicity  against  trypanosomes.  However,  an  in  vivo 
environment is a more complex setting and it is possible that a more complex dynamic 
between these biologically relevant aromatic analogues interact to bring about an, as yet 
unknown, trypanocidal effect. 
From previous studies (Owolabi et al., 1989), it was not clear if L-Dopa action was due to 
internal or exterior activity of L-Dopa itself or one or more of its derivatives. L-Dopa entry 
into the parasite seems to be mediated through an aromatic amino acid transport system, as 
shown by inhibition of tyrosine uptake. Phenylalanine and tryptophan also inhibited uptake 
of tyrosine (although to lesser degrees) suggesting a common route of uptake for these Charles E. Ebikeme, 2007     Chapter 6, 176 
amino acids. However, it seems that more than one transport system is evident. L-Dopa 
inhibited tyrosine and phenylalanine to different degrees, where if one transport system 
was apparent,  L-Dopa inhibition of phenylalanine would be  greater than phenylalanine 
self-inhibition. The data presented here seems to suggest that L-Dopa entry to the PCF 
trypanosome is mediated through a tyrosine-specific aromatic amino acid transporter, one 
which shows some affinity for phenylalanine and tryptophan. In BSF trypanosomes, this 
inhibition  of  tyrosine  by  L-Dopa  is  still  seen,  pointing  to  the  existence  of  a  similar 
transporter at work in that life cycle stage. However, it is unknown as to the exact nature of 
the  transport  system.  It  is  possible  that  glutamine  internalisation  shows  a  different 
specificity profile in BSF trypanosomes (different apparent Ki and/or a different inhibiting 
set of amino acids), which would indicate the expression of a different gene or set of genes 
specific for this stage of the parasite. 
It is possible that separate transporters exist for the three different aromatic amino acids in 
PCF trypanosomes. Indeed, separate aromatic amino acid transporters have been postulated 
in BSF trypanosomes (M.P. Hasne, thesis). With that in mind, it would be wrong to rule 
out entry of the other aromatic analogues tested just because they showed no significant 
inhibition  of  phenylalanine.  For  example,  the  analogues  5’  hydroxyl-tryptophan  and 
tryptamine, structurally similar to tryptophan are most likely targeted into the cell via a 
tryptophan specific aromatic amino acid transporter. 
L-Dopa toxicity could not be ablated by any of the 20 amino acids in high concentrations, 
suggesting that a mode of action involving amino acid usage is not at play or, at least, not 
significant. A possible mode of action involving the creation of reactive oxygen species 
has  been  postulated  (Owolabi  et  al.,  1989).  Detoxification  of  reactive  oxygen  species 
involves the transfer of reducing equivalents to redox cascade pathways (Wilkinson et al., 
2003). However, we did not find any increased sensitivity in TbSOD knock-out cell lines. 
Trypanosome  superoxide  dismutase  enzymes  detoxify  superoxide  anions  (O2
·-)  by 
catalysing  their  disproportionation  to  hydrogen  peroxide  (McCord  &  Fridovich,  1969), 
whereas  L-Dopa  auto-oxidation  produces  highly  unstable  electrophilic  Dopa-
(semi)quinones and reactive oxygen species such as H2O2, O2
- and OH (Shi et al., 2002). 
TbSOD would only protect against one class of reactive oxygen species produced by L-
Dopa auto-oxidation, which would explain why no difference in sensitivity was observed 
in mutant TbSOD cell lines.  
Growth of trypanosomes in incremental amounts of drug to generate resistant cell lines 
proved  problematic.  Progressive  darkening  of  the  medium  was  evident,  with  turbidity Charles E. Ebikeme, 2007     Chapter 6, 177 
developing from the production of quinolones and other reactive oxygen species. It seems 
probable that the trypanocidal activity of L-Dopa is as a result of secondary products of the 
analogue. Also, we have shown through inhibition of tyrosine uptake that L-Dopa can be 
transported into cells, suggesting that auto-oxidation can occur both extracellularly and 
intracellularly. This intracellular and extracellular damage caused by L-Dopa goes some 
way to explain why a resistance phenotype could not be generated. The non-enzymatic 
antioxidants L-ascorbic acid, glutathione, N-Acetyl-L-cysteine have been shown to protect 
mammalian  cells in vitro against the  cytotoxic effects induced by  L-Dopa (Lai & Yu, 
1997).  It  would  be  interesting  to  see  if  this  protective  effect  was  evident  with 
trypanosomes. 
6.3.3 Cell Penetrating Peptides 
Cell penetrating peptides as delivery agents for therapeutic compounds are an emerging 
field.  Even  with  the  plethora  of  recent  publications  in  the  field  of  CPP  research,  the 
mechanism for CPP translocation is still poorly understood. The majority of the work on 
CPPs  has  been  carried  out  using  mammalian  cells.  However,  CPP  intracellular 
accumulation has been observed in a variety of other cell systems, such as yeast (Parenteau 
et al., 2005), insect cells (Palm et al., 2006), bacteria, fungi (Nekhotiaeva et al., 2004), and 
tobacco  protoplasts  (Mae  et  al.,  2005).  It  is  evident  from  results  shown  here  that  the 
peptide TP10 also has toxic activity against BSF trypanosomes, with trypanocidal activity 
on cells occurring within 6 hours of drug exposure. CPP entry into the cell is confirmed, 
yet is highly variable within a given cell population. In some cases, there seems to be some 
co-localisation with nuclear and kinetoplast intracellular organelles. 
Quantum dots are having recent use as luminescent labels for biological systems (la Fuente 
et  al.,  2005),  mainly  because  they  possess  several  key  advantages  over  conventional 
fluorescent dyes: they emit light at a variety of precise wavelengths depending on their size 
and have long fluorescent lifetimes. In this case, the quantum dot Cadmium sulphide (CdS) 
was linked to the un-natural amino acid tiopronin which was then functionalised with a Tat 
protein  derived  peptide  sequence  (GRKKRRQRRR).  Tiopronin  is  a  pharmaceutically 
important drug used for the treatment of cystinuria and rheumatoid arthritis (Denneberg et 
al., 1983). Charles E. Ebikeme, 2007     Chapter 6, 178 
 
Figure 6-31: Synthesis of CdS-tiopronin-Tat (taken from la Fuente et al., 2005). 
 
Previous studies have shown CdS-tiopronin-QDs coupled to Tat protein-derived peptide 
sequences  were  used  to  achieve  nuclear  targeting  of  the  nanoparticles  in  hTERT-BJ1 
human fibroblasts (la  Fuente et al., 2005). Even after 15 mins incubation fluorescence 
staining was observed around the cell nucleus, showing evident translocation of the CdS-
tiopronin-Tat conjugate to the nucleus. No fluorescence staining was observed when naked 
CdS-tiopronin was incubated with the cells. Other studies have shown the Tat Peptide to be 
an efficient molecule to translocate gold nanoparticles into the cell nucleus (la Fuente & 
Berry, 2005) at a 50 µg/ml concentration after just one hour. 
In the case of trypanosomes, along with no trypanocidal activity we have shown there to be 
no accumulation of the fluorescent conjugate within the cell interior. This suggests that 
with  trypanosomes  the  tat  protein-derived  peptide  does  not  have  trypanosome  cell 
penetrating  properties.  With  no  apparent  membrane  translocating  properties  of  the  tat-
derived  peptide  seen,  we  can  rule  out  this  particular  compound  as  a  way  to  introduce 
potential trypanocidal drugs into the cell. 
6.3.4 Eflornithine 
Uptake of 10 µM 
3H-DFMO over the 2 hour time period appears to be linear, showing an 
approximate  accumulation  of  drug  at  a  rate  of  10  picomoles  per  hour  (per  10
7  cells). 
Uptake in PCF trypanosomes has been previously reported as linear with an accumulation 
of 2 nanomoles per 10
9 cells over a 70 min time period, using 0.1 mM DFMO. This is 
comparable to what is found here in bloodstream forms with 10 pmoles being accumulated 
over a one hour period using 10 times less DFMO and 100 times fewer cells. With only a 
single experiment performed in early studies, further work will need to be done to fully 
complete  the  preliminary  insight  gained  here.  The  nature  of  this  apparent  linearity  of Charles E. Ebikeme, 2007     Chapter 6, 179 
uptake will need to be explored in more detail. Is the apparent cumulative intake of DFMO 
as a result of simple diffusion or are transport processes at play? 
 
Figure 6-32: Structure of L-lysine and DFMO. 
 
DFMO is structurally similar to the basic amino acid lysine (Figure 6-32), so it is likely 
that if an active transport component is involved in uptake it would be a route of entry 
shared with at least one of these amino acids. Lysine differs from DFMO by one CH2 unit 
on  its  hydrophilic  side  chain  and  an  altered  amino  acid  recognition  motif,  with  the 
hydrogen attached to the α-carbon replaced by a difluoro-unit. There is evidence to suggest 
that  disruption  of  the  amino  acid  recognition  motif  results  in  abolished  uptake  of  the 
particular amino acid (Hasne & Barrett, 2001). With methionine transport, the core amino 
acid structure appears to be essential since analogues consisting of the side chain alone had 
no inhibitory effect. Fluorine substitution is a powerful tool in bioorganic and medicinal 
chemistry  (Welch  &  Eswarakrishnan,  1991).  Fluorine  incorporation  into  biologically 
active  compounds  can  alter  drug  metabolism,  enzyme  substrate  recognition  and  even 
affinity for natural receptors (Biffinger et al., 2004). With DFMO the hydrophobic fluoro-
carbon group is likely to result in lipid solubility. 
In  BSF  trypanosomes  there  does  possibly  seem  to  be  inhibition  of  DFMO  uptake  by 
aromatic amino acids (Figures 6-25, 6-26) although this does not seem to be reciprocal 
(Figures  6-28,  6-29).  DFMO  over  a  range  of  concentrations  showed  no  inhibition  of 
tyrosine uptake. However, other aromatic amino acids showed more significant inhibition 
of  DFMO  uptake  (Figure  6-25).  Interestingly,  when  we  tried  to  inhibit  DFMO  to Charles E. Ebikeme, 2007     Chapter 6, 180 
completion using all three aromatic amino acids (500 µM concentration each), we still saw 
significant levels of DFMO uptake. It is possible that for individual aromatic amino acids 
there is some inhibition exhibited at lower concentrations which is lost at higher ones, 
either  by  increased  capacity  of  a  transporter  or  the  transient  opening  of  a  secondary 
transporter. 
Preliminary  studies  here  have  also  highlighted  the  fact  that  trypanosome  amino  acid 
transporters may have the capacity for trans-acceleration or, at least transient regulation. 
Inhibition of DFMO by aromatic amino acids individually showed some level of inhibition 
(~80% uptake with tyrosine and ~20% uptake with phenylalanine and tryptophan, Figure 
6-26). However, combining all three aromatic amino acids restored DFMO uptake. It is 
possible that increased concentrations of certain amino acids increases the capacity of a 
particular  transporter  of  activates  another  transporter.  Trans-acceleration  and  trans-
inhibition  phenomenon  are  well  documented  in  mammalian  amino  acid  transporters 
(McDowell et al., 1995; Bracy et al., 1986; Fong et al., 1990; Volk et al., 2003; Pan et al., 
2002). 
More significantly, lysine uptake shows significant inhibition by increasing concentrations 
of DFMO (Figure 6-27) as well as a dose dependent self inhibition, giving an apparent IC50 
of 39 µM ± 4. From this, it seems evident that some transport-mediated process exists for 
the internalisation of the drug, possibly through a lysine specific transporter. 
Inhibition of DFMO uptake using amino acids has previously been looked at (Bitonti et al., 
1985). However, due to the methodology of the protocol no apparent inhibition was seen. 
DFMO inhibition was only studied at a single 60 min time point, a time point which is far 
too  long  to  report  exclusively  upon  transport  processes,  especially  when  a  diffusion 
component could also be at play. Also, inhibition studies only used concentrations barely 
20 times that of DFMO (56 µM DFMO vs 1 mM analogue). Here, a number of amino 
acids have been shown to inhibit DFMO uptake to a significant extent. The fact that cold 
DFMO only inhibits [
3H]-DFMO to a maximum of 50%, even in 500-fold excess, suggests 
that if a transport system is involved then affinity for DFMO is weak at best. It is possible 
the  accumulation  of  DFMO  observed  here  and  with  other  studies  is  the  net  effect  of 
transport and diffusion. 
What  needs  to  be  done  now  is  to  try  and  separate  the  components  involved  in  the 
internalisation of  DFMO as well  as trying to  decipher the specifics of the  amino acid 
transport  system  involved.  There  is  the  aforementioned  active  transport  versus  simple Charles E. Ebikeme, 2007     Chapter 6, 181 
diffusion debate as well as an apparent stimulation of uptake  at higher concentrations. 
Transport  versus  diffusion  can  be  easily  separated.  Uptake  studies  at  4ºC  would  help 
eliminate  the  transport  component.  Also,  with  regards  to  BSF  aromatic  amino  acid 
transporters,  further  investigation  of  individual  uptake  is  necessary  (tyrosine, 
phenylalanine, and tryptophan). Multiple aromatic amino acid transporters have already 
been  postulated  (M.P.  Hasne,  thesis).  What  needs  to  be  determined  if  these  transport 
systems have the capability of transinhibition, or what seems like a loss of inhibition at 
high concentrations of more than one inhibitor. 
It has often been mentioned that it is possible that the contribution of an active transport 
system to the therapeutic effects of DFMO would be insignificant (Bitonti et al., 1985). 
But  in  studies  with  resistant  cell  lines  only  uptake  seems  implicated  in  the  resistance 
phenotype  (Phillips  &  Wang,  1987).  It  is  entirely  possible  that  a  simple  increase  in 
ornithine uptake is enough to compensate for the effects of DFMO, as it has been seen that 
ornithine  uptake  is  significantly  faster  in  resistant  cell  lines  as  well  as  wild  type  cells 
exposed to DFMO. The resistance phenotype could simply be a result of the establishment 
of  sustained  increase  of  ornithine  uptake,  due  to  increase  in  transporter  activity.  This, 
coupled  with  increase  in  polyamine  and  arginine  intake,  could  lead  to  the  apparent 
resistance phenotype seen. 182 
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The  long-held  beliefs  on  neglected  disease  drug  development  activity  are  no  longer 
accurate (Moran, 2005). Neglected diseases, once thought of by pharmaceutical companies 
as non-profitable, are finding more research activity. This reflects the formation of more 
and more new pharmaceutical industry neglected-disease institutes, the creation of new 
drug development Public-private partnerships (PPPs), which now conduct three-quarters of 
all identified neglected disease drug development (Moran, 2005). 
There is a shifting landscape in drug discovery against neglected diseases. Safer and more 
affordable drugs are still needed for the tropical diseases of the developing world. Only 13 
new drugs have been developed for neglected tropical diseases since 1975 (Moran, 2005), 
and many have proved  to be too expensive, too toxic or too difficult  to administer in 
resource poor settings. While older front-line drugs are losing their efficacy due to the 
emergence  of  widespread  drug  resistance.  To  this  effect,  it  is  important  to  generate 
validated and druggable targets of the African trypanosome. The genome has opened up a 
vast  library  from  which  researchers  can  start  from.  Transporters  themselves  do  not 
necessarily offer much of a viable drug targets, but it has been shown that transporters 
prove a viable gateway for potential trypanocides. The role of the P2 nucleoside transporter 
as  a  transporter  for  trypanocidal  drugs  and  its  role  in  resistance  mechanisms  has  set 
precedents  for  features  of  transporters  that  make  potential  drug  carriers.  Amino  acid 
transporters share the same characteristics (Hasne & Barrett, 2000). 
A family of 46 genes encoding amino acid transporters is present in the T. brucei genome 
making it the largest, and most diverse, family of transporters encoded in the trypanosome 
genome. It was one aim of this project to evaluate amino acid transporters as a mode of 
entry  for  potential  trypanocidal  drugs.  Many  compounds  that  have  been  given  some 
attention as potential trypanocides (azaserine and eflornithine) do show targeting through 
amino acid transporters. Characterisation of amino acid transporters by molecular biology 
and biochemical techniques was performed allowing evaluation of targeting of amino acid 
analogues with trypanocidal activity through amino acid transporters. 
Targeting  amino  acid-like  compounds  through  amino  acid  transporters  proves  a  viable 
method for introducing trypanocidal compounds into the cell interior. In the mammalian 
system, there is potential for amino acid transporters as delivery systems for drugs and 
prodrugs. Recent studies have shown the potential of the human amino acid transporter 
ATB
0,+, a transporter of neutral as well as cationic amino acids, as a drug delivery system 
(Ganapathy  &  Ganapathy,  2005).  Certain  antiviral  drugs  can  be  transported  by  the 
transporter when linked to the side chain of anionic amino acids. Charles E. Ebikeme, 2007     Chapter 7, 184 
Moreover,  because  the  brain  capillary  endothelial  cells  comprising  the  BBB  greatly 
prohibits transport of certain solutes from the blood, due to tight junctions, high brain 
capillary metabolism, low pinocytic vesicular trafficking, and efficient efflux mechanisms 
(Killian et al., 2007) it is important to utilise carrier-mediated transport processes into the 
brain. Amino acid analogues offer an attractive class of compounds that can take advantage 
of brain amino acid transporters for late stage sleeping sickness. 
With  recent  studies  showing  that  a  strategy  comprising  of  covalent  coupling  of  small 
molecules to L-cysteine achieves high affinity recognition for the specific, cerebrovascular 
large neutral amino acid transporter (LAT1) (Killian et al., 2007), it may be possible to 
attach an amino acid recognition motif to other potential trypanocides that might allow 
targeting through either mammalian or trypanosome amino acid transporters. 
One amino acid transporter, TbAATP1, was characterised. It was shown to be a carrier of 
small,  neutral  amino  acids.  Its  substrate  recognition  profile  will  allow  drug  design  of 
potential  trypanocides  that  can  be  targeted  through  TbAATP1.  Moreover,  modes  of 
resistance involving loss of the transporter can be investigated with the use of the RNAi 
cell line. 
Grouping  of  amino  acid  transporter  genes  based  on  gene  sequence  (rather  than 
chromosomal  location)  aides  down-stream  functional  genomic  approaches  to 
characterisation. The fact that most genes that group together by sequence usually tend to 
group together by genomic locus means that gene knock-out approaches offer an advantage 
over conventional RNAi based approaches. However, with some large arrays, sometimes 
stretching to more than 15 kb in size, means that large gene families will prove difficult to 
knock-out by homologous recombination. The limitations of RNAi means it will prove 
difficult  to  distinguish  between  most  of  the  amino  acid  transporter  genes  in  terms  of 
functional  significance.  A  further  complication  is  functional  redundancy  in  amino  acid 
transporter repertoire.  Further investigations into amino acid transporters needs to be a 
multi-faceted  approach,  with  biochemical  and  gene  knock-out  techniques  employed  to 
allow assignment of functional phenotype to gene.  
Inhibition profiles play a major part of characterising transporters. It is important that the 
inhibition  characteristics  of  transporters  either  with  individual  amino  acids  or  multiple 
amino acids. This will allow predictions of in vivo settings and bioavailability within the 
trypanosome in the presence of changing extracellular amino acid concentrations (amino 
acid concentrations in the blood and/or cerebrospinal fluid as a function of disease state). Charles E. Ebikeme, 2007     Chapter 7, 185 
Differential regulation throughout the life cycle of amino acid transporters also needs to be 
investigated in more detail. This will not only allow functional redundancy of genes to be 
filtered out, but also highlight transporters that become essential in the mammalian host. 
Allowing,  trypanocidal  amino  acid  analogue  to  show  greater  efficacy.  Moreover, 
differential regulation of amino acid transporters modulating uptake of trypanocides might 
result in changes in susceptibility. 
Characterising amino acid transporters offers a window into amino acid metabolism in 
these parasites. L-proline utilisation has been shown to be regulated by overrall glucose 
availability.  D-glucose  exerts  an  influence  on  other  aspects  of  procyclic  trypanosome 
biology, including procyclin expression as well as mitochondrial energy generation. It is 
possible that glucose usage has implications for tsetse fly biology and could be linked to 
developmental cues of the parasite. 
Our knowledge of the parasite and parsite-host interactions are forever evolving, aided by 
new  tools  and  new  collaborative  efforts.  Systems  biology  is  such  a  field  that  brings 
together  a  multi-disciplinary  approach  to  investigate  the  biochemistry  of  the  parasite. 
Metabolomics  offers  a  powerful  technique  to  un-biasly  follow  the  fate  of  metabolites 
within  cells  exposed  to  different  conditions.  Moreover,  pertubations  and  adaptational 
processes can be seen. The greatest potential metabolomics holds for trypanosome biology 
is to build upon genome sequencing data. With only half of the genome annotated means 
the actual metabolome of African trypanosome is much larger than the in silico prediction. 
The field of metabolomics is in the early stages of development and it is important to 
follow up the changes seen with biochemical characterisation. Only then can metabolomics 
live up to its full potential. 
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8.1  Amino Acids 
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8.2  SDM80 
NaH2PO4      157 mg   
NaCl        6.8 g 
MgSO4      100 mg 
KCl        400 mg 
CaCl2        200 mg 
L-Arginine      100 mg 
L-Methionine      70 mg 
L-Phenylalanine    80 mg 
L-Threonine      350 mg 
L-Tyrosine      100 mg 
Taurine      160 mg 
L-Alanine      200 mg 
L-Asparagine      13.2 mg 
L-Aspartate      13.3 mg 
L-Glutamate      14.7 mg 
L-Glutamine      200 mg 
Glycine      7.5 mg 
L-Serine      60 mg 
HEPES      8 g 
MOPS       5 g 
NaHCO3      2.2 g 
Pyruvate      220 mg 
Mercaptoethanol (0.1 M)  2 ml 
Hypoxanthine     14 mg 
Thymidine      4 mg 
Vitamins (100 X)    10 ml 
Essential amino acids (50 X) 20 ml 
Phenol Red      4 ml 
Hemin (2.5 mg/ml)    2 ml 
Dialysed Foetal Calf Serum  10% 
 
For 1 litre. Filter sterilise. Store at 4ºC. 
 
 
 
8.3  CBSS Buffer 
HEPES      25 mM 
NaCl2        120 mM 
KCl        5.4 mM 
CaCl        0.55 mM 
MgSO4      0.4 mM     
Na2HPO4      5.6 mM 
D-glucose      11.1 mM 
 
For 1 litre. Adjust to pH 7.4 and store at –20 °C. 
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8.4  Cunningham’s Medium 
CaCl2        113 mg 
KCl        3000 mg 
MgSO4      1800 mg 
NaH2PO4.H2O     530 mg 
Glucose      700 mg 
Fructose      400 mg 
Sucrose      400 mg 
Phenol Red      21 mg 
HEPES      6000 mg 
Alanine      550 mg 
Beta alanine      2000 mg 
Arg.HCl      440 mg 
Asparagine      240 mg 
Aspartic acid      110 mg 
Cystine      110 mg 
Glutamic acid     250 mg 
Glutamine      1700 mg 
Glycine      120 mg 
Histidine.HCl.H2O    160 mg 
Isoleucine      90 mg 
Leucine      90 mg 
Lysine.HCl      187 mg 
Methionine      100 mg 
Phenylalanine     200 mg 
Proline       6900 mg 
Serine        100 mg 
Taurine      270 mg 
Threonine      50 mg 
Tryptophan      100 mg 
Tyrosine      200 mg 
Valine       100 mg 
Pyruvate      100 mg 
Hypoxanthine     116 mg 
FCS        20% 
 
For 1 litre. Filter sterilise and store at 4ºC. 
 
 
 
8.5  TELT Buffer 
Tris-HCl (pH 8)    50 mM 
EDTA (pH 9)      62.5 mM 
LiCl        2.5 M 
Triton X-100      4% v/v 
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8.6  TE Buffer 
Tris-HCl (pH 8)    10 mM 
EDTA (pH 8)      1 mM 
 
 
 
8.7  1X TAE Buffer 
Tris acetate (pH 8.5)    40 mM 
EDTA       1 mM 
 
 
 
 
8.8  LB Medium 
Bacto-tryptone    10 g 
Bacto-yeast extract    5 g 
NaCl        10 g 
 
For 1 litre. Sterilise by autoclaving. 
 
 
 
 
8.9  20X SSC 
Tri-sodium citrate    88.23 g 
NaCl        175.32 g 
 
For 1 litre. Adjust to pH 7. Store at room temperature. 
 
 
 
 
8.10   10X MOPS 
MOPS       0.2 M 
Sodium acetate    80 mM 
EDTA (pH 7)      10 mM 
 
Filter and store in the dark at 4ºC. 
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8.11   ZPFM Buffer 
NaCl        132 mM 
KCl        8 mM 
Na2H2PO3
2+      8 mM 
KH2PO3      1.5 mM 
Mg(C2H3O2)      1.5 mM 
C4H6CaO4      90 µM 
 
 
 
 
8.12   PBS 
Sodium phosphate    20 mM 
NaCl        150 mM 
 
 
8.13   100X Denhardt’s Solution 
Bovine serum albumin  2 g 
Ficoll        400.2 g 
Polyvinylpyrolidone    2 g 
 
For 100 ml. Store at -20ºC. 
 
 
 
 
8.14   Amino Acid Analogues 
Analogue          PCF  BSF  HEK 
Azaserine          176.46 10.85  1.52 
Glycine Hydroxamate       N/A  N/A  N/A 
L-Serine b-naphthylamide      38.60  43.70  179.60 
Serine Hydroxamate        N/A  N/A  N/A 
Serine Benzyl Ester        N/A  N/A  N/A 
Serine Methyl Ester        N/A  N/A  N/A 
N-acetyl D, L-serine        N/A  N/A  N/A 
Arginine Methyl Ester      N/A  N/A  N/A 
Acetyl Methionine        N/A  N/A  N/A 
N-formyl Methionine       N/A  N/A  N/A 
Alanine Ethyl Ester        N/A  N/A  N/A 
Seleno Methionine        N/A  N/A  N/A 
Lysine Methyl Ester        N/A  N/A  N/A 
Alanyl Glycine        N/A  N/A  N/A 
Adenosyl Homocysteine      N/A  N/A  N/A 
Seleno Ethionine        N/A  N/A  N/A 
Tyrosine Methyl Ester      N/A  N/A  N/A 191 
N-Acetyl Tyrosine Ethyl Ester    N/A  N/A  N/A 
Tryptophan Benzyl Ester      79.21  27.54  N/A 
Fluoro Tryptophan        N/A  N/A  N/A 
Kynurenine          N/A  N/A  N/A 
Saccharopine          N/A  N/A  N/A 
Tryptophan Ethyl Ester      28.00  N/D  N/D 
N-formyl Phenylalanine      N/A  N/A  N/A 
N3 Trimethyl Lysine        N/A  N/A  N/A 
N-formyl Tyrosine        N/A  N/A  N/A 
N-Acetyl Tyrosineamide      N/A  N/A  N/A 
N-Acetyl Tryptophanamide      N/A  N/A  N/A 
AS10            N/A  N/A  N/A 
CMC-20-1          N/A  N/A  N/A 
AJ222           N/A  N/A  N/A 
AS65            N/A  N/A  N/A 
KF38            N/A  N/A  N/A 
CMC-18-2          N/A  N/A  N/A 
AS66            N/A  N/A  N/A 
L-Alaninamide        N/A  N/A  N/A 
O-Phospho-L-Serine        N/A  N/A  N/A 
L-3,4-Dihydroxy Phenylalanine (L-DOPA)  58.60  31.58  112.21 
DL-Threo-B-Phenylserine      N/A  N/A  N/A 
L-Homocysteine Thiolactone     N/A  N/A  N/A 
Cycloserine          141.80 327.85 176.42 
N-Succinyl-L-Phenylalanine p-nitroanilide  N/A  N/A  N/A 
Hippuryl-L-Arginine        N/A  N/A  N/A 
Diazoacetyle-dl-Norleucine Methyl Ester  N/A  N/A  N/A 
N-Benzoyl-L-Propyl-L-Phenyalanyl-L-Arginine p-nitroanilide  N/A  N/A  N/A 
N-Benzoyl-L-Propyl-L-Tyrosine p-nitroanilide  46.21  23.34  110.00 
L-Propyl Glycine        N/A  N/A  N/A 
S-Benzyl L-Cysteine p-nitroanilide    N/A  N/A  N/A 
L-Phenylalanyl L-Proline      N/A  N/A  N/A 
a-N-Benzoyl L-Arginine Amide    N/A  N/A  N/A 
Benzoyl L-Valyl-Glycyl L-Arginine p-Nitroanilide  N/A  N/A  N/A 
N-Benzoyl L-Tyrosine Ethyl Ester    N/A  N/A  N/A 
Na-Acetyl-Glycyl-L-Lysine B-Naphthyl Ester  48.44  N/A  N/D 
Glycyl-L-Leucine        N/A  N/A  N/A 
CycloLeucine         N/A  N/A  N/A 
N-(p-Aminobenzoyl)-L-Glutamic Acid  N/A  N/A  N/A 
Glycine Benzyl Ester        N/A  N/A  N/A 
L-Leucine B-Naphthyl Amide    69.66  40.60  N/D 
DL-B-Hydroxy Norvaline      N/A  N/A  N/A 
Dihydrofolic Acid        N/A  N/A  N/A 
DL-Tetrahydrofolic Acid      N/A  N/A  N/A 
3,4 Dihydrophenylacetic acid     65.20  390.59 112.40 
5' Hydroxy-L-Tryptophan      N/A  N/A  N/A 
Serotonin          155.00 N/A  N/A 
Tryptamine          21.90  57.83  176.42 
Dopamine          63.25  275.05 87.07 
N-Acetyl DL Tryptophan      N/A  N/A  N/A 
DL-a-Amino Adipic Acid      N/A  N/A  N/A 
m-Flouro-DL-Tyrosine      N/A  N/A  N/A 
5-Flouro-DL-Tryptophan      N/A  N/A  N/A 
5-methly DL Tryptophan      N/A  N/A  N/A 192 
DL-p-Hydroxyphenyl-Lactic Acid    N/A  N/A  N/A 
5-Hydroxy L Tryptophan      N/A  N/A  N/A 
DL Indole-3-Lactic Acid      N/A  N/A  N/A 
Cyclophosamide        N/A  N/A  N/A 
L-Canavanine         N/A  N/A  N/A 
D-y-MethylLeucine        N/A  N/A  N/A 
O-Benzyl-L-Tyrosine       N/A  N/A  N/A 
Tri-Iodothyronine        134.44 102.17 N/A 
L-Thyroxine          N/A  56.17  N/A 
Melphalan          N/A  102.23 N/A 
Azetidine-2-Carboxylic Acid     N/A  N/A  N/A 
NorLeucine          N/A  N/A  N/A 
Methionine Sulfoximine      N/A  N/A  N/A 
Hydroxy Lysine        N/A  N/A  N/A 
Noradrenaline         N/A  N/A  27.90 
Ureidosuccinic acid-N-carbomyl Aspartate  N/A  N/A  N/A 
DON            N/D  N/D  N/A 
 
 
 
 
8.15   List of Metabolites 
Metabolite        Mass    Formula 
Acetaldehyde        44.026215  C2H4O 
Acetate        60.02113  C2H4O2 
Ethanolamine        61.052763  C2H7NO 
Pyruvaldehyde      72.02113  C3H4O2 
Glycine        75.03202841  C2H5NO2 
Pyruvate        87.00822  C3H3O3- 
Pyruvic Acid        88.016045  C3H4O3 
Putrescine        88.100048  C4H12N2 
Alanine        89.04767847  C3H7NO2 
sarcosine        89.04767847  C3H7NO2 
Dihydroxyacetone      90.03169406  C3H6O3 
glycerol        92.04734412  C3H8O3 
Ethanolamine HCl      97.02944159  C2H8ClNO 
L-a-Amino-n-butyric acid    103.0633285  C4H9NO2 
Serine          105.0425931  C3H7NO3 
D1-Pyrroline-5-carboxylic acid  113.0476785  C5H7NO2 
proline         115.0633285  C5H9NO2 
Succinate        116.01096  C4H4O4 
Amino oxobutyrate      117.042594  C4H7NO3 
valine          117.0789786  C5H11NO2 
Threonine        119.0582432  C4H9NO3 
L-homoserine       119.058244  C4H9NO3 
Cysteine        121.0197492  C3H7NO2S 
Taurine        125.0146638  C2H7NO3S 
Pyro-L-glutamic acid     129.0425931  C5H7NO3 
L-Pipecolic acid      129.0789786  C6H11NO2 
Hydroxyproline      131.0582432  C5H9NO3 
Glutamate γ-semialdehyde    131.058244  C5H9NO3 
Leucine        131.0946287  C6H13NO2 193 
Malate         132.005875  C4H4O5 
Oxaloacetate        132.005875  C4H4O5 
Asparagine        132.0534921  C4H8N2O3 
Glycyl-glycine      132.0534921  C4H8N2O3 
Ornithine        132.089878  C5H12N2O2 
Aspartic acid        133.0375077  C4H7NO4 
L-Homocysteine      135.0353992  C4H9NO2S 
Adenine        135.0544952  C5H5N5 
Phosphoethanolamine     141.0190943  C2H8NO4P 
Spermidine        145.157897  C7H19N3 
2-ketoglutarate      146.021525  C5H6O5 
L-Glutamine        146.0691422  C5H10N2O3 
Lysine         146.1055277  C6H14N2O2 
L-Glutamic acid      147.053159  C5H9NO4 
O-acetyl-L-serine      147.053159  C5H9NO4 
Mevalonic acid      148.07356  C6H12O4  
Methionine        149.0510493  C5H11NO2S 
Histidine        155.0694765  C6H9N3O2 
Orotic acid        156.0171066  C5H4N2O4 
L-a-Aminoadipic acid     161.0688078  C6H11NO4 
O-acetyl-L-homoserine    161.068809  C6H11NO4 
Carnitine        161.1051934  C7H15NO3 
Hydroxylysine       162.1004423  C6H14N2O3 
N-Acetyl-L-cysteine      163.0303139  C5H9NO3S 
L-Methionine sulfoxide    165.0459639  C5H11NO3S 
Phenylalanine       165.0789786  C9H11NO2 
Phosphoenolpyruvate     167.982378  C3H5O6P 
L-Cysteic acid       169.004493  C3H7NO5S 
N3-Methyl-L-histidine    169.0851266  C7H11N3O2 
Dihydroxyacetone phosphate   169.9980245  C3H7O6P 
Glyceraldehyde 3 phosphate    169.998028  C3H7O6P 
Glycerol 3 phosphate      172.013678  C3H9O6P 
Glycyl-L-proline      172.0847923  C7H12N2O3 
N-Acetyl-L-hydroxyproline    173.0688078  C7H11NO4 
N-Acetyl-L-ornithine     174.1004423  C7H14N2O3 
Arginine        174.111676  C6H14N4O2 
L-Citrulline        175.0956913  C6H13N3O3 
Glucose        180.0633881  C6H12O6 
L-Methionine sulfone     181.0408785  C5H11NO4S 
Tyrosine        181.0738932  C9H11NO3 
DFMO         182.086684  C6H12F2N2O2 
L-Homocysteic acid      183.0201431  C4H9NO5S 
Glycerate 3-phosphate    185.9929391  C3H7O7P 
NE-Acetyl-L-lysine      188.1160924  C8H16N2O3 
L-Homocitrulline      189.1113414  C7H15N3O3 
gamma-Carboxyglutamate    191.042987  C6H9NO6 
Citrate         192.027005  C6H8O7 
L-3-(3,4-Dihydroxyphenyl)-alanine  197.0688078  C9H11NO4 
erythrose-4-phosphate     200.008593  C4H9O7P 
S-Sulfo-L-cysteine      200.9765637  C3H7NO5S2 
NG,NG-Dimethylarginine    202.1429758  C8H18N4O2 
Spermine        202.215746  C10H26N4 
Tryptophan        204.0898776  C11H12N2O2 
L-Kynurenine       208.0847923  C10H12N2O3 194 
1-deoxy-D-xylulose 5-phosphate   214.024242  C5H11O7P  
2-C-methyl-D-erythritol 4-phosphate 216.039892  C5H13O7P 
O-succinyl-L-homoserine    219.074289  C8H13NO6 
5-Hydroxy-L-tryptophan    220.0847923  C11H12N2O3 
L-Cystathionine      222.0674276  C7H14N2O4S 
cystathionine        222.06743  C7H14N2O4S 
3-Hydroxy-L-kynurenine    224.0797069  C10H12N2O4 
Carnosine        226.1065903  C9H14N4O3 
phosphatidic acid      228.0035038  C5H9O8P 
Mevalonate-5-phosphate    228.039892  C6H13O7P  
Ribose-5-phosphate      230.019158  C5H11O8P 
Ribulose-5-phosphate     230.019158  C5H11O8P 
Xyulose-5-phosphate      230.019158  C5H11O8P 
L-Cystine        240.0238483  C6H12N2O4S2 
Anserine        240.1222404  C10H16N4O3 
Isopentenyl diphosphate    246.005831  C5H12O7P2  
Dimethylallyl diphosphate (DMAPP)246.005831  C5H12O7P2  
gamma-glutamylcysteine    250.062345  C8H14N2O5S 
L-Cysteine-L-homocysteine    254.0394983  C7H14N2O4S2 
palmitic acid        256.2402303  C16H32O2 
6-phosphogluconolactone    258.014073  C6H11O9P 
Fructose-6-phosphate     260.029723  C6H13O9P 
Glucose-6-phosphate      260.029723  C6H13O9P 
HMBDP        262.000746  C5H12O8P2  
1,3-Bisphosphoglycerate    265.9592695  C3H8O10P2 
Adenosine        267.096755  C10H13N5O4 
L-Homocystine      268.0551484  C8H16N2O4S2 
Inosine         268.0807695  C10H12N4O5 
6-phosphogluconate      276.024638  C6H13O10P 
L-Saccharopine      276.1321364  C11H20N2O6 
MEcPP         277.995661  C5H12O9P2  
linolenic acid        278.2245802  C18H30O2 
linoleic acid        280.2402303  C18H32O2 
Oleic acid        282.2558803  C18H34O2 
Melanostatin        284.1848407  C13H24N4O3 
Stearic acid        284.2715304  C18H36O2 
Orotidine        288.0593654  C10H12N2O8 
Sedoheptulose-7-phosphate    290.040288  C7H15O10P 
L-Argininosuccinic acid    290.1226343  C10H18N4O6 
Aspartame        294.1215717  C14H18N2O5 
Methylthioadenosine (MTA)   297.089562  C11H15N5O3S 
lysophosphatidylcholine    299.1133886  C10H22NO7P 
arachidonic acid      304.2402303  C20H32O2 
Glutathion (GSH)      306.099793  C10H18N4O5S 
glutathione        307.083806  C10H17N3O6S 
Mevalonate-5-pyrophosphate   308.006226  C6H14O10P2 
gondoic acid        310.2871805  C20H38O2 
Glorin         327.1794209  C15H25N3O5 
Docosahexaenoic acid      328.2402303  C22H32O2 
beta-Aspartylglucosamine    335.1328647  C12H21N3O8 
Kyotorphin        337.1750043  C15H23N5O4 
erucic acid        338.3184806  C22H42O2 
Fructose 1,6 bisphosphate    339.996056  C6H14O12P2  
AMP          347.063086  C10H14N5O7P 195 
d S-adenosylmethionine (dSAM)  354.147411  C14H22N6O3S 
S-Adenosyl-L-homocysteine   384.1215885  C14H20N6O5S 
phosphatidylserine      385.1137825  C13H24NO10P 
cholesterol        386.3548661  C27H46O 
Ergosterol        396.339214  C28H44O 
S-adenosylmethionine (SAM)  398.1372385  C15H22N6O5S 
acylcarnitine        399.1450636  C15H23N6O5S+ 
S-adenosylmethionine     415.139981  C15H23N6O6S 
ADP          427.0294148  C10H15N5O10P2 
glutathionylspermidine    434.231141  C17H34N6O5S 
phosphatidyl glycerol     455.2046089  C19H36O10P- 
ATP (Oxidised)      504.980104  C10H14N5O13P3 
ATP          506.9957452  C10H16N5O13P3 
CDP-ME        521.081183  C14H25N3O14P2  
CDP-MEP        601.047516  C14H26N3O17P3  
Glutathione        612.1519619  C20H32N6O12S2 
sphingomyelin       647.5127996  C35H72N2O6P+ 
NAD          663.1091216  C21H27N7O14P2 
NAD (oxidised)      664.116954  C21H28N7O14P2+ 
phosphatidylglycerol      670.405714  C32H63O12P 
Trypanothione (oxidised)    721.288735  C27H47N9O10S2 
Trypanothione       722.2965552  C27H48N9O10S2 
Trypanothione (reduced)    723.304384  C27H49N9O10S2 
NADP         743.075458  C21H28N7O17P3 
NADP (oxidised)      744.0832771  C21H29N7O17P3+ 
NADPH        745.0911021  C21H30N7O17P3 
phosphatidylethanolamine    748.5856302  C41H83NO8P+ 
phosphatidylcholine      759.5778051  C42H82NO8P 
Acetyl-CoA        809.1257731  C23H38N7O17P3S 
Acetoacetyl-CoA      851.136349  C25H40N7O18P3S  
succinyl-CoA       867.131264  C25H40N7O19P3S 
HMG-CoA        911.157479  C27H44N7O20P3S  
phosphatidylinositol      1046.48979  C47H85O19P3 
cardiolipin        1150.800075  C58H120O17P2 
Galactose        180.06339  C6H12O6 
D-Galactono-1,4-lactone    178.04774  C6H10O6 
D-Galactonate       196.058305  C6H12O7 
2-Dehydro-3-deoxy-D-galactonate  178.04774  C6H10O6 
2-DD-galactonate 6-phosphate  258.014073  C6H11O9P 
 
 
 
 
8.16   Biochemical Transformations 
Alanine          C3H5NO  71.037113835 
Arginine          C6H12N4O  156.101111124 
Asparagine          C4H6N2O2  114.042927522 
Aspartic Acid         C4H5NO3  115.026943115 
Cysteine          C3H5NOS  103.009185635 
Cystine          C6H10N2O3S2  222.01328591 
Glutamic Acid         C5H7NO3  129.042593189 
Glutamine          C5H8N2O2  128.058577596 196 
Glycine          C2H3NO  57.021463761 
Histidine          C6H7N3O  137.058911929 
Isoleucine          C6H11NO  113.084064057 
Leucine          C6H11NO  113.084064057 
Lysine           C6H12N2O  128.094963104 
Methionine          C5H9NOS  131.040485783 
Phenylalanine         C9H9NO  147.068413983 
Proline           C5H7NO  97.052763909 
Serine            C3H5NO2  87.032028475 
Threonine          C4H7NO2  101.047678549 
Tryptophan          C11H10N2O  186.07931303 
Tyrosine          C9H9NO2  163.063328623 
Valine           C5H9NO  99.068413983 
acetotacetate (-H2O)        C4H4O2  84.021129428 
acetone (-H)          C3H5O  57.034039825 
adenylate (-H2O)        C10H12N5O6P  329.052521734 
biotinyl (-H)          C10H15N2O3S  243.080339295 
biotinyl (-H2O)        C10H14N2O2S  226.077599618 
carbamoyl P transfer (-H2PO4)    CH2ON  44.013638724 
co-enzyme A (-H)        C21H34N7O16P3S  765.099565568 
co-enzyme A (-H2O)        C21H33N7O15P3S  748.096825891 
glutathione (-H2O)        C10H15N3O5S  289.073242585 
isoprene addition (-H)       C5H7  67.054775259 
malonyl group (-H2O)      C3H2O3  86.000393994 
palmitoylation (-H2O)      C16H30O  238.22966575 
pyridoxal phosphate (-H2O)      C8H8NO5P  229.014010906 
urea addition (-H)        CH3N2O  59.024537771 
adenine (-H)          C5H4N5  134.046670198 
adenosine (-H2O)        C10H11N5O3 249.086189377 
Adenosine 5'-diphosphate (-H2O)    C10H13N5O9P2  409.018854091 
Adenosine 5'monophosphate (-H2O)   C10H12N5O6P  329.052521734 
cytidine 5' diphosphate (-H2O)    C9H13N3O10P2  385.007620711 
cytidine 5' monophsophate (-H2O)    C9H12N3O7P 305.041288354 
cytosine (-H)          C4H4N3O  110.035436818 
Guanosine 5- diphosphate (-H2O)    C10H13N5O10P2  425.013768731 
Guanosine 5- monophosphate (-H2O)  C10H12N5O7P  345.047436374 
guanine (-H)          C5H4N5O  150.041584838 
guanosine (-H2O)        C10H11N5O4 265.081104017 
deoxythymidine 5' diphosphate (-H2O)  C10H14N2O10P2  384.012371738 
thymidine (-H2O)        C10H12N2O4 224.079707024 
thymine (-H)          C5H5N2O2  125.035102485 
thymidine 5' monophosphate (-H2O)   C10H13N2O7P  304.046039381 
uridine 5' diphosphate (-H2O)    C9H12N2O11P2  385.991636304 
uridine 5' monophosphate (-H2O)    C9H11N2O8P 306.025303947 
uracil (-H)          C4H3N2O2  111.019452411 
uridine (-H2O)        C9H10N2O5  226.05897159 
acetylation (-H)        C2H3O2  59.013304391 
acetylation (-H2O)        C2H2O  42.010564714 
C2H2            C2H2  26.015650074 
Carboxylation         CO2  43.98982928 
CHO2           CHO2 44.997654317 
condensation/dehydration      H2O  18.010564714 
diphosphate          H3O6P2  160.940489751 
ethyl addition (-H2O)       C2H4  28.031300148 197 
Formic Acid (-H2O)        CO  27.99491464 
glyoxylate (-H2O)        C2O2  55.98982928 
hydrogenation/dehydrogenation    H2  2.015650074 
hydroxylation (-H)        O  15.99491464 
Inorganic Phosphate        P  30.9737634 
ketol group (-H2O)        C2H2O  42.010564714 
methanol (-H2O)        CH2  14.015650074 
phosphate          HPO3  79.966332357 
primary amine         NH2  16.018724084 
pyrophosphate         PP  61.9475268 
secondary amine        NH  15.010899047 
sulfate (-H2O)         SO3  79.95681572 
tertiary amine         N  14.00307401 
C6H10O5          C6H10O5  162.05282357 
C6H10O6          C6H10O6  178.04773821 
D-Ribose (-H2O) (ribosylation)    C5H8O4  132.042258856 
disaccharide (-H2O)        C12H20O11  340.10056178 
glucose-N-Phosphate (-H2O)     C6H11O8P  242.019155927 
Glucuronic Acid (-H2O)      C6H8O6  176.032088136 
monosaccharide (-H2O)      C6H10O5  162.05282357 
trisaccharide (-H2O)        C18H30O15  486.15847071 
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